trial_id	trialacronym	phase	recruitmentstatus	recruitmentstate	approvaldate	actualstartdate	drug_list	drug_classes	combo_list	combo_classes	secondaryid	studytitle	healthcondition	postcode	ext_weblink
ACTRN12613000279729	HPV-Oropharynx	Phase 3	Recruiting	ACT, WA, NZ, NSW, SA, QLD, VIC	8/03/2013	17/06/2013	Cetuximab; Cetuximab + Radiotherapy; Cisplatin; Radiotherapy	platinum-based_antineoplastic_agent; anti-EGFR_monoclonal_antibody; radiotherapy; anti-EGFR_monoclonal_antibody + radiotherapy	Cetuximab + Radiotherapy	anti-EGFR_monoclonal_antibody + radiotherapy	Nil	TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma	HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)	Palmerston North; Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000279729
ACTRN12613000297729	ENG2	Phase 1 / Phase 2	Stopped early	NSW, VIC	18/03/2013	8/02/2013	Doxorubicin; Doxorubicin + Panitumumab; Ifosfamide; Panitumumab	alkylating_agent; anti-EGFR_monoclonal_antibody; doxorubicin; anthracycline; anthracycline + anti-EGFR_monoclonal_antibody	Doxorubicin + Panitumumab	anthracycline + anti-EGFR_monoclonal_antibody	ENG2	A Phase 1/2 study to determine the effect of EGFR targeted Doxorubicin loaded EnGeneIC Delivery Vehicles (VEDVDox) on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM) Expressing Epidermal Growth Factor Receptor (EGFR)	Recurrent Glioblastoma Multiforme		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000297729
ACTRN12613000496718	P3BEP	Phase 3	Recruiting	NZ, TAS, ACT, WA, SA, VIC, QLD, NSW	3/05/2013	3/04/2014	Bleomycin; Bleomycin + Cisplatin + Etoposide + Filgrastim; Bleomycin + Cisplatin + Etoposide + Pegfilgrastim; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	topoisomerase_inhibitor; granulocyte_colony_stimulating_factor; antineoplastic_antibiotic; platinum-based_antineoplastic_agent; antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Bleomycin; Bleomycin + Cisplatin + Etoposide + Filgrastim; Bleomycin + Cisplatin + Etoposide + Pegfilgrastim	antineoplastic_antibiotic; antineoplastic_antibiotic + granulocyte_colony_stimulating_factor + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	Nil	In patients with intermediate and poor-risk metastatic germ cell tumours is an accelerated BEP chemotherapy regimen as good as, or better than, the standard BEP chemotherapy regimen for response rate.	Intermediate and poor-risk metastatic germ cell tumours (GCTs)	3690 - Wodonga; 6150 - Murdoch	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000496718
ACTRN12613000556741	ACTRN12613000556741		Stopped early	NT, ACT, WA, TAS, NSW, SA, QLD, VIC	17/05/2013	9/09/2013	Napabucasin; Placebo	placebo; cancer_stemness_inhibitor	Napabucasin	cancer_stemness_inhibitor	None	A randomised phase III double-blind study to evaluate the effect of BBI608 or placebo on overall survival in patients with pretreated advanced colorectal carcinoma	Advanced (metastatic or locally advanced) colorectal cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000556741
ACTRN12613000866707	ACTRN12613000866707	Phase 1 / Phase 2	Stopped early	QLD	6/08/2013	16/09/2015					Nil	Phase I/II open-label clinical trial of autologous Epstein-Barr virus-specific T cell therapy as consolidative treatment following chemotherapy for metastatic EBV-associated nasopharyngeal carcinoma.	Metastatic nasopharyngeal carcinoma		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613000866707
ACTRN12613001061729	PMCC-12-79	Phase 1	STATUS_UNKNOWN	VIC	23/09/2013	22/07/2013	Pidnarulex	RNA_polymerase_I_transcription_inhibitor	Pidnarulex	RNA_polymerase_I_transcription_inhibitor	Peter MacCallum Cancer Centre Protocol No. PMCC 12/79	A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CX-5461 in Patients with Advanced Haematologic Malignancies	Any advanced Haematologic Malignancy	3002 - East Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12613001061729
ACTRN12614000365662	ACTRN12614000365662	Phase 1	Recruiting	NZ	7/04/2014	28/04/2014	Oraxol; Oraxol + Paclitaxel; Paclitaxel	taxane	Oraxol + Paclitaxel; Paclitaxel	taxane	Nil	Patients with cancer for whom IV paclitaxel (at a dose of 80 mg/m2 IV over 1 hour) is indicated will be treated with intravenous paclitaxel and Oraxol (Paclitaxel + HM30181AK-US) to evaluate bioavailability, safety and tolerability of Oraxol.	Cancer	Dunedin	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000365662
ACTRN12614000612617	LL1	Phase 1 / Phase 2	Stopped early	SA	6/06/2014		Monepantel	anthelmintics	Monepantel	anthelmintics	LL1	A Phase I/II Study of the Tolerability, Safety and Pharmacokinetics of Oral Monepantel (MPL) in Individuals with Treatment-Refractory Solid Tumours.	Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000612617
ACTRN12614000789662	ACTRN12614000789662	Phase 2	Not yet recruiting	NSW	24/07/2014		Luminespib	HSP90_inhibitor	Luminespib	HSP90_inhibitor	Nil	A Randomised controlled Phase II trial of the pharmacodynamic effects of the heat shock protein 90 (Hsp90) inhibitor AUY922 in high-risk, localised prostate cancer	Prostate Cancer	2050 - Missenden Road	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614000789662
ACTRN12614001181695	BOSTON-II	Phase 1	Recruiting	VIC	11/11/2014	2/11/2015	Pembrolizumab; Radiotherapy	radiotherapy; anti-PD-1_monoclonal_antibody	Pembrolizumab; Radiotherapy	anti-PD-1_monoclonal_antibody; radiotherapy	Nil	A pilot study to assess the safety and feasibility of stereotactic ablative body radiosurgery combined with MK-3475 in patients with oligometastases from breast cancer.	Metastatic Breast Cancer (1-5 metastases)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001181695
ACTRN12614001248651	MesomiR-1	Phase 1	Recruiting	NSW	28/11/2014	29/09/2014	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs	glucocorticoid + miR-16_miRNA_mimic; miR-16_miRNA_mimic; glucocorticoid	Dexamethasone; Dexamethasone + TargomiRs; TargomiRs	glucocorticoid; glucocorticoid + miR-16_miRNA_mimic; miR-16_miRNA_mimic	Nil	MesomiR 1: A Phase I study of intravenously administered Epidermal Growth Factor Receptor (EGFR)-targeted, EnGeneIC Delivery Vehicle (EDV)-packaged, miR-16 mimic (TargomiRs) for patients with Malignant Pleural Mesothelioma (MPM) and advanced Non-Small Cell Lung Cancer (NSCLC) failing on standard therapy	Advanced Non Small Cell Lung Cancer; Malignant Pleural Mesothelioma	2050 - Camperdown; 2139 - Concord Repatriation Hospital; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001248651
ACTRN12614001292662	CLRX301-101	Phase 1 / Phase 2	Stopped early	NSW, VIC	11/12/2014	16/12/2014	CRLX301	docetaxel-loaded_nanopharmaceutical	CRLX301	docetaxel-loaded_nanopharmaceutical	CLRX301-101	Phase 1/2a Dose-Escalation Study of CRLX301 in Patients with Advanced Solid Tumor Malignancies	Solid Tumours; Taxane-naive castration resistant prostate cancer (CRPC)	2170 - Liverpool; 3165 - Bentleigh East; 2109 - Macquarie University	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12614001292662
ACTRN12615000504516	NAP-CAPABIL	Phase 2	NOT_RECRUITING	NSW	20/05/2015		Capecitabine; Capecitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel	taxane; antimetabolite; antimetabolite + taxane	Capecitabine + Nab-paclitaxel	antimetabolite + taxane	Nil	Patients with advanced biliary cancer to be treated with second line combination chemotherapy of NAB Paclitaxel and capecitabine in a single arm pilot study to assess feasibility	advanced biliary cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000504516
ACTRN12615000516583	ACTIVATE-trial	Phase 1	Stopped early	NSW	22/05/2015	3/09/2015	RGSH4K	anticancer_vaccine,autologous	RGSH4K	anticancer_vaccine,autologous	Nil	In patients with advanced solid tumours, is an autologous cancer vaccine (RGSH4K), safe and tolerable, and can a biologically active dose be identified?	Advanced solid tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000516583
ACTRN12615000571572	ACTRN12615000571572	Phase 1 / Phase 2	Stopped early	QLD	3/06/2015	23/03/2015	Metformin; Placebo	placebo; biguanide_antihyperglycaemic_agent	Metformin	biguanide_antihyperglycaemic_agent	Nil Known	The effectiveness of a combination of Metformin and Atrovastatin compared with each drug alone and placebo in modulating tumour aggressiveness in men with high risk prostate cancer undergoing radical prostatectomy	Prostate cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615000571572
ACTRN12615001072505	ACED	Phase 2	Stopped early	NSW, VIC, QLD, SA, WA, TAS	13/10/2015	19/07/2016	Acetazolamide; Dexamethasone; Placebo	carbonic_anhydrase_inhibitor; glucocorticoid; placebo	Acetazolamide	carbonic_anhydrase_inhibitor	Nil known	A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone – The ACED trial	Cerebral Oedema in recurrent, progressive and/or persistent High Grade Glioma	6009 - Nedlands; 5042 - Bedford Park; 2170 - Liverpool; 2010 - Darlinghurst; 7000 - Hobart; 3065 - Fitzroy; 3121 - Richmond; 4029 - Herston; 2217 - Kogarah; 2031 - Randwick; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001072505
ACTRN12615001088538	TIDAL-Melanoma	Phase 2	Recruiting	QLD	16/10/2015	6/01/2017	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod	topical_immune_response_modifier	Diphencyprone; Diphencyprone + Imiquimod; Imiquimod	topical_immune_response_modifier	Nil known	The effect of topical imiquimod or diphenylcyclopropenone on complete clinical response in patients with cutaneous in-transit melanoma metastases - A Phase II Single Centre Prospective Randomised Pilot Study.	Cutaneous in-transit melanoma metastases	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001088538
ACTRN12615001291572	FRAME	Phase 2	Stopped early	WA	26/11/2015	7/04/2016	AZD4547	FGFR1/2/3_inhibitor	AZD4547	FGFR1/2/3_inhibitor	None	A two stage, open-label, phase II trial assessing the efficacy of a single oral agent AZD4547 in malignant mesothelioma.	Malignant Mesothelioma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001291572
ACTRN12615001328561	DESNET2	Phase 2	Not yet recruiting		4/12/2015		Octreotide; Octreotide + Pasireotide; Pasireotide	somatostatin_analog	Octreotide + Pasireotide; Pasireotide	somatostatin_analog	Novartis Protocol Number: CSOM230FAU04T	Phase II study evaluating the efficacy of Pasireotide LAR (SOM230) dose escalation in patients with refractory non-functional GEP NETs	Gastro-entero-pancreatic neuroendocrine tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12615001328561
ACTRN12616000008426	ACTRN12616000008426		Recruiting	NSW	12/01/2016	3/06/2015	RX108	sodium-potassium_ATPase_inhibitor	RX108	sodium-potassium_ATPase_inhibitor	None	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.	Advanced or Metastatic Solid Tumours		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000008426
ACTRN12616000228482	ACT001-AU-001	Phase 1	Recruiting	NSW, VIC, SA	19/02/2016	19/09/2016	ACT001	NFKB_inhibitor	ACT001	NFKB_inhibitor	ACT001-AU-001 (Sponsor protocol code)	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors	Solid tumors	3004 - Melbourne; 3121 - Richmond; 2031 - Randwick; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000228482
ACTRN12616000420448	INTEGRATE-IIa	Phase 3	Recruiting	NSW, SA, VIC, QLD, NT, ACT, WA, NZ, TAS	1/04/2016	10/11/2016	Placebo; Regorafenib	PDGFR_inhibitor; KIT_inhibitor,first_generation; VEGFR_inhibitor; pan-FGFR_inhibitor; placebo; RET_inhibitor	Regorafenib	KIT_inhibitor,first_generation; PDGFR_inhibitor; RET_inhibitor; VEGFR_inhibitor; pan-FGFR_inhibitor	AG0315OG  CTC0140	A Randomised Phase III Double-Blind Placebo-Controlled Study to determine if regorafenib improves overall survival in refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Advanced (metastatic or locally recurrent) Gastro-Oesophageal Cancer (AGOC)	2485 - Tweed Heads; 2450 - Coffs Harbour; 6008 - Subiaco; 7000 - Hobart; 2250 - Gosford; 2010 - Darlinghurst; 2139 - Concord; 2605 - Garran; 3168 - Clayton; 2444 - Port Macquarie; 5042 - Bedford Park; 0810 - Tiwi; 6009 - Nedlands; 3690 - Wodonga; 2065 - St Leonards; 5037 - Kurralta Park; 3084 - Heidelberg; 4029 - Herston; 5011 - Woodville; 2305 - New Lambton Heights; 2217 - Kogarah; 2031 - Randwick; 3355 - Wendouree; 4814 - Douglas; 4575 - Birtinya; 3165 - East Bentleigh; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000420448
ACTRN12616000440426	PRIME001	Phase 1 / Phase 2	NOT_RECRUITING; STATUS_UNKNOWN	NSW	6/04/2016	21/02/2017	Carboplatin; Carboplatin + Decitabine; Decitabine	platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	Carboplatin + Decitabine	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent	None	Pilot Early phase II study of Decitabine and Carboplatin in patients with advanced melanoma	Metastatic melanoma	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000440426
ACTRN12616000958482	NABNEC	Phase 2	Recruiting	WA, NZ, TAS, NSW, SA, VIC, QLD	21/07/2016	17/11/2016	Carboplatin; Carboplatin + Nab-paclitaxel; Nab-paclitaxel	taxane; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent	Carboplatin + Nab-paclitaxel	platinum-based_antineoplastic_agent + taxane	AG0215NET	A phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.	Gastrointestinal Neuroendocrine Carcinomas		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616000958482
ACTRN12616001019493	MoST-addendum-2	Phase 2	NOT_RECRUITING	WA, NSW	2/08/2016	16/12/2016	Durvalumab; Durvalumab + Tremelimumab; Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	CTC0141 Addendum 2	Single arm, open label, signal seeking, phase IIa trial of the activity of Durvalumab (MEDI4736) in combination with Tremelimumab in patients with advanced rare or neglected cancers.	Cancer	2050 - Camperdown; 2217 - Kogarah; 6009 - Nedlands; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001019493
ACTRN12616001187437	MatchMel	Phase 2	Not yet recruiting	NSW	29/08/2016		Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	AXL_inhibitor; BCR-ABL1_inhibitor,second_generation; KIT_inhibitor,first_generation; VEGFR2_inhibitor; CRAF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation; VEGFR_inhibitor; ALK_inhibitor,second_generation; MET_inhibitor,type_2; MET_inhibitor,type_1; HDAC_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; MTORC1_inhibitor; FLT3_inhibitor; KIT_inhibitor,ATP-competitive; ERBB2_inhibitor,first_generation; SRC_inhibitor; ROS1_inhibitor; PARP_inhibitor; EGFR_inhibitor,type_II; CDK4/6_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; pan-FGFR_inhibitor; proteasome_inhibitor; KIT_inhibitor; ALK_inhibitor,first_generation; RET_inhibitor; YES1_inhibitor; EGFR_inhibitor,first_generation; anti-VEGFR2_monoclonal_antibody; MEK_inhibitor	Bortezomib; Cabozantinib; Ceritinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Olaparib; Palbociclib; Pazopanib; Ramucirumab; Regorafenib; Sorafenib; Sunitinib; Trametinib; Vorinostat	ALK_inhibitor,first_generation; ALK_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; EGFR_inhibitor,type_II; ERBB2_inhibitor,first_generation; FLT3_inhibitor; HDAC_inhibitor; KIT_inhibitor; KIT_inhibitor,ATP-competitive; KIT_inhibitor,first_generation; MEK_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_2; MTORC1_inhibitor; PARP_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; RET_inhibitor; ROS1_inhibitor; SRC_inhibitor; VEGFR2_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anti-VEGFR2_monoclonal_antibody; pan-FGFR_inhibitor; proteasome_inhibitor	Protocol Number MIA2015/174	Molecular profiling to identify patients with BRAF/NRAS wild type melanoma and the proportion of these patients that undergo matched targeted therapy as a result of extended molecular testing.	Metastatic Melanoma	2050 - Camperdown; 2145 - Westmead; 2065 - Wollstonecraft	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001187437
ACTRN12616001637437	ACTRN12616001637437	Phase 1	NOT_RECRUITING	ACT	25/11/2016	7/10/2016	Complete Freund’s Adjuvant; Pembrolizumab	immunopotentiator; anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	Nil known	Phase I Study of the safety of Complete Freund’s Adjuvant (CFA) in Patients with Refractory and Relapsed Solid Tumours	Solid Tumours	2605 - Garran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12616001637437
ACTRN12617000741381	Protocol-CA209-993ISR	Phase 1	Recruiting	SA, VIC, NSW	22/05/2017	31/08/2017	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	Protocol CA209-993ISR	Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study.	Renal Transplant; Cancer	2050 - Camperdown; 5000 - Adelaide; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000741381
ACTRN12617000855325	EMBRACE-study	Phase 2	Recruiting	SA, QLD, VIC, NSW, WA	9/06/2017	12/09/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	CTC0160	Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study	Triple negative breast cancer; High grade serous ovarian cancer	3000 - Melbourne; 6150 - Murdoch; 4029 - Herston; 2217 - Kogarah; 4217 - Benowa; 3355 - Wendouree; 4066 - Auchenflower; 5000 - Adelaide; 2450 - Coffs Harbour; 2640 - Albury; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617000855325
ACTRN12617001000392	MoST-Addendum-3	Phase 2	NOT_RECRUITING	NSW, SA	11/07/2017	21/11/2017	Durvalumab; Durvalumab + Olaparib; Olaparib	anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor	Durvalumab; Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Nil	Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects	Cancer	2050 - Camperdown; 2217 - Kogarah; 2010 - Darlinghurst; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001000392
ACTRN12617001181392	SP51616	Phase 1	Stopped early	NSW	11/08/2017	9/10/2017	A-337; A-337 + Dexamethasone; Dexamethasone	bispecific_CD3/EpCAM_antibody; glucocorticoid; bispecific_CD3/EpCAM_antibody + glucocorticoid	A-337; A-337 + Dexamethasone; Dexamethasone	bispecific_CD3/EpCAM_antibody; bispecific_CD3/EpCAM_antibody + glucocorticoid; glucocorticoid	SP51616	A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of A-337 in Patients with Advanced Solid Tumors	Cancer	2031 - Randwick; 2148 - Blacktown; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001181392
ACTRN12617001190392	PIT-Study	Phase 1 / Phase 2	STATUS_UNKNOWN	SA	15/08/2017		Irinotecan; Irinotecan + Panitumumab; Panitumumab; Trifluridine/Tipiracil	topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; Tipiracil Hydrochloride; thymidine_phosphorylase_inhibitor; antimetabolite; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; Trifluridine	Irinotecan + Panitumumab; Trifluridine/Tipiracil	Tipiracil Hydrochloride; Trifluridine; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor; antimetabolite; thymidine_phosphorylase_inhibitor	None	An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer	colorectal cancer	5011 - Woodville; 5042 - Bedford Park; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001190392
ACTRN12617001325392	DIAmOND	Phase 2	Recruiting	TAS, WA, SA, VIC, QLD, NSW	15/09/2017	22/11/2018	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody	Durvalumab; Durvalumab + Trastuzumab; Durvalumab + Trastuzumab + Tremelimumab; Durvalumab + Tremelimumab; Trastuzumab; Tremelimumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	BCT 1703	BCT 1703 (DIAmOND): An investigator-initiated, non-randomised, phase II study of combination CTLA-4 and PD-L1 blockade in advanced HER2-positive breast cancers who have progressed on prior trastuzumab-based therapy.	Advanced HER2-positive breast cancer	7000 - Hobart; 5042 - Bedford Park; 3084 - Heidelberg; 6150 - Murdoch; 3000 - Melbourne; 3550 - Bendigo; 2217 - Kogarah; 4575 - Birtinya; 4101 - South Brisbane; 2145 - Westmead	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001325392
ACTRN12617001573347	ZU545102--CA209-9KJ	Phase 1	NOT_RECRUITING	NSW, VIC, QLD, SA	22/11/2017	24/10/2017	Nivolumab; Nivolumab + Pixatimod; Pixatimod	angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; angiogenesis_inhibitor	Nivolumab + Pixatimod	angiogenesis_inhibitor + anti-PD-1_monoclonal_antibody	ZU545102  CA209-9KJ	An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer	Colorectal cancer; Advanced solid tumours; Pancreatic Cancer	4029 - Herston; 3004 - Prahran; 2065 - St Leonards; 5000 - Adelaide	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12617001573347
ACTRN12618000053224	PRIME002	Phase 2	NOT_RECRUITING	NSW, QLD	16/01/2018	22/03/2018	Avelumab; Azacitidine; Azacitidine + Carboplatin; Carboplatin	anti-PD-L1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	Avelumab; Azacitidine + Carboplatin	DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent	Nil known	PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy.	Immunotherapy resistant; Metastatic melanoma	2298 - Waratah; 4870 - Cairns	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000053224
ACTRN12618000233224	MONARCC	Phase 2	Recruiting	TAS, WA, VIC, QLD, SA, NSW	14/02/2018	16/07/2018	Fluorouracil; Panitumumab	anti-EGFR_monoclonal_antibody; antimetabolite	Panitumumab	anti-EGFR_monoclonal_antibody	AG0116CR / CTC 0151	MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.	metastatic colorectal cancer	3168 - Clayton; 2010 - Darlinghurst; 7000 - Hobart; 2485 - Tweed Heads; 2450 - Coffs Harbour; 3084 - Heidelberg; 2065 - St Leonards; 3690 - Wodonga; 5042 - Bedford Park; 4032 - Chermside; 3021 - St Albans; 4029 - Herston; 5011 - Woodville; 4102 - Woolloongabba; 2541 - Nowra; 4215 - Southport; 2747 - Kingswood; 4575 - Birtinya	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000233224
ACTRN12618000281291	MoST-Addendum-4	Phase 2	Recruiting	TAS, NT, ACT, WA, SA, QLD, VIC, NSW	22/02/2018	7/12/2018	Vismodegib	SMO_inhibitor,first_generation	Vismodegib	SMO_inhibitor,first_generation	CTC0141-addendum 4	Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations	Cancer	4102 - Woolloongabba; 2050 - Camperdown; 2217 - Kogarah; 3000 - Melbourne; 0810 - Tiwi; 6009 - Nedlands; 2605 - Garran; 7000 - Hobart; 5000 - Adelaide; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000281291
ACTRN12618000309280	ACTRN12618000309280	Phase 1 / Phase 2	Stopped early	NSW	1/03/2018	9/07/2018	67Cu-SARTATE; 67Cu-SARTATE + Octreotate; Octreotate	peptide_receptor_radionuclide_therapy; MeCOSar-Tyr3-octreotate_peptide_receptor_radionuclide_therapy; MeCOSar-Tyr3-octreotate_peptide_receptor_radionuclide_therapy + peptide_receptor_radionuclide_therapy	67Cu-SARTATE + Octreotate	MeCOSar-Tyr3-octreotate_peptide_receptor_radionuclide_therapy + peptide_receptor_radionuclide_therapy	None	Peptide Receptor Radionuclide Therapy administered to Participants with Meningioma with 67Cu-SARTATE™: A single-centre, open-label, nonrandomised, Phase I-IIa Theranostic Clinical Trial	Meningioma	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000309280
ACTRN12618000357257	MoST-Addendum-5	Phase 2	*NOT_RECRUITING	NSW, VIC, QLD, SA, WA, NT, ACT, TAS	9/03/2018	11/04/2019	Eribulin	macrocyclic_ketone_analogue	Eribulin	macrocyclic_ketone_analogue	CTC0141-addendum 5	Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas.	Angiosarcoma; Cancer 306453 0; Sarcoma	3000 - Melbourne; 2050 - Camperdown; 2217 - Kogarah; 4102 - Woolloongabba; 7000 - Hobart; 5000 - Adelaide; 2010 - Darlinghurst; 2605 - Garran; 0810 - Tiwi; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000357257
ACTRN12618000686202	SOLACE-2	Phase 2	Recruiting	NSW, SA, QLD, VIC, TAS	27/04/2018	8/05/2019	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib	alkylating_agent; PARP_inhibitor; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + alkylating_agent	Cyclophosphamide; Cyclophosphamide + Durvalumab + Olaparib; Cyclophosphamide + Olaparib; Durvalumab; Durvalumab + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + alkylating_agent + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; alkylating_agent; anti-PD-L1_monoclonal_antibody	CTC 0178 / ANZGOG 1723/2018	A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.	Peritoneal cancer; Fallopian tube cancer; Ovarian cancer	4101 - South Brisbane; 3000 - Melbourne; 2217 - Kogarah; 2031 - Randwick; 2050 - Camperdown; 2305 - New Lambton Heights; 2065 - St Leonards; 3050 - Parkville; 5042 - Bedford Park; 3199 - Frankston; 2650 - Wagga Wagga; 2250 - Gosford; 5000 - Adelaide; 2485 - Tweed Heads; 2450 - Coffs Harbour; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000686202
ACTRN12618000941268	PLA001	Phase 0	Recruiting	NSW	4/06/2018	21/02/2018	PLA2 inhibitor	PLA2_inhibitor			None	Safety, tolerability, and pharmacokinetics of single and multiple doses of a PLA2 inhibitor (c2) in men with prostate cancer: A Phase 0 and limited dose-escalation trial	Prostate Cancer	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000941268
ACTRN12618000954224	ICE-PAC	Phase 2	Recruiting	VIC	6/06/2018	1/12/2017	Avelumab; Avelumab + Radiotherapy; Radiotherapy	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + radiotherapy; radiotherapy	Avelumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + radiotherapy	MS100070-0082	A phase II study of Avelumab + stereotactic ablative body radiosurgery (SABR) for metastatic castration-resistant prostate cancer (mCRPC). To assess radiographic progression-free survival (rPFS).	Metastatic castration-resistant prostate cancer (mCRPC).	3128 - Box Hill; 3168 - Clayton	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618000954224
ACTRN12618001070224	AM-ATX101-01	Phase 1	Recruiting	WA, SA, NSW	27/06/2018	15/10/2018	ATX-101; Dexamethasone	cell_penetrating_peptide; glucocorticoid	ATX-101; Dexamethasone	cell_penetrating_peptide; glucocorticoid	AM ATX101-01	A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours	Advanced Solid Tumors	6009 - Nedlands; 5042 - Bedford Park; 5000 - Adelaide; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001070224
ACTRN12618001073291	LuPin	Phase 1	Recruiting	NSW	27/06/2018	4/12/2017	Idronoxil; Lutetium-177-PSMA-617	idronoxil_suppository; 177Lu-PSMA-radioconjugate	Idronoxil	idronoxil_suppository	Nil Known	Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil	Castrate-resistant prostate cancer	2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001073291
ACTRN12618001112257	AM-ATX101-02	Phase 1	Recruiting	WA, NSW, SA	5/07/2018	11/12/2018	ATX-101; Dexamethasone	cell_penetrating_peptide; glucocorticoid	ATX-101; Dexamethasone	cell_penetrating_peptide; glucocorticoid	AM ATX101-02	A long term follow up study, to evaluate the long term safety and efficacy, of single agent ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours	Advanced Solid Tumors	6009 - Nedlands; 5000 - Adelaide; 2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001112257
ACTRN12618001121257	POPCORN	Phase 1 / Phase 2	Recruiting	QLD	6/07/2018	22/05/2019	Denosumab; Denosumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Denosumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	20177440 Amgen ISS	Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial	Non-small cell lung cancer (NSCLC)	4029 - Herston; 4102 - Woolloongabba; 4032 - Chermside	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001121257
ACTRN12618001337268	ACTRN12618001337268	Not Applicable	Not yet recruiting		8/08/2018						None	The safety and efficacy of immunotherapy with the activited T cells from from umbilical cord blood mononuclear cells ex vivo for small cell lung cancer,Kidney cancer and Primary liver cancer treatment	Histopathologically confirmed Liver cancer; Histopathologically confirmed Kidney cancer; Histopathologically confirmed small cell lung cancer (SCLC)		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001337268
ACTRN12618001480279	ALT-TRACC	Phase 2	Recruiting	VIC	4/09/2018	6/09/2018	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin	platinum-based_antineoplastic_agent; folinic_acid; antimetabolite; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody; topoisomerase_inhibitor	Bevacizumab; Capecitabine; Fluorouracil; Irinotecan; Irinotecan + Oxaliplatin; Leucovorin; Oxaliplatin	anti-VEGF_monoclonal_antibody; antimetabolite; folinic_acid; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor	Nil known	Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial	Metastatic Colorectal Cancer	3076 - Epping; 3128 - Box Hill; 3084 - Heidelberg; 3011 - Footscray; 3844 - Traralgon; 3021 - St Albans; 3280 - Warrnambool; 3000 - Melbourne; 3065 - Fitzroy	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001480279
ACTRN12618001573246	CRIO	Phase 2	Not yet recruiting	QLD	20/09/2018		Carboplatin; Carboplatin + Durvalumab + Radiotherapy; Durvalumab; Radiotherapy	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy; platinum-based_antineoplastic_agent; radiotherapy	Carboplatin + Durvalumab + Radiotherapy	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + radiotherapy	Nil known	A prospective study investigating the efficacy and toxicity of definitive chemoradiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma	squamous cell carcinoma; skin cancer	4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001573246
ACTRN12618001742268	ILLUMINATE	Phase 2	Recruiting	SA, QLD, VIC, NSW, TAS, WA	23/10/2018	4/04/2019	Carboplatin; Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Cisplatin; Durvalumab; Durvalumab + Pemetrexed; Pemetrexed; Tremelimumab	anti-PD-L1_monoclonal_antibody + antimetabolite; anti-CTLA-4_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Durvalumab + Pemetrexed + Tremelimumab; Durvalumab + Pemetrexed	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite	CTC 0209  ALTG 16/009	A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE).	EGFR mutant advanced non small cell lung cancer.	2170 - Liverpool; 5042 - Bedford Park; 4032 - Chermside; 6009 - Nedlands; 3168 - Clayton; 7000 - Hobart; 2250 - Gosford; 4102 - Woolloongabba; 3065 - Fitzroy; 2200 - Bankstown; 2217 - Kogarah; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001742268
ACTRN12618001825246	2014-000259-99	Phase 2 / Phase 3	Recruiting	NZ, WA, SA, QLD, VIC, NSW	9/11/2018	25/11/2014	Carboplatin; Carboplatin + Etoposide; Cyclophosphamide; Cyclophosphamide + Topotecan; Docetaxel; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Temozolomide; Topotecan	antimetabolite; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; alkylating_agent; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; taxane	Carboplatin + Etoposide; Cyclophosphamide + Topotecan; Docetaxel + Gemcitabine + Irinotecan + Temozolomide; Ifosfamide	alkylating_agent; alkylating_agent + antimetabolite + taxane + topoisomerase_inhibitor; alkylating_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	RG_13-277  ISRCTN36453794  EudraCT Number: 2014-000259-99	International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	Ewing Sarcoma	3052 - Parkville; 6009 - Nedlands; 3168 - Clayton; 5006 - North Adelaide; 5000 - Adelaide; 2145 - Westmead; 4102 - Woolloongabba; 2305 - New Lambton; 2031 - Randwick; 2050 - Camperdown; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12618001825246
ACTRN12619000385145	ENG9	Phase 1 / Phase 2	Recruiting	NSW, VIC	12/03/2019	4/03/2019	PNU-159682	anthracycline	PNU-159682	anthracycline	Nil known	A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying an immunomodulator (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate.	Advanced Cancer (Solid Tumours); Pancreatic Cancer	3199 - Frankston; 2076 - Wahroonga	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000385145
ACTRN12619000566134	OXTOX	Phase 2	Recruiting	NSW	10/04/2019	28/01/2021	Ibudilast; Ibudilast + Oxaliplatin; Oxaliplatin	PDE4_inhibitor; PDE4_inhibitor + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent	Ibudilast + Oxaliplatin	PDE4_inhibitor + platinum-based_antineoplastic_agent	None	OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study	Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer	2800 - Orange; 2747 - Kingswood; 2139 - Concord; 2065 - St Leonards; 2500 - Wollongong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000566134
ACTRN12619000567123	EnzAdapt	Phase 1 / Phase 2	Recruiting	NSW	11/04/2019	29/08/2019	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	EnzAdapt	EnzAdapt: Feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer	castrate resistant prostate cancer; Prostate cancer	2430 - Taree; 2340 - Tamworth; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000567123
ACTRN12619000640101	ACTRN12619000640101	Phase 2	STATUS_UNKNOWN	NSW, QLD, VIC, ACT	30/04/2019	10/02/2020	PAX-1	sodium_arsenite	PAX-1	sodium_arsenite	None	A Phase 2, open label study of orally administered PAX-1 monotherapy in patients with recurrent glioblastoma.	Glioblastoma	3168 - Clayton; 2605 - Garran; 4120 - Greenslopes	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000640101
ACTRN12619000769189	ATTAC	Phase 1	Recruiting	WA	23/05/2019						None	A pilot study to evaluate the safety and immunogenicity of a personalised tumour neo-antigen peptide vaccine strategy in patients with completely resected non-small cell lung cancer.	Lung Cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000769189
ACTRN12619000844145	ALKternate	Phase 1 / Phase 2	Recruiting	VIC, NSW	13/06/2019	14/06/2019	Crizotinib; Crizotinib + Lorlatinib; Lorlatinib	ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation + MET_inhibitor,type_1; MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ROS1_inhibitor; ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1 + ROS1_inhibitor	Crizotinib + Lorlatinib; Lorlatinib	ALK_inhibitor,first_generation + ALK_inhibitor,third_generation; ALK_inhibitor,first_generation + ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,third_generation + MET_inhibitor,type_1; ALK_inhibitor,third_generation + ROS1_inhibitor; MET_inhibitor,type_1 + ROS1_inhibitor; ROS1_inhibitor	None	A single arm multi-centre translational proof of concept study investigating the safety and efficacy of alternating lorlatinib with crizotinib in a pre-treated advanced ALK-rearranged non-small cell lung cancer population with disease progression on a 2nd generation ALK tyrosine kinase inhibitor	ALK-rearranged advanced non-small cell lung cancer	3000 - Melbourne; 2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000844145
ACTRN12619000900112	AtTEnd	Phase 3	Not yet recruiting	WA, TAS, NZ, NSW, QLD, VIC, SA	27/06/2019		Atezolizumab; Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel; Paclitaxel; Placebo	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; taxane; placebo; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent	Atezolizumab + Carboplatin + Paclitaxel; Carboplatin; Carboplatin + Paclitaxel	anti-PD-L1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	IRFMN-EN-7556  CTC 0246  ANZGOG 1807/2019	Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer.	Endometrial Cancer	3083 - Bundoora; 4217 - Benowa; 4101 - South Brisbane; 2217 - Kogarah; 4029 - Herston; 3000 - Melbourne; 2170 - Liverpool; 3199 - Frankston; 4350 - Toowoomba; 6008 - Subiaco; 2640 - Albury; 7000 - Hobart; 3128 - Box Hill; 2298 - Waratah; 5000 - Adelaide; 5006 - North Adelaide; Auckland	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000900112
ACTRN12619001117101	CAPTURE	Phase 2	Recruiting	SA, VIC, QLD, NSW, NT, WA	12/08/2019	3/08/2020	Alpelisib; Alpelisib + Fulvestrant; Capecitabine; Fulvestrant; Goserelin	GnRH_analogue; antimetabolite; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; GnRH_agonist; PI3K_alpha_inhibitor	Alpelisib; Alpelisib + Fulvestrant; Goserelin	GnRH_agonist; GnRH_analogue; PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	BCT 1901	BCT 1901 (CAPTURE): A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.	Advanced Breast Cancer	3121 - Richmond; 4102 - Woolloongabba; 2747 - Kingswood; 2145 - Westmead; 3135 - Ringwood East; 2060 - North Sydney; 5011 - Woodville; 3280 - Warrnambool; 3000 - Melbourne; 5112 - Elizabeth Vale; 3199 - Frankston; 2170 - Liverpool; 0810 - Tiwi; 3844 - Traralgon; 2444 - Port Macquarie; 3168 - Clayton; 3350 - Ballarat Central; 2640 - Albury; 6008 - Subiaco; 2298 - Waratah; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001117101
ACTRN12619001147178	MoST-Addendum-6	Phase 2	Recruiting	VIC, QLD, SA, NSW, TAS, WA, NT, ACT	16/08/2019	2/11/2020	Larotrectinib	TRK_inhibitor,first_generation	Larotrectinib	TRK_inhibitor,first_generation	CTC0141-Addendum 6	Single arm, open label, signal seeking, phase IIa trial of the activity of Larotrectinib in patients with advanced NTRK1-3 positive tumours.	Cancer	2605 - Garran; 5000 - Adelaide; 2010 - Darlinghurst; 7000 - Hobart; 0810 - Tiwi; 6009 - Nedlands; 2217 - Kogarah; 2050 - Camperdown; 3000 - Melbourne; 4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001147178
ACTRN12619001185156	IGNITE	Phase 2	Recruiting	NSW, SA, VIC, QLD, WA, TAS	22/08/2019	26/03/2020	Adavosertib	WEE1_inhibitor	Adavosertib	WEE1_inhibitor	Nil known	A Phase II signal-seeking trial of Adavosertib (AZD1775) targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate.	Ovarian Cancer; Primary peritoneal cancer; Cancer of the falllopian tube	2065 - St Leonards; 6009 - Nedlands; 5042 - Bedford Park; 7000 - Hobart; 4101 - South Brisbane; 2145 - Westmead; 3000 - Melbourne; 2031 - Randwick; 2800 - Orange; 2050 - Camperdown; 3021 - St Albans	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001185156
ACTRN12619001265167	MoST-Addendum-8	Phase 2	Recruiting	VIC, QLD, SA, NSW, TAS, WA, ACT, NT	12/09/2019	25/06/2020	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate	CTC0141-addendum 8	Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations	Cancer	4102 - Woolloongabba; 3000 - Melbourne; 2050 - Camperdown; 2217 - Kogarah; 0810 - Tiwi; 6009 - Nedlands; 7000 - Hobart; 5000 - Adelaide; 2010 - Darlinghurst; 2605 - Garran	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001265167
ACTRN12619001298101	ASN-002-IL	Phase 2	Not yet recruiting	QLD	20/09/2019		Fluorouracil; Fluorouracil + Gusacitinib; Gusacitinib	SYK/JAK_inhibitor + antimetabolite; SYK/JAK_inhibitor; antimetabolite	Fluorouracil + Gusacitinib; Gusacitinib	SYK/JAK_inhibitor; SYK/JAK_inhibitor + antimetabolite	SP-002	A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas	Basal Cell Carcinoma; Basal Cell Nevus Syndrome (BCNS)	4000 - Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001298101
ACTRN12619001324101	ANTHEM	Phase 2	Recruiting	WA	27/09/2019	25/02/2020	Anamorelin; Placebo	placebo; Growth_hormone_secretagogue_receptor_agonist	Anamorelin	Growth_hormone_secretagogue_receptor_agonist	Nil known	A single centre phase II, randomised placebo controlled cross over study to examine the effect of anamorelin on cancer cachexia in patients with mesothelioma	Mesothelioma	6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001324101
ACTRN12619001407189	QB46C-H03--CTRI-2019-11-022032	Phase 1 / Phase 2	Recruiting	NSW, QLD	14/10/2019	29/11/2019	Tigilanol Tiglate	protein_kinase_C_regulator	Tigilanol Tiglate	protein_kinase_C_regulator	QB46C-H03  CTRI/2019/11/022032	Exploratory Phase Ib/IIa Study of Intratumourally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Squamous Cell Carcinoma	Head and neck squamous cell carcinoma.	4102 - Woolloongabba; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001407189
ACTRN12619001527156	CESTEM-1	Phase 1	Recruiting	QLD	5/11/2019	1/06/2017	Cetuximab; Cetuximab + Prochlorperazine; Prochlorperazine	anti-EGFR_monoclonal_antibody + antihistamine; antihistamine; anti-EGFR_monoclonal_antibody	Cetuximab + Prochlorperazine	anti-EGFR_monoclonal_antibody + antihistamine	None	Open-label Phase I study investigating the safety and efficacy of Cetuximab and prochlorperazine (STEMetil) combination therapy in patients with metastatic Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer (CESTEM study)	Cancer	4102 - Woolloongabba	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001527156
ACTRN12619001533189	FP101A	Phase 1	Recruiting	NSW	6/11/2019	9/03/2020	Fluorouracil; Fluorouracil + Leucovorin; Ifosfamide; Leucovorin	antimetabolite + folinic_acid; alkylating_agent; folinic_acid; antimetabolite	Fluorouracil + Leucovorin	antimetabolite + folinic_acid	TGA CT-2019-CTN-02849-1	A Phase 1 Study of Deflexifol: To determine pharmacokinetic (PK) in patients administered a combined dose of bolus and continuous 46hr infusion of Deflexifol in patients with advanced malignancy after failure of standard treatment	Advanced Malignant Cancer	2500 - Wollongong	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001533189
ACTRN12620000008921	CTIV1708	Phase 1	Recruiting	SA, VIC	8/01/2020	17/09/2020	MVR-T3011	oncolytic_HSV_virus	MVR-T3011	oncolytic_HSV_virus	Theravir Protocol Number: CTIV1708	A Phase I, Open-Label, Multiple Ascending Dose Study of the Safety and Tolerability of T3011 in advanced Cutaneous or Subcutaneous Malignancies	Any malignancy with cutaneous and/or subcutaneous tumours	3004 - St Kilda Road Melbourne; 5042 - Bedford Park; 3199 - Frankston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000008921
ACTRN12620000244909	VG161-A101	Phase 1	Recruiting	NSW, QLD, SA	26/02/2020	27/04/2020	VG-161	oncolytic_virus	VG-161	oncolytic_virus	VG161-A101	A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG161 in Subjects with Advanced Malignant Solid Tumors that are Refractory to Conventional Therapies	Advanced malignant solid tumors	4029 - Herston; 5042 - Bedford Park; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000244909
ACTRN12620000440921	ALMB-0168-AU-101	Phase 1	Recruiting	NSW, VIC, SA	6/04/2020	23/10/2020	ALMB-0168	anti-Cx43_agonist_antibody	ALMB-0168	anti-Cx43_agonist_antibody	ALMB-0168-AU-101	Phase 1, Multicenter, First-in-Human Dose Escalation Study of ALMB-0168 Administered IV as a Single Agent to Patients with Malignant Bone Disease	Osteosarcoma or any other solid tumor cancer with bone metastases	2031 - Randwick; 3199 - Frankston; 5042 - Bedford Park	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000440921
ACTRN12620000568910	MoST-Addendum-10	Phase 2	Recruiting	SA, QLD, VIC, NSW, TAS, NT, ACT, WA	15/05/2020	3/05/2021	Avelumab; Avelumab + Palbociclib; Palbociclib	CDK4/6_inhibitor; anti-PD-L1_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody	Avelumab; Avelumab + Palbociclib; Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	CTC0141-addendum 10	Single arm, open label, signal seeking, phase II trial of the activity of Palbociclib in combination with Avelumab in patients with tumours with amplified D-type cyclins or CDK4/6 or inactivation of CDKN2A.	Cancer	0810 - Tiwi; 6009 - Nedlands; 2605 - Garran; 5000 - Adelaide; 7000 - Hobart; 4102 - Woolloongabba; 2050 - Camperdown; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000568910
ACTRN12620000583943	EOHC-1001-01	Phase 1 / Phase 2	Not yet recruiting	VIC	20/05/2020		EO1001	EGFR_inhibitor; ERBB4_inhibitor; ERBB2_inhibitor	EO1001	EGFR_inhibitor; ERBB2_inhibitor; ERBB4_inhibitor	EOHC-1001-01	An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.	ErbB-1(EGFR) positive cancer; ERbB-4 (HER4) positive cancer; ErbB-2(HER2) positive cancer	3168 - Clayton; 3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000583943
ACTRN12620000592943	GQCT001--GQ1001X2101	Phase 1	Recruiting	NSW	21/05/2020	25/06/2020	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQCT001  GQ1001X2101	A Phase I, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously in Adult Patients with HER2-Positive Advanced Solid Tumors	HER2-Positive Advanced Solid Tumors	2031 - Randwick	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000592943
ACTRN12620000767909	MoST-Addendum-9	Phase 2	Recruiting	QLD, VIC, SA, NSW, TAS, WA, ACT, NT	27/07/2020		Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor,third_generation	Trastuzumab; Trastuzumab + Tucatinib; Tucatinib	ERBB2_inhibitor,third_generation; ERBB2_inhibitor,third_generation + anti-ERBB2_monoclonal_antibody; anti-ERBB2_monoclonal_antibody	CTC0141- addendum 9	Single arm, open label, signal seeking, phase II trial of the activity of tucatinib plus trastuzumab in patients with tumours harbouring HER2 amplifications or mutations	Cancer	2050 - Camperdown; 2217 - Kogarah; 3000 - Melbourne; 4102 - Woolloongabba; 2605 - Garran; 7000 - Hobart; 5000 - Adelaide; 2010 - Darlinghurst; 0810 - Tiwi; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000767909
ACTRN12620000849998	ACTRN12620000849998	Phase 1 / Phase 2	Recruiting	QLD, NSW	27/08/2020	12/05/2020	MG010; MG010 + Sorafenib; Sorafenib	KIT_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; FLT3_inhibitor; CRAF_inhibitor + VEGFR_inhibitor; PDGFR_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + FLT3_inhibitor; VEGFR_inhibitor; CRAF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor + PDGFR_inhibitor	MG010 + Sorafenib	CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor + CRAF_inhibitor; CRAF_inhibitor; CRAF_inhibitor + FLT3_inhibitor; CRAF_inhibitor + KIT_inhibitor; CRAF_inhibitor + PDGFR_inhibitor; CRAF_inhibitor + VEGFR_inhibitor	Nil	A phase I/II, open label, multi-centre study to assess the safety, tolerability, and efficacy of MG010 in combination with sorafenib in subjects with solid tumours who have failed existing treatments.	Metastatic solid tumours having failed existing treatments.	4101 - South Brisbane; 2050 - Camperdown; 2031 - Randwick; 2139 - Concord	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000849998
ACTRN12620000861954	MoST-Addendum-12	Phase 2	Recruiting	NSW	28/08/2020		Cobimetinib; Cobimetinib + Vemurafenib; Vemurafenib	BRAF_V600_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	Cobimetinib + Vemurafenib	BRAF_V600_inhibitor + MEK_inhibitor	CTC 0141 / ALTG 20/002 – addendum 12	Single arm, open label, phase II trial of vemurafenib and cobimetinib in patients with metastatic non-squamous non-small cell lung cancer and other tumours harbouring BRAF V600 mutations detected by comprehensive genomic profiling	Cancer; non-small cell lung cancer	2010 - Darlinghurst; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000861954
ACTRN12620000918921	MoST-addendum-7	Phase 2	Recruiting	NSW, QLD, VIC, SA, WA, ACT, NT, TAS	17/09/2020	30/11/2020	Tremelimumab	anti-CTLA-4_monoclonal_antibody	Tremelimumab	anti-CTLA-4_monoclonal_antibody	CTC0141 Addendum 7	Single arm, open label, signal seeking, phase IIa trial of the activity of Tremelimumab in patients with advanced rare or neglected cancers	cancer	6009 - Nedlands; 2065 - St Leonards; 0810 - Tiwi; 2010 - Darlinghurst; 5000 - Adelaide; 7000 - Hobart; 2605 - Garran; 4102 - Woolloongabba; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000918921
ACTRN12620000984998	MoST-Addendum-11	Phase 2	Recruiting	WA, ACT, NT, TAS, NSW, VIC, QLD, SA	30/09/2020	9/03/2021	Tildrakizumab	anti-IL-23_monoclonal_antibody	Tildrakizumab	anti-IL-23_monoclonal_antibody	CTC0141-addendum 11	Single arm, open label signal seeking, phase II trial to study the clinical activity of Tildrakizumab in patients with advanced osteosarcoma and soft tissue sarcomas	Cancer; Advanced Osteosarcoma; Soft Tissue Sarcoma	0810 - Tiwi; 6009 - Nedlands; 7000 - Hobart; 5000 - Adelaide; 2605 - Garran; 4102 - Woolloongabba; 3000 - Melbourne; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000984998
ACTRN12620001146987	ACTRN12620001146987	Phase 1	Recruiting	NSW, VIC, WA	2/11/2020		PMR-116	RNA_polymerase_I_transcription_inhibitor	PMR-116	RNA_polymerase_I_transcription_inhibitor	Nil known	Investigating the safety and tolerability of PMR-116 in Patients with Advanced Malignancies	Advanced solid tumours	6009 - Nedlands; 2031 - Randwick; 3000 - Melbourne; 3004 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001146987
ACTRN12620001198910	MODERN-LUNG	Phase 2	Recruiting	NSW	10/11/2020	15/04/2021	Carboplatin; Carboplatin + Paclitaxel; Durvalumab; Paclitaxel; Radiotherapy	taxane; radiotherapy; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel; Durvalumab; Radiotherapy	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; radiotherapy	CMNDRO-2005	Phase 2 Study of a Moderately Hypofractionated Schedule of Chemoradiation followed by Immunotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer	lung cancer	2170 - Liverpool; 2560 - Campbelltown; 2298 - Waratah; 2145 - Westmead; 2148 - Blacktown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001198910
ACTRN12621000093886	ACT001-AU-004	Phase 2	Not yet recruiting	VIC	1/02/2021		ACT001; ACT001 + Radiotherapy; Radiotherapy	NFKB_inhibitor; radiotherapy; NFKB_inhibitor + radiotherapy	ACT001 + Radiotherapy	NFKB_inhibitor + radiotherapy	ACT001-AU-004	A Phase 2, open label, multicentre study assessing the safety and efficacy of ACT001 in combination with whole brain radiation therapy (WBRT) for brain metastases from solid tumours.	Metastatic Brain Cancer; Solid Tumours	3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000093886
ACTRN12621000156886	ACE-IT001	Phase 1 / Phase 2	Not yet recruiting	NSW	15/02/2021		Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Perindopril	anti-CTLA-4_monoclonal_antibody; ACE_inhibitor; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab; Perindopril	ACE_inhibitor; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NONE	A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma- ACE-IT 001	Melanoma - Metastatic; Melanoma - Unresectable		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000156886
ACTRN12621000269831	HYNOVA	Not Applicable	Not yet recruiting	VIC, QLD, NSW	11/03/2021		Cisplatin	platinum-based_antineoplastic_agent	Cisplatin	platinum-based_antineoplastic_agent	CTC 0302  ANZGOG 1901 /2020	The safety of hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer (HYNOVA).	Ovarian cancer; Primary peritoneal cancer; Fallopian tube cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000269831
ACTRN12621000273886	ADELE	Phase 2	Not yet recruiting	NSW, VIC	11/03/2021		Carboplatin; Carboplatin + Paclitaxel + Tislelizumab; Paclitaxel; Tislelizumab	taxane; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent	Carboplatin + Paclitaxel + Tislelizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	ANZGOG 1910/2020  CTC0299	The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial	Endometrial Cancer	3052 - Parkville; 2031 - Randwick; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000273886
ACTRN12621000284864	MoST-Addendum-13	Phase 2	Recruiting	SA, QLD, VIC, NSW, TAS, NT, ACT, WA	16/03/2021		Entrectinib	ROS1_inhibitor; ALK_inhibitor,third_generation; TRK_inhibitor,first_generation	Entrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,first_generation	CTC0141-addendum 13	A single-arm, open-label, phase II trial of the tumour response to entrectinib in patients with advanced tumours harbouring NTRK fusions or ROS1 gene rearrangements detected by comprehensive genomic profiling	Cancer	2145 - Westmead; 4102 - Woolloongabba; 3065 - Fitzroy; 3000 - Melbourne; 0810 - Tiwi; 2065 - St Leonards; 6009 - Nedlands; 4032 - Chermside; 2605 - Garran; 5000 - Adelaide; 7000 - Hobart	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000284864
ACTRN12621000312842	MoST-Addendum-14	Phase 2	Recruiting	QLD, VIC, SA, NSW, TAS, WA, ACT	22/03/2021	3/09/2021	Alectinib	ALK_inhibitor,second_generation	Alectinib	ALK_inhibitor,second_generation	CTC 0141 – addendum 14	A Single arm, open label, phase II trial of tumour response to alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling	Cancer; ALK gene alterations; Non-small cell lung cancer	2065 - St Leonards; 6009 - Nedlands; 7000 - Hobart; 5000 - Adelaide; 4102 - Woolloongabba; 2145 - Westmead; 2217 - Kogarah; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000312842
ACTRN12621000479808	ATTACK-1-trial	Phase 1	Recruiting	NSW, VIC, SA	22/04/2021	16/06/2021	Auceliciclib; Auceliciclib + Temozolomide; Ifosfamide; Temozolomide	alkylating_agent; CDK4/6_inhibitor; CDK4/6_inhibitor + alkylating_agent	Auceliciclib; Auceliciclib + Temozolomide	CDK4/6_inhibitor; CDK4/6_inhibitor + alkylating_agent	Nil known	A Phase 1a/b, open-label, dose-exploration, combination/ expansion study to evaluate the safety, tolerability and pharmacokinetics of Auceliciclib in advanced solid tumours and in combination with temozolomide in recurrent or newly diagnosed Glioblastoma multiforme (GBM).	Ovarian cancer; Glioblastoma multiforme (GBM); Solid tumors; Colorectal cancer; Cancer	5042 - Bedford Park; 2170 - Liverpool; 3084 - Heidelberg	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000479808
ACTRN12621000507886	MoST-Addendum-15	Phase 2	Recruiting	QLD, SA	30/04/2021	7/09/2021	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab	BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Acalabrutinib; Acalabrutinib + Durvalumab; Durvalumab	BTK_inhibitor; BTK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	CTC0141- addendum 15	A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma	High grade B cell lymphoma; Cancer	5000 - Adelaide; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000507886
ACTRN12621000611820	PICAASO	Phase 2	Not yet recruiting	NSW, VIC	21/05/2021		Dasatinib	BCR-ABL1_inhibitor,second_generation; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor; KIT_inhibitor	Dasatinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	Nil Known	Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction	metastatic castration-resistant prostate cancer	3000 - Melbourne; 2010 - Darlinghurst	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000611820
ACTRN12621000639820	PARAGON-II	Phase 2	Not yet recruiting	NSW, QLD, VIC, WA, TAS	28/05/2021		Alpelisib; Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib; Ribociclib	PI3K_alpha_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor + aromatase_inhibitor; CDK4/6_inhibitor	Alpelisib + Letrozole; Letrozole; Letrozole + Ribociclib	CDK4/6_inhibitor + aromatase_inhibitor; PI3K_alpha_inhibitor + aromatase_inhibitor; aromatase_inhibitor	None	The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .	Platinum resistant high-grade epithelial cancers of ovary; Endometrial cancer; Other gynaecological cancers (excluding endometrial cancers); Platinum resistant high-grade epithelial cancers of fallopian tube; Platinum resistant high-grade epithelial cancers of primary peritoneum; Endometrial stromal sarcomas; Leiomyosarcomas; Low grade epithelial cancers of ovary; Granulosa cell tumours	4029 - Herston; 3000 - Melbourne; 2050 - Camperdown; 2305 - New Lambton Heights; 2217 - Kogarah; 2031 - Randwick; 4101 - South Brisbane; 2145 - Westmead; 7000 - Hobart; 2640 - Albury; 3168 - Clayton; 6009 - Nedlands; 2065 - St Leonards; 3052 - Parkville	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000639820
ACTRN12621000747820	TaxAdapt	Phase 1 / Phase 2	Not yet recruiting	NSW	11/06/2021		Docetaxel	taxane	Docetaxel	taxane	Nil known	TaxAdapt: Feasibility, acceptability and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer	Castration-resistant prostate cancer	2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000747820
ACTRN12621000762853	ACTRN12621000762853	Phase 1	Recruiting	QLD	18/06/2021	21/07/2021	Cyclophosphamide; Cyclophosphamide + Fludarabine + Tisagenlecleucel; Fludarabine; Tisagenlecleucel	CD19-directed_CAR_T_cell + alkylating_agent + antimetabolite; CD19-directed_CAR_T_cell; antimetabolite; alkylating_agent	Cyclophosphamide + Fludarabine + Tisagenlecleucel; Tisagenlecleucel	CD19-directed_CAR_T_cell; CD19-directed_CAR_T_cell + alkylating_agent + antimetabolite	None	Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy	B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.	4029 - Herston; 4029 - Royal Brisbane Hospital	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000762853
ACTRN12621000802808	LU-TEMP	Phase 2	Not yet recruiting	NSW	25/06/2021		Temozolomide	alkylating_agent	Temozolomide	alkylating_agent	Nil	A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults.	Cancer	2065 - St Leonards	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000802808
ACTRN12621000811808	MoST-Addendum-17	Phase 2	Recruiting	NSW, SA, QLD, VIC, ACT, NT, WA, TAS	28/06/2021	9/11/2021	Tepotinib	MET_inhibitor,type_1	Tepotinib	MET_inhibitor,type_1	CTC0141- addendum 17	A single arm, open label, signal-seeking, phase II trial of tepotinib in patients with advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations detected by comprehensive genomic profiling	Advanced non-small cell lung cancer harbouring MET exon 14 skipping mutations	3084 - Heidelberg; 4032 - Chermside; 0810 - Tiwi; 6009 - Nedlands; 2065 - St Leonards; 2605 - Garran; 7000 - Hobart; 5000 - Adelaide; 4102 - Woolloongabba; 2145 - Westmead; 3065 - Fitzroy; 2217 - Kogarah; 3000 - Melbourne	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000811808
ACTRN12621000991819	PDCCiHNC	Not Applicable	Not yet recruiting	NSW	28/07/2021		Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	anthracycline; doxorubicin; PDGFR_inhibitor; PDGFRA_inhibitor; JAK1/JAK2_inhibitor; MET_inhibitor,type_1; taxane; azole_antifungal; topoisomerase_inhibitor; VEGFR_inhibitor; PI3K/mTOR_inhibitor; ATR_inhibitor; CRAF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; BCR-ABL1_inhibitor,second_generation; EGFR_inhibitor,first_generation; YES1_inhibitor; MTORC1/MTORC2_inhibitor; vinca_alkaloid; ALK_inhibitor,first_generation; KIT_inhibitor; CDK4/6_inhibitor; ROS1_inhibitor; antimetabolite; SRC_inhibitor; platinum-based_antineoplastic_agent; antifolate; FLT3_inhibitor	Carboplatin; Ceralasertib; Cisplatin; Crizotinib; Dactolisib; Dasatinib; Docetaxel; Doxorubicin; Erlotinib; Etoposide; Fluorouracil; Gemcitabine; Itraconazole; Methotrexate; Paclitaxel; Palbociclib; Pemetrexed; Ruxolitinib; Sorafenib; Vinorelbine; Vistusertib	ALK_inhibitor,first_generation; ATR_inhibitor; BCR-ABL1_inhibitor,second_generation; CDK4/6_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; EGFR_inhibitor,first_generation; FLT3_inhibitor; JAK1/JAK2_inhibitor; KIT_inhibitor; MET_inhibitor,type_1; MTORC1/MTORC2_inhibitor; PDGFRA_inhibitor; PDGFR_inhibitor; PI3K/mTOR_inhibitor; ROS1_inhibitor; SRC_inhibitor; VEGFR_inhibitor; YES1_inhibitor; anthracycline; antifolate; antimetabolite; azole_antifungal; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor; vinca_alkaloid	Nil known	A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC)	Head and Neck Carcinoma	2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000991819
ACTRN12621001155886	PRIME005	Phase 1 / Phase 2	Recruiting	QLD, NSW	27/08/2021	13/09/2021	Azacitidine; Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Carboplatin; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; DNA_methyltransferase_inhibitor; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent	Azacitidine + Carboplatin; Azacitidine + Carboplatin + Ipilimumab + Nivolumab; Ipilimumab + Nivolumab	DNA_methyltransferase_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; DNA_methyltransferase_inhibitor + platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	CA184-602	Phase Ib/II study of safety and clinical response to Azacitidine and Carboplatin priming for Ipilimumab and Nivolumab re-challenge in patients with advanced melanoma who are resistant to immunotherapy.	Advanced Melanoma	2298 - Waratah West; 4870 - Cairns; 2298 - Waratah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001155886
ACTRN12621001172897	ACT001-AU-001	Phase 1	Recruiting	VIC, SA, NSW	31/08/2021	15/04/2021	ACT001; ACT001 + Pembrolizumab; Pembrolizumab	NFKB_inhibitor; anti-PD-1_monoclonal_antibody; NFKB_inhibitor + anti-PD-1_monoclonal_antibody	ACT001 + Pembrolizumab	NFKB_inhibitor + anti-PD-1_monoclonal_antibody	ACT001-AU-001 (Sponsor protocol code) - PART B	A phase 1 dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of ACT001 in patients with advanced solid tumors (PART B).	Glioblastoma Multiforme	5042 - Bedford Park; 2031 - Randwick; 3121 - Richmond	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001172897
ACTRN12621001183875	MoST-Addendum-16	Phase 2	Recruiting	QLD, SA	3/09/2021		Pamiparib	PARP_inhibitor	Pamiparib	PARP_inhibitor	CTC0141- addendum 16	Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/ refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function.	Cancer	5000 - Adelaide; 4029 - Herston	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001183875
ACTRN12621001225808	MoST-Addendum-18	Phase 2	Recruiting	NSW	13/09/2021		Carboplatin; Carboplatin + Cisplatin + Etoposide; Cisplatin; Durvalumab; Etoposide	topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Etoposide; Durvalumab	anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor	CTC0141- addendum 18	A single-arm, open-label, signal-seeking, phase II trial of durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma	Extra-pulmonary small cell carcinoma	2050 - Camperdown; 2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001225808
ACTRN12621001342808	CL001-559	Phase 1	Recruiting	WA, NSW, SA, VIC	7/10/2021	2/08/2021	CCX559	PD-L1_inhibitor,oral	CCX559	PD-L1_inhibitor,oral	CL001_559	A Phase 1 First In Human, Multicenter, Open label Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In Subjects With Solid Tumors	Neoplastic Disorder - Solid Tumors	3144 - Malvern	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001342808
ACTRN12621001347853	SPEAR	Phase 2	Not yet recruiting	VIC, QLD, SA, NSW, WA	7/10/2021		Sulfasalazine	SLC7A11_inhibitor	Sulfasalazine	SLC7A11_inhibitor	None	A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma	Pancreatic cancer		https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001347853
ACTRN12621001403820	IMBO-Pilot-study	Phase 2	Not yet recruiting	VIC, NSW	18/10/2021		Dexamethasone; Placebo	placebo; glucocorticoid	Dexamethasone	glucocorticoid	054/20	A phase II, multi-site, double blind, randomised placebo-controlled feasibility trial of crushed oral famotidine for management of Inoperable Malignant Bowel Obstruction (IMBO)	Malignant Bowel Obstruction; Bowel Obstruction; Bowel cancer	2176 - Prairiewood; 2010 - Darlinghurst; 3084 - Heidelberg; 2170 - Liverpool; 2217 - Kogarah	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001403820
ACTRN12621001419853	OP-1250-002	Phase 1	Not yet recruiting	WA, NSW, QLD, VIC	21/10/2021		Fulvestrant; Fulvestrant + Palbociclib; OP-1250; OP-1250 + Palbociclib; Palbociclib	complete_estrogen_receptor_antagonist; CDK4/6_inhibitor; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + complete_estrogen_receptor_antagonist	Fulvestrant + Palbociclib; OP-1250; OP-1250 + Palbociclib	CDK4/6_inhibitor + complete_estrogen_receptor_antagonist; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; complete_estrogen_receptor_antagonist	OP-1250-002	A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer	Breast Cancer	3168 - Clayton; 6000 - Perth; 3220 - Geelong; 4101 - South Brisbane	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001419853
ACTRN12621001436864	CTB-02-01	Phase 1 / Phase 2	Not yet recruiting	NSW	25/10/2021		Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib	anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; CDK4/6_inhibitor; MEK_inhibitor	Cetuximab; Cetuximab + Cobimetinib + Palbociclib; Cobimetinib; Palbociclib	CDK4/6_inhibitor; CDK4/6_inhibitor + MEK_inhibitor + anti-EGFR_monoclonal_antibody; MEK_inhibitor; anti-EGFR_monoclonal_antibody	CTB-02-01	A two-part open label Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the combination of cetuximab, cobimetinib and palbociclib in subjects with K-RAS wild-type BRAF V600E mutated, or K-RAS mutated, advanced or metastatic colorectal cancer who have failed all available standard therapies	Colorectal Cancer	2298 - Waratah; 2050 - Camperdown	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001436864
ACTRN12621001458820	CHARMM	Phase 1	Not yet recruiting	NSW	26/10/2021		Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Dexamethasone; Hydroxychloroquine	anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid + proteasome_inhibitor; glucocorticoid; anti-malarial_agent; proteasome_inhibitor	Carfilzomib; Carfilzomib + Dexamethasone; Carfilzomib + Dexamethasone + Hydroxychloroquine; Hydroxychloroquine	anti-malarial_agent; anti-malarial_agent + glucocorticoid + proteasome_inhibitor; glucocorticoid + proteasome_inhibitor; proteasome_inhibitor	none	Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib	Myeloma; Cancer	2170 - Liverpool	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001458820
ACTRN12621001537842	NOX66-IS-002--CA209-66P,	Phase 1 / Phase 2	Recruiting	NSW	10/11/2021	25/10/2021	Idronoxil; Idronoxil + Nivolumab; Nivolumab	idronoxil_suppository; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository	Idronoxil; Idronoxil + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + idronoxil_suppository; idronoxil_suppository	NOX66-IS-002  CA209-66P,	Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours – a pilot study (IONIC-1).	Patients with solid tumours	2076 - Wahroonga; 2217 - Kogarah; 2148 - Blacktown; 2228 - Miranda	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001537842
ACTRN12621001690842	MoST-addendum-19	Phase 2	Not yet recruiting	SA, VIC, NSW, TAS, WA	10/12/2021		Sotorasib	KRAS_G12C_inhibitor	Sotorasib	KRAS_G12C_inhibitor	CTC 0141 – addendum 19	Single arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation.	Cancer	3000 - Melbourne; 2145 - Westmead; 7000 - Hobart; 2010 - Darlinghurst; 5000 - Adelaide; 6009 - Nedlands	https://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621001690842
NCT01728155	LINES	Phase 3	Recruiting		13/11/2012	1/12/2011	Isotretinoin; Isotretinoin + Radiotherapy; Radiotherapy	13-cis-retinoic_acid + radiotherapy; 13-cis-retinoic_acid; radiotherapy	Isotretinoin + Radiotherapy	13-cis-retinoic_acid + radiotherapy	LINES	European Low and Intermediate Risk Neuroblastoma Protocol	LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES		https://clinicaltrials.gov/ct2/show/NCT01728155
NCT01791387	DILIGENCE-1	Phase 2	Unknown status	NZ	15/02/2013	1/03/2012	Dovitinib	FGFR1/2/3_inhibitor; VEGFR_inhibitor; PDGFRB_inhibitor	Dovitinib	FGFR1/2/3_inhibitor; PDGFRB_inhibitor; VEGFR_inhibitor	ACTRN12612000140853  CTKI258AAU02T	Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study	Clear Cell Renal Cell Carcinoma	Auckland	https://clinicaltrials.gov/ct2/show/NCT01791387
NCT01878617	NCI-2013-01125--SJMB12	Phase 2	Recruiting	QLD, VIC, NSW, NZ, WA	17/06/2013	23/06/2013	Cisplatin; Cisplatin + Cyclophosphamide + Gemcitabine + Pemetrexed + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine + Vismodegib; Cyclophosphamide; Gemcitabine; Pemetrexed; Radiotherapy; Vincristine; Vismodegib	SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; antimetabolite; platinum-based_antineoplastic_agent; alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; alkylating_agent; vinca_alkaloid; radiotherapy; alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; SMO_inhibitor,first_generation	Cisplatin + Cyclophosphamide + Gemcitabine + Pemetrexed + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine; Cisplatin + Cyclophosphamide + Radiotherapy + Vincristine + Vismodegib	SMO_inhibitor,first_generation + alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; alkylating_agent + antimetabolite + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid; alkylating_agent + platinum-based_antineoplastic_agent + radiotherapy + vinca_alkaloid	NCI-2013-01125  SJMB12	A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma	Medulloblastoma	1142 - Auckland - Starship Children's Hospital; 2031 - Randwick - Sydney Children's Hospital - (Active, not recruiting); 2145 - Westmead - Children's Hospital at Westmead; 3052 - Melbourne - Royal Children's Hospital, Melbourne; 4029 - Brisbane - Queensland Children's Hospital; 6008 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT01878617
NCT01953926	SUMMIT	Phase 2	Recruiting	VIC	1/10/2013	30/09/2013	Fulvestrant; Fulvestrant + Neratinib + Trastuzumab; Neratinib; Neratinib + Trastuzumab; Trastuzumab	ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody; selective_estrogen_receptor_degrader; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody; ERBB3_inhibitor; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB2_inhibitor; EGFR_inhibitor,second_generation; anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader	Fulvestrant + Neratinib + Trastuzumab; Neratinib; Neratinib + Trastuzumab	EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody; EGFR_inhibitor,second_generation + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB2_inhibitor; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody; ERBB2_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; ERBB3_inhibitor; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody; ERBB3_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader	2013-002872-42  PUMA-NER-5201	An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations	Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations	8006 - East Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT01953926
NCT02051868	InterAACT	Phase 2	Unknown status	NSW	31/01/2014	1/12/2013	Carboplatin; Carboplatin + Paclitaxel; Cisplatin; Cisplatin + Fluorouracil; Fluorouracil; Paclitaxel	taxane; antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane; antimetabolite; platinum-based_antineoplastic_agent	Carboplatin + Paclitaxel; Cisplatin + Fluorouracil	antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + taxane	2013-001949-13  CCR 3847 InterAACT	An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease	Squamous Cell Carcinoma of the Anus	NSW 1450 - Sydney - Margot Gorzeman - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT02051868
NCT02132754	4166-001	Phase 1	NOT_RECRUITING	NSW	5/05/2014	27/06/2014	MK-4166; MK-4166 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-GITR_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	MK-4166; MK-4166 + Pembrolizumab	anti-GITR_monoclonal_antibody; anti-GITR_monoclonal_antibody + anti-PD-1_monoclonal_antibody	4166-001	Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies	Solid Tumor	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02132754
NCT02135042	NCI-2014-00635--NRG-HN001	Phase 2/Phase 3	Recruiting	VIC	9/05/2014	1/04/2014	Cisplatin; Cisplatin + Fluorouracil; Fluorouracil; Gemcitabine; Gemcitabine + Paclitaxel; Paclitaxel; Radiotherapy	taxane; antimetabolite + platinum-based_antineoplastic_agent; radiotherapy; antimetabolite + taxane; antimetabolite; platinum-based_antineoplastic_agent	Cisplatin + Fluorouracil; Gemcitabine + Paclitaxel	antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + taxane	NCI-2014-00635  NRG-HN001	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	Stage III Nasopharyngeal Carcinoma; Epstein-Barr Virus Infection; Stage II Nasopharyngeal Carcinoma; Stage IVA Nasopharyngeal Carcinoma; Stage IVB Nasopharyngeal Carcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT02135042
NCT02215447	NABNEC	Phase 2	Unknown status	NSW, VIC	13/08/2014	1/05/2015	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel	taxane; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent	Carboplatin + Nab-paclitaxel + Paclitaxel	platinum-based_antineoplastic_agent + taxane	ALCC 14.01	A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas	Gastrointestinal Neuroendocrine Carcinomas	2065 - St Leonards - Royal North Shore Hospital; 3050 - Parkville - Royal Melbourne Hospital; 3220 - Geelong - Barwon Health	https://clinicaltrials.gov/ct2/show/NCT02215447
NCT02216487	Chime	Phase 2	Unknown status	NSW, VIC	15/08/2014	1/06/2014	Cetuximab; Cetuximab + Irinotecan; Irinotecan	topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	Cetuximab + Irinotecan	anti-EGFR_monoclonal_antibody + topoisomerase_inhibitor	ACO-004	Phase II Single Arm Trial of FOLF(HA)Iri Plus Cetuximab in Irinotecan-naïve Second Line Patients With KRAS Wild Type Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	1871 - Sydney - Liverpool Hospital - (Not yet recruiting); 2500 - Wollongong - Southern Medical Day Care Centre - (Not yet recruiting); 3021 - Melbourne - Western General Hospital	https://clinicaltrials.gov/ct2/show/NCT02216487
NCT02233049	BIOMEDE	Phase 2	Recruiting		5/09/2014	1/10/2014	Dasatinib; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus; Erlotinib; Everolimus	EGFR_inhibitor,first_generation + SRC_inhibitor; EGFR_inhibitor,first_generation + MTORC1_inhibitor + YES1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor + MTORC1_inhibitor; KIT_inhibitor + MTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation; EGFR_inhibitor,first_generation + MTORC1_inhibitor + PDGFRA_inhibitor; BCR-ABL1_inhibitor,second_generation + MTORC1_inhibitor; PDGFRA_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + MTORC1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; SRC_inhibitor; MTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; EGFR_inhibitor,first_generation; YES1_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; KIT_inhibitor; EGFR_inhibitor,first_generation + MTORC1_inhibitor + SRC_inhibitor; MTORC1_inhibitor + PDGFRA_inhibitor; MTORC1_inhibitor + SRC_inhibitor; MTORC1_inhibitor + YES1_inhibitor	Dasatinib; Dasatinib + Erlotinib; Dasatinib + Erlotinib + Everolimus; Dasatinib + Everolimus	BCR-ABL1_inhibitor,second_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation; BCR-ABL1_inhibitor,second_generation + EGFR_inhibitor,first_generation + MTORC1_inhibitor; BCR-ABL1_inhibitor,second_generation + MTORC1_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor; EGFR_inhibitor,first_generation + KIT_inhibitor + MTORC1_inhibitor; EGFR_inhibitor,first_generation + MTORC1_inhibitor + PDGFRA_inhibitor; EGFR_inhibitor,first_generation + MTORC1_inhibitor + SRC_inhibitor; EGFR_inhibitor,first_generation + MTORC1_inhibitor + YES1_inhibitor; EGFR_inhibitor,first_generation + PDGFRA_inhibitor; EGFR_inhibitor,first_generation + SRC_inhibitor; EGFR_inhibitor,first_generation + YES1_inhibitor; KIT_inhibitor; KIT_inhibitor + MTORC1_inhibitor; MTORC1_inhibitor + PDGFRA_inhibitor; MTORC1_inhibitor + SRC_inhibitor; MTORC1_inhibitor + YES1_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	2014/2126  2014-001929-32	Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication	Diffuse Intrinsic Pontine Glioma		https://clinicaltrials.gov/ct2/show/NCT02233049
NCT02254785	OZM-054	Phase 2	Unknown status	VIC	2/10/2014	1/10/2014	Abiraterone; Abiraterone + Enzalutamide; Cabazitaxel; Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; taxane; CYP17A1_inhibitor; antiandrogen,nonsteroidal,second_generation	Abiraterone + Enzalutamide; Cabazitaxel	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; taxane	OZM-054	A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer	Metastatic Castration-Resistant Prostatic Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; 3128 - Box Hill - Box Hill Hospital; 3168 - Clayton - Monash Health-Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT02254785
NCT02358356	CONTROL-NETS	Phase 2	Unknown status	QLD, VIC, NSW, WA	9/02/2015	1/11/2015	Capecitabine; Capecitabine + Octreotate + Temozolomide; Capecitabine + Temozolomide; Octreotate; Temozolomide	alkylating_agent + antimetabolite; antimetabolite; alkylating_agent + antimetabolite + peptide_receptor_radionuclide_therapy; alkylating_agent; peptide_receptor_radionuclide_therapy	Capecitabine + Octreotate + Temozolomide; Capecitabine + Temozolomide; Octreotate	alkylating_agent + antimetabolite; alkylating_agent + antimetabolite + peptide_receptor_radionuclide_therapy; peptide_receptor_radionuclide_therapy	CTC0120 / AG0114NET	Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study	Pancreatic Neuroendocrine Tumours; Midgut Neuroendocrine Tumours	2065 - St Leonards - Royal North Shore Hospital; 4029 - Herston - Royal Brisbane and Women's Hospital; 6150 - Murdoch - Fiona Stanley Hospital; 8006 - East Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT02358356
NCT02365441	ALT-GIST	Phase 2	Unknown status	TAS, ACT, WA, SA, VIC, QLD, NSW	19/02/2015	1/02/2015	Imatinib; Imatinib + Regorafenib; Regorafenib	KIT_inhibitor + VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + VEGFR_inhibitor; PDGFR_inhibitor; PDGFRA_inhibitor; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor,first_generation; BCR-ABL1_inhibitor,first_generation + PDGFR_inhibitor; KIT_inhibitor,first_generation + PDGFRA_inhibitor; VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation; PDGFRA_inhibitor + PDGFR_inhibitor; KIT_inhibitor; PDGFRA_inhibitor + RET_inhibitor; pan-FGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + pan-FGFR_inhibitor; RET_inhibitor; BCR-ABL1_inhibitor,first_generation + RET_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; PDGFRA_inhibitor + pan-FGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + KIT_inhibitor,first_generation; KIT_inhibitor + pan-FGFR_inhibitor; PDGFRA_inhibitor + VEGFR_inhibitor; KIT_inhibitor + RET_inhibitor	Imatinib; Imatinib + Regorafenib	BCR-ABL1_inhibitor,first_generation; BCR-ABL1_inhibitor,first_generation + KIT_inhibitor,first_generation; BCR-ABL1_inhibitor,first_generation + PDGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + RET_inhibitor; BCR-ABL1_inhibitor,first_generation + VEGFR_inhibitor; BCR-ABL1_inhibitor,first_generation + pan-FGFR_inhibitor; KIT_inhibitor; KIT_inhibitor + KIT_inhibitor,first_generation; KIT_inhibitor + PDGFR_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR_inhibitor; KIT_inhibitor + pan-FGFR_inhibitor; KIT_inhibitor,first_generation + PDGFRA_inhibitor; PDGFRA_inhibitor; PDGFRA_inhibitor + PDGFR_inhibitor; PDGFRA_inhibitor + RET_inhibitor; PDGFRA_inhibitor + VEGFR_inhibitor; PDGFRA_inhibitor + pan-FGFR_inhibitor	ACTRN12614000950662  AG1013GST	A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)	Gastrointestinal Stromal Tumour	2031 - Sydney - Prince of Wales Hospital; 2310 - Newcastle - Calvary Mater Newcastle Hospital; 2606 - Canberra - Canberra Hospital; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 3690 - Wodonga - Border Medical Oncology; 4120 - Brisbane - Princess Alexandra Hospital; 5037 - Adelaide - Ashford Cancer Centre Research; 5042 - Adelaide - Flinders Medical Centre; 6009 - Perth - Sir Charles Gairdner; 7001 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT02365441
NCT02375204	U10CA180821--A031102	Phase 3	Recruiting	VIC, QLD, NSW	2/03/2015	1/03/2015	Carboplatin; Cisplatin; Dexamethasone; Dexamethasone + Paclitaxel; Etoposide; Filgrastim; Filgrastim + Pegfilgrastim; Ifosfamide; Ifosfamide + Mesna; Mesna; Paclitaxel; Pegfilgrastim	glucocorticoid; platinum-based_antineoplastic_agent; glucocorticoid + taxane; alkylating_agent + sodium_mercaptoethanesulfonate; granulocyte_colony_stimulating_factor; alkylating_agent; sodium_mercaptoethanesulfonate; topoisomerase_inhibitor; taxane	Carboplatin; Cisplatin; Dexamethasone + Paclitaxel; Etoposide; Filgrastim; Filgrastim + Pegfilgrastim; Ifosfamide; Ifosfamide + Mesna; Paclitaxel; Pegfilgrastim	alkylating_agent; alkylating_agent + sodium_mercaptoethanesulfonate; glucocorticoid + taxane; granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; taxane; topoisomerase_inhibitor	U10CA180821  A031102	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors	Germinoma; Germ Cell Tumor; Non-seminomatous Germ Cell Tumor; Yolk Sac Tumor; Malignant Germ Cell Neoplasm; Childhood Teratoma; Teratoma; Mixed Germ Cell Tumor; Extragonadal Seminoma; Seminoma; Choriocarcinoma	2050 - Camperdown - Royal Prince Alfred Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3128 - Box Hill - Box Hill Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT02375204
NCT02408861	NCI-2015-00461--NCI-2015-00461	Phase 1	Recruiting	NSW	6/04/2015	27/08/2015	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	NCI-2015-00461  NCI-2015-00461	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Unresectable Solid Neoplasm; Recurrent Classic Hodgkin Lymphoma; Anal Carcinoma; Refractory Classic Hodgkin Lymphoma; HIV Infection; Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Advanced Malignant Solid Neoplasm; Kaposi Sarcoma	2010 - Darlinghurst - Saint Vincent's Hospital - (Suspended); 2052 - Sydney - University of New South Wales	https://clinicaltrials.gov/ct2/show/NCT02408861
NCT02477826	CheckMate-227	Phase 3	Recruiting	ACT, WA, NSW, SA, QLD, VIC	23/06/2015	5/08/2015	Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Paclitaxel; Pemetrexed	antimetabolite; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; taxane	Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2014-003630-23  CA209-227	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer	2148 - Blacktown - Blacktown Hospital - (Active, not recruiting); 2250 - Gosford - Local Institution - (Active, not recruiting); 2340 - Tamworth - Tamworth Hospital - (Active, not recruiting); 2605 - Garran - Local Institution - (Active, not recruiting); 3065 - Fitzroy - St Vincent's Hospital - (Active, not recruiting); 3168 - Clayton - Local Institution - (Active, not recruiting); 4102 - Brisbane - Princess Alexandra Hospital - (Active, not recruiting); 6150 - Murdoch - Local Institution - (Active, not recruiting); 6150 - Perth - Local Institution - (Active, not recruiting); Elizabeth Vale - Local Institution - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT02477826
NCT02506556	PIKNIC	Phase 2	Unknown status	VIC	23/07/2015	1/07/2015	Alpelisib	PI3K_alpha_inhibitor	Alpelisib	PI3K_alpha_inhibitor	LL14/02	A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.	Metastatic Breast Cancer	3002 - East Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT02506556
NCT02516553	2015-001111-12--1367.1	Phase 1	Recruiting	NSW	6/08/2015	8/07/2015	BI 894999	BET_inhibitor			2015-001111-12  1367.1	An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit	Neoplasms; NUT Carcinoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT02516553
NCT02521493	NCI-2015-00324--AAML1531	Phase 3	Recruiting	NSW, VIC, WA, NZ	13/08/2015	23/11/2015	Asparaginase; Cytarabine; Cytarabine + Daunorubicin + Thioguanine; Cytarabine + Mitoxantrone; Daunorubicin; Etoposide; Mitoxantrone; Thioguanine	antimetabolite; asparaginase; anthracycline; anthracycline + antimetabolite; antineoplastic_antibiotic; antimetabolite + antineoplastic_antibiotic; topoisomerase_inhibitor	Cytarabine + Daunorubicin + Thioguanine; Cytarabine + Mitoxantrone	anthracycline + antimetabolite; antimetabolite + antineoplastic_antibiotic	NCI-2015-00324  AAML1531	Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	Acute Myeloid Leukemia; Myeloproliferative Neoplasm; Myelodysplastic Syndrome; Myeloid Leukemia Associated With Down Syndrome; Down Syndrome	1145 - Grafton - Starship Children's Hospital; 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 2310 - Hunter Regional Mail Centre - John Hunter Children's Hospital; 3052 - Parkville - Royal Children's Hospital; 6008 - Perth - Princess Margaret Hospital for Children - (Active, not recruiting); 6009 - Perth - Perth Children's Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT02521493
NCT02567435	NCI-2015-01644--NCI-2015-01644	Phase 3	Recruiting	NSW, QLD, WA, NZ	5/10/2015	23/05/2016	Cyclophosphamide; Cyclophosphamide + Dactinomycin + Irinotecan + Temsirolimus + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Irinotecan + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Vincristine; Dactinomycin; Irinotecan; Radiotherapy; Temsirolimus; Vincristine; Vinorelbine	antineoplastic_antibiotic; topoisomerase_inhibitor; radiotherapy; alkylating_agent + antineoplastic_antibiotic + vinca_alkaloid; alkylating_agent; vinca_alkaloid; MTORC1_inhibitor; alkylating_agent + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; MTORC1_inhibitor + alkylating_agent + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid	Cyclophosphamide + Dactinomycin + Irinotecan + Temsirolimus + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Irinotecan + Vincristine + Vinorelbine; Cyclophosphamide + Dactinomycin + Vincristine	MTORC1_inhibitor + alkylating_agent + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + topoisomerase_inhibitor + vinca_alkaloid; alkylating_agent + antineoplastic_antibiotic + vinca_alkaloid	NCI-2015-01644  NCI-2015-01644	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)	Embryonal Rhabdomyosarcoma; Sclerosing Rhabdomyosarcoma; Alveolar Rhabdomyosarcoma; Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma	1145 - Grafton - Starship Children's Hospital; 2031 - Randwick - Sydney Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 2310 - Hunter Regional Mail Centre - John Hunter Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 6008 - Perth - Princess Margaret Hospital for Children; 6009 - Perth - Perth Children's Hospital; 8011 - Christchurch - Christchurch Hospital	https://clinicaltrials.gov/ct2/show/NCT02567435
NCT02568267	STARTRK-2	Phase 2	Recruiting	NSW, SA, VIC	5/10/2015	19/11/2015	Crizotinib; Entrectinib	TRK_inhibitor,first_generation; MET_inhibitor,type_1; ROS1_inhibitor; ALK_inhibitor,third_generation; ALK_inhibitor,first_generation	Crizotinib; Entrectinib	ALK_inhibitor,first_generation; ALK_inhibitor,third_generation; MET_inhibitor,type_1; ROS1_inhibitor; TRK_inhibitor,first_generation	2015-003385-84  RXDX-101-02	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Breast Cancer; Primary Brain Tumors; Pancreatic Cancer; Ovarian Cancer; Papillary Thyroid Cancer; Melanoma; Lymphoma, Large-Cell, Anaplastic; Non-Small Cell Lung Cancer; Colorectal Cancer; Cholangiocarcinoma; Renal Cell Carcinoma; Salivary Gland Cancers; Sarcomas; Head and Neck Neoplasms; Adult Solid Tumor; Neuroendocrine Tumors	2170 - Liverpool - Liverpool Hospital; 2305 - New Lambton Heights - Newcastle Private Hospital - (Completed); 2640 - Albury - Border Medical Oncology Research Unit - (Withdrawn); 3084 - Heidelberg - Austin Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT02568267
NCT02576431	NAVIGATE	Phase 2	Recruiting	NSW, WA, NT	15/10/2015	30/09/2015	BAY2757556; Larotrectinib	TRK_inhibitor,first_generation			LOXO-TRK-15002  20289	A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	Solid Tumors Harboring NTRK Fusion	0810 - Tiwi - Royal Darwin Hospital; 2109 - Macquarie University - Macquarie University Hospital; 6008 - Subiaco - St John of God Healthcare; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT02576431
NCT02582697	P3BEP	Phase 3	Recruiting	VIC, QLD, SA, NSW, NZ, TAS, WA	21/10/2015	1/02/2014	Bleomycin; Cisplatin; Etoposide; Filgrastim; Pegfilgrastim	granulocyte_colony_stimulating_factor; platinum-based_antineoplastic_agent; antineoplastic_antibiotic; topoisomerase_inhibitor			ACTRN12613000496718  ANZUP1302	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours	Germ Cell Tumor	1023 - Grafton - Starship Children's Hospital; 1142 - Grafton - Auckland Hospital; 2031 - Sydney - Prince of Wales Hospital; 2050 - Sydney - Chris O'Brien Lifehouse; 2065 - St Leonards - Royal North Shore Hospital; 2076 - Wahroonga - SAN Clinical Trials Unit; 2109 - Sydney - Macquarie Cancer Clinical Trials; 2139 - Sydney - Concord Repatriation General Hospital; 2145 - Sydney - Westmead Hospital - (Withdrawn); 2298 - Newcastle - Calvary Mater Newcastle; 2485 - Tweed Heads - Tweed Hospital; 2751 - Sydney - Nepean Hospital; 3002 - East Melbourne - Peter MacCallum Cancer Centre; 3021 - St Albans - Sunshine Hospital - (Withdrawn); 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3690 - Wodonga - Border Medical Oncology; 4029 - Brisbane - Royal Brisbane &amp; Women's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 4102 - Woolloongabba - Princess Alexandra; 4442 - Roslyn - Palmerston North Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Bedford Park - Flinders Medical Centre - (Active, not recruiting); 6847 - Murdoch - Fiona Stanley Hospital; 7000 - Hobart - Royal Hobart Hospital; 8011 - Christchurch - Christchurch Hospital; 9054 - Dunedin - Dunedin Hospital - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT02582697
NCT02601950	EZH-202	Phase 2	Recruiting	NSW, QLD	11/11/2015	22/12/2015	Tazemetostat	EZH2_inhibitor	Tazemetostat	EZH2_inhibitor	EZH-202	A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma	Atypical Teratoid Rhabdoid Tumors (ATRT); Synovial Sarcoma; Rhabdoid Tumors of the Kidney (RTK); Selected Tumors With Rhabdoid Features; Any Solid Tumor With an EZH2 GOF Mutation; Epithelioid Sarcoma; Malignant Rhabdoid Tumors (MRT); Malignant Rhabdoid Tumor of Ovary; INI1-negative Tumors; Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval); Renal Medullary Carcinoma	2050 - Camperdown - Chris O'Brien Lifehouse - (Active, not recruiting); QLD 4102 - Woolloongabba - Metro South Hospital and Health Service via Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT02601950
NCT02609776	CHRYSALIS	Phase 1	Recruiting	WA, NSW, QLD, VIC	20/11/2015	24/05/2016	Amivantamab; Amivantamab + Lazertinib; Carboplatin; Lazertinib; Pemetrexed	bispecific_c-Met_EGFR_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody	Amivantamab + Lazertinib	EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody	61186372EDI1001  CR108064	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer	Non-Small-Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2217 - Kogarah - St George Hospital; 3084 - Heidelberg - Austin Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; 6150 - Murdoch - St John of God Hospital Murdoch - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT02609776
NCT02611960	Keynote-122	Phase 3	NOT_RECRUITING	NSW	19/11/2015	18/04/2016	Capecitabine; Capecitabine + Docetaxel + Gemcitabine; Docetaxel; Gemcitabine; Pembrolizumab	taxane; anti-PD-1_monoclonal_antibody; antimetabolite + taxane; antimetabolite	Capecitabine + Docetaxel + Gemcitabine; Pembrolizumab	anti-PD-1_monoclonal_antibody; antimetabolite + taxane	MK-3475-122  3475-122	A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)	Nasopharyngeal Neoplasms	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02611960
NCT02628067	KEYNOTE-158	Phase 2	Recruiting	NSW	11/12/2015	18/12/2015	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2015-002067-41  3475-158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	Cholangiocarcinoma; Advanced Solid Tumors; Salivary Cancer; Bile Duct Cancer; Salivary Gland Carcinoma; Carcinoid Tumor; Small Cell Lung Carcinoma; Cervical Cancer; Biliary Cancer; Anal Cancer; Vulvar Carcinoma; Thyroid Cancer; Salivary Gland Cancer; Vulvar Cancer; Endometrial Carcinoma; Neuroendocrine Tumor; Mesothelioma; Endometrial Cancer; Anal Carcinoma; Small Cell Lung Cancer (SCLC); Parotid Gland Cancer; Thyroid Carcinoma; Cervical Carcinoma; Colorectal Carcinoma; Advanced Cancer	North Ryde - Merck Sharp &amp; Dohme	https://clinicaltrials.gov/ct2/show/NCT02628067
NCT02645149	MatchMel	Phase 2	Recruiting	NSW	1/01/2016	22/11/2021	Dabrafenib; Ribociclib; Ribociclib + Trametinib; Trametinib	BRAF_V600_inhibitor; CDK4/6_inhibitor; MEK_inhibitor; CDK4/6_inhibitor + MEK_inhibitor	Ribociclib + Trametinib; Trametinib	CDK4/6_inhibitor + MEK_inhibitor; MEK_inhibitor	MIA2015/174	Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Melanoma	2145 - Westmead - Westmead Hospital - (Not yet recruiting); 2260 - Wollstonecraft - Melanoma Institute Australia	https://clinicaltrials.gov/ct2/show/NCT02645149
NCT02702414	KEYNOTE-224	Phase 2	Recruiting	NSW, VIC	3/03/2016	31/05/2016	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	2015-004566-28  3475-224	A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224)	Hepatocellular Carcinoma	2050 - Camperdown; 3168 - Melbourne; 3004 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT02702414
NCT02705482	D6060C00002	Phase 1	NOT_RECRUITING	NSW, VIC, QLD	4/03/2016	30/03/2016	Durvalumab; Durvalumab + Tavolimab; Immune Therapeutic Agent; Tavolimab; Tavolimab + Tremelimumab; Tremelimumab	immune_checkpoint_blockade; anti-CTLA-4_monoclonal_antibody; anti-OX40_agnostic_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-OX40_agnostic_monoclonal_antibody; anti-OX40_agnostic_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Durvalumab + Tavolimab; Tavolimab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-OX40_agnostic_monoclonal_antibody; anti-OX40_agnostic_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	D6060C00002	A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors	Select Advanced Solid Tumors	4068 - Woolloongabba; 3168 - Clayton; 2217 - Kogarah; 2298 - Waratah; 2109 - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT02705482
NCT02709512	ATOMIC	Phase 2/Phase 3	Recruiting	NSW, QLD, VIC, SA, WA	16/03/2016	1/08/2017	Cisplatin; Pegargiminase; Pemetrexed; Placebo	platinum-based_antineoplastic_agent; antimetabolite; placebo; arginine_deiminase-polyethylene_glycol_conjugate	Pegargiminase	arginine_deiminase-polyethylene_glycol_conjugate	POLARIS2015-003	Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)	Mesothelioma	2050 - Camperdown; 3084 - Heidelberg; 2486 - Tweed Heads; 4102 - Woolloongabba; 6009 - Perth; 5042 - Bedford Park	https://clinicaltrials.gov/ct2/show/NCT02709512
NCT02724579	NCI-2016-00150--ACNS1422	Phase 2	Recruiting	WA, SA, NSW	31/03/2016	2/10/2017	Cisplatin; Cyclophosphamide; Lomustine; Radiotherapy; Vincristine	radiotherapy; platinum-based_antineoplastic_agent; vinca_alkaloid; alkylating_agent	Radiotherapy	radiotherapy	NCI-2016-00150  ACNS1422	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients	Medulloblastoma	2310 - Hunter Regional Mail Centre - John Hunter Children's Hospital; 5006 - North Adelaide - Women's and Children's Hospital-Adelaide; 6008 - Perth - Princess Margaret Hospital for Children - (Active, not recruiting); 6009 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT02724579
NCT02775435	KEYNOTE-407	Phase 3	NOT_RECRUITING	NSW	15/05/2016	9/06/2016	Carboplatin; Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Placebo	taxane; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent + taxane; glucocorticoid; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; placebo	Carboplatin + Nab-paclitaxel + Paclitaxel; Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	2016-000229-38  3475-407	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)	Non-small Cell Lung Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02775435
NCT02787005	KEYNOTE-199	Phase 2	NOT_RECRUITING	NSW	26/05/2016	1/07/2016	Enzalutamide; Enzalutamide + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation	Enzalutamide + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation	2015-003644-40  3475-199	Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)	Metastatic Castration-resistant Prostate Cancer	- North Ryde	https://clinicaltrials.gov/ct2/show/NCT02787005
NCT02794571	2016-000944-33--GO30103	Phase 1	Recruiting	NSW, VIC	9/06/2016	23/05/2016	Atezolizumab; Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Capecitabine + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Bevacizumab; Capecitabine; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pembrolizumab; Pembrolizumab + Tiragolumab; Pemetrexed; Tiragolumab	anti-PD-1_monoclonal_antibody; taxane; topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-TIGIT_monoclonal_antibody; antimetabolite; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Atezolizumab + Bevacizumab + Tiragolumab; Atezolizumab + Capecitabine + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Etoposide + Tiragolumab; Atezolizumab + Carboplatin + Cisplatin + Pemetrexed + Tiragolumab; Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab; Atezolizumab + Tiragolumab; Pembrolizumab + Tiragolumab; Tiragolumab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody	2016-000944-33  GO30103	A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors	Advanced/Metastatic Tumors	2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital - (Active, not recruiting); 3002 - East Melbourne - Peter MacCallum Cancer Center - (Completed)	https://clinicaltrials.gov/ct2/show/NCT02794571
NCT02821013	STOP-GAP	Phase 3	Recruiting	South A.VIC, NSW, SA, QLD, VIC	1/07/2016	4/07/2016					UQ-QMP-0001  ME13	A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma	Unresectable/Metastatic Melanoma	2145 - Westmead - Westmead Hospital; 2298 - Waratah - Calvary Mater Newcastle Hospital; 2450 - Coffs Harbour - Coffs Habour Health Campus - NCCI; 2650 - Wagga Wagga - Riverina Cancer Care Centre Wagga Wagga; 3004 - Melbourne - Alfred Hospital; 3128 - Box Hill - Box Hill Hospital; 3168 - Clayton - Monash Medical Centre; 4029 - Herston - Royal Brisbane and Womens Hospital; 4102 - Brisbane - Princess Alexandra Hospital; 4215 - Southport - Gold Coast University Hospital; 4870 - Cairns - Cairns Hospital; 5011 - Woodville - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT02821013
NCT02829099	64457107CAN1001--CR108186	Phase 1	Recruiting	QLD, VIC, NSW	7/07/2016	21/09/2016	Mitazalimab	anti-CD40_agonist_antibody	Mitazalimab	anti-CD40_agonist_antibody	64457107CAN1001  CR108186	A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors	Advanced Solid Neoplasms	3168 - Clayton; 2050 - Camperdown; 4120 - Greenslopes; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT02829099
NCT02861573	KEYNOTE-365	Phase 1	Recruiting	NZ	10/08/2016	17/11/2016	Abiraterone; Abiraterone + Pembrolizumab + Prednisone; Dexamethasone; Docetaxel; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide; Enzalutamide + Pembrolizumab; Olaparib; Olaparib + Pembrolizumab; Pembrolizumab; Prednisone	CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; taxane; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; glucocorticoid; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Abiraterone + Pembrolizumab + Prednisone; Docetaxel + Pembrolizumab + Prednisone; Enzalutamide + Pembrolizumab; Olaparib + Pembrolizumab	CYP17A1_inhibitor + anti-PD-1_monoclonal_antibody + glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane	2016-002312-41  3475-365	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	Metastatic Castration-Resistant Prostate Cancer	Auckland	https://clinicaltrials.gov/ct2/show/NCT02861573
NCT02913313	2016-002263-34--CA020-002	Phase 1/Phase 2	Recruiting	WA	23/09/2016	30/11/2016	BMS-986207; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	BMS-986207; BMS-986207 + Ipilimumab + Nivolumab; BMS-986207 + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	2016-002263-34  CA020-002	Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors	Broad Solid Tumor	6009 - Nedlands - Local Institution - (Completed)	https://clinicaltrials.gov/ct2/show/NCT02913313
NCT02960022	2016-001694-32--9785-CL-0123	Phase 2	Recruiting	NZ, WA, NSW	9/11/2016	22/12/2016	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Enzalutamide; Prednisone	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; glucocorticoid; CYP17A1_inhibitor	Abiraterone + Enzalutamide + Prednisone; Enzalutamide	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; antiandrogen,nonsteroidal,second_generation	2016-001694-32  9785-CL-0123	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Prostate Cancer	2485 - Tweed Heads - Site AU61001 - (Completed); Ashford - Site AU61006 - (Active, not recruiting); Hamilton - Site NZ64001 - (Active, not recruiting); Malvern - Site AU61009 - (Active, not recruiting); South Brisbane - Site AU61008 - (Completed); Westmead - Site AU61004 - (Completed)	https://clinicaltrials.gov/ct2/show/NCT02960022
NCT02964013	MK-7684-001--7684-001	Phase 1	Recruiting	NSW	15/11/2016	13/12/2016	Carboplatin; Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Cisplatin; Etoposide; Pembrolizumab; Pembrolizumab + Vibostolimab; Pemetrexed; Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor	Carboplatin + Cisplatin + Etoposide + Pembrolizumab + Vibostolimab; Carboplatin + Pembrolizumab + Pemetrexed + Vibostolimab; Pembrolizumab + Vibostolimab; Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-TIGIT_monoclonal_antibody	MK-7684-001  7684-001	A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Neoplasms	North Ryde - Merck Sharp &amp; Dohme	https://clinicaltrials.gov/ct2/show/NCT02964013
NCT02974725	2016-004293-18--CLXH254X2102	Phase 1	Recruiting	NSW, VIC	28/11/2016	24/02/2017	LTT462; LTT462 + Naporafenib; Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; Ribociclib; Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor; CDK4/6_inhibitor; RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor	LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	2016-004293-18  CLXH254X2102	A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma	Non-Small Cell Lung Cancer; Melanoma	2145 - Westmead - Novartis Investigative Site; 3000 - Melbourne - Novartis Investigative Site - (Completed); 3181 - Prahran - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT02974725
NCT02975934	TRITON3	Phase 3	Recruiting	TAS, WA, VIC, NSW	29/11/2016	13/06/2017	Abiraterone; Abiraterone + Docetaxel + Enzalutamide + Prednisolone + Prednisone; Docetaxel; Enzalutamide; Prednisolone; Prednisone; Rucaparib	CYP17A1_inhibitor; taxane; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid + taxane; antiandrogen,nonsteroidal,second_generation; PARP_inhibitor; glucocorticoid	Abiraterone + Docetaxel + Enzalutamide + Prednisolone + Prednisone; Rucaparib	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid + taxane; PARP_inhibitor	CO-338-063	TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency	Metastatic Castration Resistant Prostate Cancer	2065 - Saint Leonards - Northern Cancer Insitute, St. Leonards; 2228 - Miranda - Southside Cancer Care Centre; 2650 - Wagga Wagga - Riverina Cancer Care Centre - (Completed); 2800 - Orange - Orange Health Service; 3199 - Frankston - Peninsula &amp; Southeast Oncology; 3220 - Geelong - Barwon Health, University Hospital Geelong; 6008 - Subiaco - St John of God Hospital, Subiaco; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT02975934
NCT02996110	FRACTION-RCC	Phase 2	Recruiting	VIC, NSW	19/12/2016	17/01/2017	BMS-813160; BMS-813160 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Linrodostat; Linrodostat + Nivolumab; Nivolumab; Nivolumab + Relatlimab; Relatlimab	CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CCR2/CCR5_antagonist; IDO1_inhibitor; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-813160 + Nivolumab; Ipilimumab + Nivolumab; Linrodostat + Nivolumab; Nivolumab + Relatlimab	CCR2/CCR5_antagonist + anti-PD-1_monoclonal_antibody; IDO1_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-003082-26  CA018-005	A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)	Advanced Cancer	2145 - Westmead - Westmead Hospital; 3165 - Bentleigh - Monash Medical Centre Clayton	https://clinicaltrials.gov/ct2/show/NCT02996110
NCT03005782	2016-002789-30--R3767-ONC-1613	Phase 1	Recruiting	VIC, WA	29/12/2016	7/11/2016	Cemiplimab; Cemiplimab + Fianlimab; Fianlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Cemiplimab + Fianlimab; Fianlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2016-002789-30  R3767-ONC-1613	A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies	Malignancies	06009 - Perth - The University of Western Australia - The Queen Elizabeth II Medical Centre (QEIIMC) - Sir Charles Gairdner Hospital (SCGH); 3000 - Melbourne - Peter Maccallum Cancer Centre (PMCC); 4029 - Brisbane - Royal Brisbane and Women's Hospital	https://clinicaltrials.gov/ct2/show/NCT03005782
NCT03036098	CheckMate901	Phase 3	Recruiting	QLD, VIC, NSW, WA	30/01/2017	24/03/2017	Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent			2016-003881-14  CA209-901	A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer	Urothelial Cancer	2010 - Darlinghurst - Local Institution - (Withdrawn); 2145 - Westmead - Local Institution; 2298 - Waratah - Local Institution; 3084 - Heidelberg - Local Institution; 4101 - South Brisbane - Local Institution; 4224 - Tugun - Local Institution; 6009 - Nedlands - Local Institution	https://clinicaltrials.gov/ct2/show/NCT03036098
NCT03049189	COMPETE	Phase 3	Recruiting	WA, NSW, VIC	9/02/2017	2/02/2017	177Lu-edotreotide; Everolimus	177Lu-DOTA-radioconjugate; MTORC1_inhibitor	177Lu-edotreotide; Everolimus	177Lu-DOTA-radioconjugate; MTORC1_inhibitor	ITM-LET-01	A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)	Neuroendocrine Tumors	2065 - Saint Leonards - Royal North Shore Hospital; 2170 - Liverpool - Liverpool Hospital; 2217 - Kogarah - St George Hospital - (Withdrawn); 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Olivia Newton-John Cancer &amp; Wellness Centre, Austin Hospital; 6150 - Murdoch - Fiona Stanley Hospital - (Terminated)	https://clinicaltrials.gov/ct2/show/NCT03049189
NCT03059823	INCMGA-0012-101	Phase 1	Recruiting	NZ, NSW	23/02/2017	15/11/2016	Retifanlimab	anti-PD-1_monoclonal_antibody	Retifanlimab	anti-PD-1_monoclonal_antibody	INCMGA 0012-101	A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors	Metastatic Solid Tumors; Locally Advanced Solid Tumors	01023 - Auckland - Auckland City Hospital - (Completed); 02010 - Darlinghurst - St Vincent'S Hospital Sydney; 02050 - Camperdown - Chris Obrien Lifehouse; 06021 - Wellington - Wellington Hospital - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03059823
NCT03069469	DCC-3014-01-001	Phase 1/Phase 2	Recruiting	VIC	3/03/2017	16/02/2017	Vimseltinib	CSF1R_inhibitor	Vimseltinib	CSF1R_inhibitor	DCC-3014-01-001	A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor	Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor, Diffuse; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor; Advanced Malignant Neoplasm	Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03069469
NCT03093116	TRIDENT-1	Phase 1/Phase 2	Recruiting	VIC, SA, NSW	28/03/2017	27/02/2017	Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	Repotrectinib	ALK_inhibitor,third_generation; ROS1_inhibitor; TRK_inhibitor,second_generation	TPX-0005-01	A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Metastatic Solid Tumors; Locally Advanced Solid Tumors	2050 - Camperdown - The Chris O-Brien Lifehouse PHASE 2; 3501 - Melbourne - Peter MacCallum Cancer Center PHASE 2; 5042 - Bedford Park - Flinders Medical Centre PHASE 2	https://clinicaltrials.gov/ct2/show/NCT03093116
NCT03110107	2017-000597-11--CA022-001	Phase 1/Phase 2	Recruiting	NSW, WA	12/04/2017	4/05/2017	BMS-986218; BMS-986218 + Ipilimumab; BMS-986218 + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BMS-986218; BMS-986218 + Ipilimumab; BMS-986218 + Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2017-000597-11  CA022-001	Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors	Advanced Cancer	2065 - Wollstonecraft - Local Institution - (Active, not recruiting); 2145 - Westmead - Local Institution; 6150 - Murdoch - Local Institution	https://clinicaltrials.gov/ct2/show/NCT03110107
NCT03138889	PROPEL	Phase 1/Phase 2	Recruiting	VIC	3/05/2017	9/06/2017	Bempegaldesleukin; Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab; Carboplatin; Cisplatin; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed	antimetabolite; IL-2_variant; platinum-based_antineoplastic_agent; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody; taxane	Bempegaldesleukin + Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Bempegaldesleukin + Carboplatin + Nab-paclitaxel + Paclitaxel + Pembrolizumab; Bempegaldesleukin + Pembrolizumab	IL-2_variant + anti-PD-1_monoclonal_antibody; IL-2_variant + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; IL-2_variant + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	16-214-05	A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors	Non-Small Cell Lung Cancer	3121 - Richmond - Epworth HealthCare	https://clinicaltrials.gov/ct2/show/NCT03138889
NCT03150810	2017-001553-14--BGB-290-103	Phase 1/Phase 2	Recruiting	QLD, VIC, NSW	12/05/2017	28/06/2017	Pamiparib; Pamiparib + Temozolomide; Temozolomide	PARP_inhibitor + alkylating_agent; alkylating_agent; PARP_inhibitor	Pamiparib + Temozolomide	PARP_inhibitor + alkylating_agent	2017-001553-14  BGB-290-103	A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors	2010 - Darlinghurst - Saint Vincent's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 4032 - Chermside - Icon Cancer Centre Chermside; 4066 - Auchenflower - Icon Cancer Centre Wesley; 4101 - South Brisbane - Icon Cancer Centre South Brisbane; 4215 - Southport - Icon Cancer Centre Southport; 4509 - North Lakes - Icon Cancer Centre North Lakes	https://clinicaltrials.gov/ct2/show/NCT03150810
NCT03157128	LIBRETTO-001	Phase 1/Phase 2	Recruiting	VIC, NSW	17/05/2017	2/05/2017	Selpercatinib	RET_inhibitor	Selpercatinib	RET_inhibitor	J2G-OX-JZJA  17477	A Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)	Any Solid Tumor; Colon Cancer; Medullary Thyroid Cancer; Non-Small Cell Lung Cancer	2065 - St. Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03157128
NCT03161756	CHARLI	Phase 1/Phase 2	Recruiting	WA, TAS, NSW, QLD, VIC	22/05/2017	7/12/2017	Denosumab; Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab; Ipilimumab; Nivolumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-RANK_L_monoclonal_antibody	Denosumab + Ipilimumab + Nivolumab; Denosumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-RANK_L_monoclonal_antibody	01.15	A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma	Melanoma Stage Iii; Melanoma Stage Iv; Melanoma	2298 - Waratah - Calvary Mater Newcastle; 2640 - Albury - Border Medical Oncology Research Unit; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Health; 3084 - Heidelberg - Austin Health; 3128 - Box Hill - Box Hill Hospital; 3550 - Bendigo - Bendigo Health; 4029 - Herston - Royal Brisbane and Women's Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT03161756
NCT03170960	XL184-021	Phase 1/Phase 2	Recruiting	NSW, VIC	31/05/2017	5/09/2017	Abiraterone; Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Apalutamide; Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Cisplatin; Docetaxel; Enzalutamide; Irinotecan; Irinotecan + Oxaliplatin; Oxaliplatin	VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; topoisomerase_inhibitor; taxane; ROS1_inhibitor; platinum-based_antineoplastic_agent; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation; RET_inhibitor; KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor	Abiraterone + Apalutamide + Enzalutamide; Abiraterone + Enzalutamide; Atezolizumab + Cabozantinib; Cisplatin; Docetaxel; Irinotecan + Oxaliplatin	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent + topoisomerase_inhibitor; taxane	XL184-021	A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Gastric Cancer; Ovarian Cancer; Urothelial Carcinoma; Endometrial Cancer; Colorectal Cancer; Triple Negative Breast Cancer; Castration-resistant Prostate Cancer; Lower Esophageal Cancer; Head and Neck Cancer; Differentiated Thyroid Cancer; Gastroesophageal Junction Adenocarcinoma; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma	2031 - Randwick - Exelixis Clinical Site #123; 2050 - Camperdown - Exelixis Clinical Site #101; 2109 - North Ryde - Exelixis Clinical Site #112; 2250 - Gosford - Exelixis Clinical Site #115; 2640 - Albury - Exelixis Clinical Site #98; 3021 - St Albans - Exelixis Clinical Site #99	https://clinicaltrials.gov/ct2/show/NCT03170960
NCT03175224	SPARTA	Phase 1/Phase 2	Recruiting	WA, VIC, SA	5/06/2017	27/09/2017	Bozitinib	MET_inhibitor,type_1	Bozitinib	MET_inhibitor,type_1	APL-101-01	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Gastroesophageal Junction Adenocarcinoma; Brain Tumor; Solid Tumor; NSCLC; Lung Cancer; Gastric Cancer; Advanced Cancer; Renal Cancer; Glioblastoma Multiforme	Albury - Border Medical Oncology; Bedford Park - Flinders Medical Centre; Melbourne - St Vincents Hospital Melbourne; Nedlands - Sir Charles Gairdner Hospital; North Adelaide - Calvary Central Districts Hospita	https://clinicaltrials.gov/ct2/show/NCT03175224
NCT03178552	B-FAST	Phase 2/Phase 3	Recruiting	NZ, WA, VIC, QLD, SA, NSW	7/06/2017	22/09/2017	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Bevacizumab; Carboplatin; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Cobimetinib; Entrectinib; Gemcitabine; Pemetrexed; Vemurafenib	antimetabolite; ROS1_inhibitor; platinum-based_antineoplastic_agent; BRAF_V600_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; ALK_inhibitor,third_generation; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; ALK_inhibitor,second_generation; antimetabolite + platinum-based_antineoplastic_agent; TRK_inhibitor,first_generation	Alectinib; Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed; Atezolizumab + Cobimetinib + Vemurafenib; Carboplatin + Cisplatin + Gemcitabine; Carboplatin + Cisplatin + Pemetrexed; Entrectinib	ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2017-000076-28  BO29554	A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Non-Small Cell Lung Cancer	1023 - Auckland - Auckland City Hospital; 2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology; 3084 - Heidelberg - Austin Hospital; Medical Oncology; 4032 - Chermside - The Prince Charles Hospital; Oncology Dept.; 5037 - Kurralta Park - Ashford Cancer Center Research - (Completed); 6009 - Nedlands - Sir Charles Gairdner Hospital - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03178552
NCT03188159	GY01-05-16	Phase 2	Recruiting	VIC	15/06/2017	1/07/2017	Vinorelbine	vinca_alkaloid	Vinorelbine	vinca_alkaloid	GY01/05/16	Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP)	Fallopian Tube Cancer; Ovarian Cancer	Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03188159
NCT03207867	2017-000241-49--CNIR178X2201	Phase 2	Recruiting	NSW	5/07/2017	28/08/2017	NIR178; NIR178 + Spartalizumab; Spartalizumab	adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist	NIR178; NIR178 + Spartalizumab	adenosine_A2A_receptor_antagonist; adenosine_A2A_receptor_antagonist + anti-PD-1_monoclonal_antibody	2017-000241-49  CNIR178X2201	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma	mCRPC, Metastatic Castration Resistant Prostate Cancer 0 0; Head and Neck Cancer; Melanoma; TNBC, Triple Negative Breast Cancer; Urothelial Cancer; MSS, Microsatellite Stable Colon Cancer; Pancreatic Cancer; NSCLC, Non Small Cell Lung Cancer; DLBCL, Diffused Large B Cell Lymphoma; RCC, Renal Cell Cancer	2148 - Blacktown - Novartis Investigative Site - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03207867
NCT03212404	CK-301-101	Phase 1	Recruiting	NSW, VIC, QLD, NZ	11/07/2017	20/09/2017	Cosibelimab	anti-PD-L1_monoclonal_antibody	Cosibelimab	anti-PD-L1_monoclonal_antibody	CK-301-101	A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers	Lung Neoplasms; Classical Hodgkin Lymphoma; Urothelial Carcinoma; Endometrial Cancer; Malignant Mesothelioma, Advanced; Non Hodgkin Lymphoma; Carcinoma, Non-Small-Cell Lung; Head and Neck Cancer; Melanoma; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Carcinoma, Small Cell; Renal Cell Carcinoma	2500 - Wollongong - Research Site; 3128 - Box Hill - Research Site; 3144 - Malvern - Research Site; 4101 - South Brisbane - Research Site; 4102 - Woolloongabba - Research Site; 4120 - Greenslopes - Research Site; 4217 - Benowa - Research Site; 4556 - Buderim - Research Site; 8140 - Christchurch - Research Site	https://clinicaltrials.gov/ct2/show/NCT03212404
NCT03255070	ARX788-1711	Phase 1	Recruiting	NSW, VIC, QLD	21/08/2017	20/03/2018	ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788	anti-ERBB2_antibody-drug_conjugate	ARX788-1711	A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression	Gastric Neoplasm; Breast Neoplasms; Solid Tumors; Solid Tumour	2640 - East Albury - Albury Wodonga University Hospital; 3168 - Clayton - Monash Health; 4101 - South Brisbane - Mater Misericordiae Limited; 4102 - Woolloongabba - Princess Alexandria Hospital	https://clinicaltrials.gov/ct2/show/NCT03255070
NCT03261011	AK104-101	Phase 1	Unknown status	VIC, WA	24/08/2017	3/10/2017	AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody	AK104-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors	Advanced Cancer	3002 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research/Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT03261011
NCT03278717	ICON9	Phase 3	Recruiting	ACT, TAS, NZ, NSW, QLD, VIC, SA	12/09/2017	15/06/2018	Cediranib; Cediranib + Olaparib; Olaparib	VEGF_inhibitor; PARP_inhibitor + VEGF_inhibitor; PARP_inhibitor	Cediranib + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + VEGF_inhibitor	UCL/14/0795	International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy	Ovarian Cancer	Albury - Border Medical Oncology; Auckland - Auckland City Hospital; Bedford Park - Flinders Medical Centre; Benowa - Pindara Private Hospital; Camperdown - Chris O'Brien Lifehouse; Canberra - Canberra Hospital; Christchurch - Christchurch Hospital; Clayton - Monash Health; Gosford - Gosford Hospital; Hobart - Royal Hobart Hospital; Melbourne - Peter MacCallum Cancer Centre; South Brisbane - ICON Cancer Centre; South Brisbane - Mater Cancer Centre; Sydney - Calvary Mater Hospital; Sydney - Campbelltown Hospital; Sydney - Prince of Wales Hospital; Townsville - Townsville Hospital; Westmead - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03278717
NCT03281369	2016-004529-17--YO39609	Phase 1/Phase 2	Recruiting	VIC, NSW	13/09/2017	13/10/2017	Atezolizumab; Atezolizumab + Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cobimetinib + Linagliptin; Atezolizumab + Cobimetinib + Paclitaxel + Ramucirumab; Atezolizumab + Cobimetinib + rHuPH20; Cisplatin; Cisplatin + Fluorouracil; Cobimetinib; Fluorouracil; Leucovorin; Linagliptin; Oxaliplatin; Paclitaxel; Ramucirumab; Tiragolumab; rHuPH20	taxane; dipeptidyl_peptidase-4_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; recombinant_human_hyaluronidase; MEK_inhibitor; anti-VEGFR2_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; platinum-based_antineoplastic_agent; folinic_acid; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; antimetabolite	Atezolizumab + Cisplatin + Fluorouracil; Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab; Atezolizumab + Cobimetinib; Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin; Atezolizumab + Cobimetinib + Linagliptin; Atezolizumab + Cobimetinib + Paclitaxel + Ramucirumab; Atezolizumab + Cobimetinib + rHuPH20; Cisplatin + Fluorouracil	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGFR2_monoclonal_antibody + taxane; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2016-004529-17  YO39609	A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)	Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	2148 - Blacktown - Blacktown Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology; 3168 - Clayton - Monash Medical Centre-Moorabbin Campus	https://clinicaltrials.gov/ct2/show/NCT03281369
NCT03286842	D0816C00018	Phase 3	NOT_RECRUITING	NSW	14/09/2017	17/01/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	D0816C00018	A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.	HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations; Somatic BRCA1/2 Mutations	NSW 2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT03286842
NCT03287427	MYPHISMO	Phase 1	Not yet recruiting	VIC	19/09/2017		TetMYB; TetMYB + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; MYB-targeting_vaccine; MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody	TetMYB + Tislelizumab	MYB-targeting_vaccine + anti-PD-1_monoclonal_antibody	MYPHISMO	First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.	Colorectal Cancer; Adenoid Cystic Carcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03287427
NCT03294083	JX594-REN026	Phase 1/Phase 2	Recruiting	SA, NSW	26/09/2017	7/06/2018	Cemiplimab; Cemiplimab + Pexastimogene Devacirepvec; Pexastimogene Devacirepvec	thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	Cemiplimab; Cemiplimab + Pexastimogene Devacirepvec; Pexastimogene Devacirepvec	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF; thymidine_kinase-deleted_oncolytic_vaccinia_virus_expressing_human_GM-CSF	JX594-REN026	A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)	Renal Cell Carcinoma	Camperdown - Site 2631 - (Withdrawn); SA5042 - Bedford Park - Site 2632 Flinders Medical Centre - (Terminated)	https://clinicaltrials.gov/ct2/show/NCT03294083
NCT03319628	XMT-1536-1	Phase 1/Phase 2	Recruiting	VIC, NSW	24/10/2017	12/12/2017	XMT-1536	anti-NaPi2b_antibody-drug_conjugate	XMT-1536	anti-NaPi2b_antibody-drug_conjugate	XMT-1536-1	A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b	Platinum Resistant Ovarian Cancer; Non Small Cell Lung Cancer Metastatic	2148 - Blacktown - Blacktown Hospital; Camperdown - Chris O'Brien Lifehouse; Heidelberg - Austin Health - Olivia Newton John Cancer Center; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03319628
NCT03319940	NCT03319940	Phase 1	Recruiting	NSW	24/10/2017	26/12/2017	AMG 757; AMG 757 + Pembrolizumab; Pembrolizumab	bispecific_T_cell_engager_targeting_DLL3; anti-PD-1_monoclonal_antibody + bispecific_T_cell_engager_targeting_DLL3; anti-PD-1_monoclonal_antibody	AMG 757; AMG 757 + Pembrolizumab	anti-PD-1_monoclonal_antibody + bispecific_T_cell_engager_targeting_DLL3; bispecific_T_cell_engager_targeting_DLL3	20160323	A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer	Small Cell Lung Carcinoma	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT03319940
NCT03337698	Morpheus-Lung	Phase 1/Phase 2	Recruiting	NSW, VIC	9/11/2017	2/01/2018	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Carboplatin; Cibisatamab; Ciforadenant; Cobimetinib; Docetaxel; Gemcitabine; Ipatasertib; Linagliptin; Pemetrexed; Radiotherapy; Sacituzumab Govitecan; Tocilizumab	radiotherapy; adenosine_A2aR_and_A2bR_antagonist; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + taxane; anti-IL-6_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-CEA/CD3_bispecific_antibody; anti-CEA/CD3_bispecific_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; taxane; anti-Trop2_antibody-drug_conjugate; dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; MEK_inhibitor + anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + Bevacizumab + Radiotherapy; Atezolizumab + Carboplatin + Gemcitabine; Atezolizumab + Carboplatin + Pemetrexed; Atezolizumab + Cibisatamab; Atezolizumab + Ciforadenant; Atezolizumab + Cobimetinib; Atezolizumab + Docetaxel; Atezolizumab + Ipatasertib; Atezolizumab + Linagliptin; Atezolizumab + Sacituzumab Govitecan; Docetaxel	MEK_inhibitor + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-CEA/CD3_bispecific_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + radiotherapy; anti-PD-L1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + dipeptidyl_peptidase-4_inhibitor; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; taxane	2017-001267-21  BO39610	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)	Carcinoma, Non-Small-Cell Lung	2148 - Blacktown - Blacktown Hospital; 3002 - East Melbourne - Peter Mac Callum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT03337698
NCT03352531	AK105-101	Phase 1	Unknown status	QLD, SA, NSW	24/11/2017	22/12/2017	Penpulimab	anti-PD-1_monoclonal_antibody	Penpulimab	anti-PD-1_monoclonal_antibody	AK105-101	A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors	Advanced Cancer	2010 - Darlinghurst - St Vincent's Hospital, Sydney (The Kinghorn Cancer Centre) - (Not yet recruiting); 2170 - Liverpool - Liverpool Hospital - (Not yet recruiting); 4101 - South Brisbane - ICON Cancer Foundation; 5037 - Kurralta Park - Adelaide Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03352531
NCT03358875	2018-000245-39--BGB-A317-303	Phase 3	NOT_RECRUITING	NZ	2/12/2017	30/11/2017	Docetaxel; Tislelizumab	taxane; anti-PD-1_monoclonal_antibody	Docetaxel; Tislelizumab	anti-PD-1_monoclonal_antibody; taxane	2018-000245-39  BGB-A317-303	A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	Non-small Cell Lung Cancer	Hamilton; Tauranga; Wellington	https://clinicaltrials.gov/ct2/show/NCT03358875
NCT03363776	2017-002199-24--CA034-001	Phase 1/Phase 2	NOT_RECRUITING	NSW, VIC, QLD	6/12/2017	24/11/2017	BMS-986277; BMS-986277 + Nivolumab; Nivolumab	anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus; anti-PD-1_monoclonal_antibody; replication-competent_oncolytic_adenovirus	BMS-986277; BMS-986277 + Nivolumab	anti-PD-1_monoclonal_antibody + replication-competent_oncolytic_adenovirus; replication-competent_oncolytic_adenovirus	2017-002199-24  CA034-001	Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors	Cancer	2050 - Camperdown; 4029 - Herston; 3050 - Parkville	https://clinicaltrials.gov/ct2/show/NCT03363776
NCT03363867	BEACON	Phase 2	Recruiting	VIC	6/12/2017	10/07/2018	Atezolizumab; Atezolizumab + Bevacizumab + Cobimetinib; Bevacizumab; Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody; MEK_inhibitor; anti-PD-L1_monoclonal_antibody	Atezolizumab + Bevacizumab + Cobimetinib	MEK_inhibitor + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	BEACON	BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Patients With Recurrent Platinum Resistant High Grade Serous Ovarian Cancer	Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03363867
NCT03369223	2018-000416-21--CA030-001	Phase 1/Phase 2	Recruiting	NSW, SA, VIC	11/12/2017	6/12/2017	BMS-986249; BMS-986249 + Nivolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; CTLA-4-directed_probody + anti-PD-1_monoclonal_antibody; CTLA-4-directed_probody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	BMS-986249; BMS-986249 + Nivolumab; Ipilimumab + Nivolumab; Nivolumab	CTLA-4-directed_probody; CTLA-4-directed_probody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-000416-21  CA030-001	A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors	Advanced Cancer	2060 - North Sydney - Local Institution; 3084 - Heidelberg - Austin Hospital; 3199 - Frankston - Local Institution - (Completed); 5000 - Adelaide - Local Institution	https://clinicaltrials.gov/ct2/show/NCT03369223
NCT03377361	CheckMate-9N9	Phase 1/Phase 2	Recruiting	QLD, VIC, SA, NSW	19/12/2017	1/02/2018	Ipilimumab; Ipilimumab + Nivolumab + Trametinib; Nivolumab; Nivolumab + Trametinib; Regorafenib; Trametinib	KIT_inhibitor,first_generation; anti-CTLA-4_monoclonal_antibody; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; PDGFR_inhibitor; anti-PD-1_monoclonal_antibody; pan-FGFR_inhibitor; MEK_inhibitor; RET_inhibitor	Ipilimumab + Nivolumab + Trametinib; Nivolumab + Trametinib; Regorafenib	KIT_inhibitor,first_generation; MEK_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; MEK_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; RET_inhibitor; VEGFR_inhibitor; pan-FGFR_inhibitor	2017-001830-24  CA209-9N9	A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers	Colorectal Tumors; Colorectal Cancer; Colorectal Neoplasm; Colorectal Carcinoma	2145 - Blacktown - Local Institution; 3084 - Heidelberg - Local Institution; 3168 - Clayton - Local Institution; 4215 - Southport - Local Institution; 5112 - Elizabeth Vale - Local Institution; Herston - Local Institution - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03377361
NCT03382340	IMX-110-001	Phase 1/Phase 2	Recruiting	NSW, QLD	22/12/2017	15/02/2018	IMX-110	nanoparticle_Stat3/NF-kB/poly-TKI; doxorubicin	IMX-110	doxorubicin; nanoparticle_Stat3/NF-kB/poly-TKI	IMX-110-001	A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors	Advanced Solid Tumors; Pancreatic Cancer; Ovarian Cancer; Breast Cancer; Solid Tumor, Adult	QLD 4487 - Sydney - St George Hospital	https://clinicaltrials.gov/ct2/show/NCT03382340
NCT03386721	2017-003182-94--BP40234	Phase 2	Recruiting	NZ	29/12/2017	19/02/2018	Atezolizumab; Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine; Gemcitabine; RO-6874281; Vinorelbine	antimetabolite; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; antimetabolite + taxane + vinca_alkaloid; anti-PD-L1_monoclonal_antibody; vinca_alkaloid; anti-FAP/interleukin-2_fusion_protein; taxane; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane	Atezolizumab + Docetaxel + RO-6874281; Atezolizumab + RO-6874281; Docetaxel; Docetaxel + Gemcitabine + Vinorelbine	anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein + anti-PD-L1_monoclonal_antibody + taxane; antimetabolite + taxane + vinca_alkaloid; taxane	2017-003182-94  BP40234	An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers	Auckland	https://clinicaltrials.gov/ct2/show/NCT03386721
NCT03390504	2017-002932-18--CR108401	Phase 3	Recruiting	WA, VIC, NSW	4/01/2018	23/03/2018	Docetaxel; Docetaxel + Vinflunine; Erdafitinib; Pembrolizumab; Vinflunine	taxane + vinca_alkaloid; vinca_alkaloid; pan-FGFR_inhibitor; anti-PD-1_monoclonal_antibody; taxane	Docetaxel + Vinflunine; Erdafitinib; Pembrolizumab	anti-PD-1_monoclonal_antibody; pan-FGFR_inhibitor; taxane + vinca_alkaloid	2017-002932-18  CR108401	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Urothelial Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2109 - North Ryde - Macquarie University - (Withdrawn); 2217 - Kogarah - St George Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 3199 - Melbourne - Frankston Hospital; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT03390504
NCT03392428	TheraP	Phase 2	Unknown status	NSW, SA, QLD, VIC, WA	8/01/2018	29/01/2018	Cabazitaxel; Lutetium-177-PSMA-617	taxane; 177Lu-PSMA-radioconjugate	Cabazitaxel; Lutetium-177-PSMA-617	177Lu-PSMA-radioconjugate; taxane	ANZUP 1603	TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)	Metastatic Cancer; Cancer of the Prostate	2010 - Sydney - St Vincent's Hospital; 2065 - Sydney - Royal North Shore Hospital; 2170 - Liverpool - Liverpool Hospital; 2298 - Waratah - Calvary Mater Newcastle Hospital; 3008 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Melbourne - Austin Hospital; 3165 - Moorabbin - Monash Moorabbin Hospital; 4029 - Brisbane - Royal Brisbane and Womens Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6450 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT03392428
NCT03424005	Morpheus-TNBC	Phase 1/Phase 2	Recruiting	VIC	6/02/2018	2/04/2018	Atezolizumab; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Bevacizumab; Capecitabine; Carboplatin; Eribulin; Gemcitabine; Ipatasertib; Ladiratuzumab Vedotin; Nab-paclitaxel; Sacituzumab Govitecan; Selicrelumab; Tocilizumab	anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; taxane; anti-Trop2_antibody-drug_conjugate; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-CD40_agonist_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; anti-CD40_agonist_antibody; anti-VEGF_monoclonal_antibody; anti-LIV-1_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; macrocyclic_ketone_analogue; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; antimetabolite; anti-LIV-1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; platinum-based_antineoplastic_agent	Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Carboplatin + Eribulin + Gemcitabine; Atezolizumab + Ipatasertib; Atezolizumab + Ladiratuzumab Vedotin; Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-paclitaxel + Tocilizumab; Atezolizumab + Sacituzumab Govitecan; Capecitabine	anti-CD40_agonist_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-IL-6_monoclonal_antibody + anti-PD-L1_monoclonal_antibody + taxane; anti-LIV-1_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + antimetabolite + macrocyclic_ketone_analogue + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody + pan-AKT_inhibitor; anti-PD-L1_monoclonal_antibody + taxane; antimetabolite	2017-002038-21  CO40115	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)	Triple Negative Breast Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre-East Melbourne	https://clinicaltrials.gov/ct2/show/NCT03424005
NCT03430063	2017-003684-35--R2810-ONC-1763	Phase 2	NOT_RECRUITING	NSW	9/02/2018	29/05/2018	Cemiplimab; Ipilimumab	anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody			2017-003684-35  R2810-ONC-1763	A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer	Advanced Non-Small Cell Lung Carcinoma	- Wollongong	https://clinicaltrials.gov/ct2/show/NCT03430063
NCT03446040	2019-000442-35--CA031-002	Phase 1/Phase 2	Recruiting	VIC, NSW	26/02/2018	8/03/2018	BMS-986258; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20; Nivolumab; rHuPH20	recombinant_human_hyaluronidase; anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase	BMS-986258; BMS-986258 + Nivolumab; BMS-986258 + rHuPH20	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody + recombinant_human_hyaluronidase	2019-000442-35  CA031-002	A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors	Advanced Cancer	2145 - Westmead - Local Institution - (Active, not recruiting); 3084 - Heidelberg - Local Institution - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03446040
NCT03448042	GO40311	Phase 1	Recruiting	VIC	27/02/2018	6/06/2018	BTRC4017A	bispecific_ERBB2/CD3_monoclonal_antibody	BTRC4017A	bispecific_ERBB2/CD3_monoclonal_antibody	GO40311	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers	Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03448042
NCT03454451	CPI-006-001	Phase 1	Recruiting	NSW, QLD, VIC	6/03/2018	25/04/2018	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab; Ciforadenant; Pembrolizumab	anti-PD-1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CPI-006; CPI-006 + Ciforadenant; CPI-006 + Pembrolizumab	adenosine_A2aR_and_A2bR_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CPI-006-001	A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS	Ovarian Cancer; Pancreatic Cancer; Renal Cell Cancer; Colorectal Cancer; Triple Negative Breast Cancer; Endometrial Cancer; Cervical Cancer; Bladder Cancer; Squamous Cell Carcinoma of the Head and Neck; Non-hodgkin Lymphoma; Sarcoma; Non-Small Cell Lung Cancer; Metastatic Castration Resistant Prostate Cancer	2010 - Darlinghurst - St. Vincent's Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 3168 - Clayton - Monash Health; 3168 - Westmead - Westmead Hospital; 4029 - Herston - Royal Brisbane and Women's Hospital	https://clinicaltrials.gov/ct2/show/NCT03454451
NCT03459222	2018-000058-22--CA224-048	Phase 1/Phase 2	Recruiting	NSW, WA	8/03/2018	30/05/2018	Ipilimumab; Ipilimumab + Nivolumab + Relatlimab; Linrodostat; Linrodostat + Nivolumab + Relatlimab; Nivolumab; Relatlimab	IDO1_inhibitor; IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Ipilimumab + Nivolumab + Relatlimab; Linrodostat + Nivolumab + Relatlimab	IDO1_inhibitor + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-000058-22  CA224-048	A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors	Advanced Cancer	2060 - North Sydney - Melanoma Institute Australia; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT03459222
NCT03475251	ACTRN12618000382279--CS1003-101	Phase 1	Unknown status	NSW	23/03/2018	9/05/2018	CS1003; CS1003 + Regorafenib; Regorafenib	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + pan-FGFR_inhibitor; PDGFR_inhibitor; VEGFR_inhibitor; RET_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,first_generation; KIT_inhibitor,first_generation + anti-PD-1_monoclonal_antibody; RET_inhibitor; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; pan-FGFR_inhibitor; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody	CS1003; CS1003 + Regorafenib	KIT_inhibitor,first_generation + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + pan-FGFR_inhibitor	ACTRN12618000382279  CS1003-101	A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors	Advanced Cancer	2031 - Randwick - Scientia Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT03475251
NCT03477175	2017-003668-11--E7080-G000-604	Phase 2	Recruiting	VIC	26/03/2018	16/08/2018	Lenvatinib; Sorafenib	VEGFR_inhibitor; VEGF_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; PDGFR_inhibitor; FLT3_inhibitor; KIT_inhibitor	Lenvatinib	VEGF_inhibitor	2017-003668-11  E7080-G000-604	An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials	Solid Tumors	3181 - Melbourne - The Alfred Hospital - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03477175
NCT03484923	PLATforM	Phase 2	Recruiting	NSW	2/04/2018	10/09/2018	Capmatinib; Capmatinib + Spartalizumab; Ieramilimab; Ieramilimab + Spartalizumab; Ribociclib; Ribociclib + Spartalizumab; Spartalizumab; Spartalizumab + canakinumab; canakinumab	CDK4/6_inhibitor; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-IL-1beta_antibody; MET_inhibitor,type_1; anti-IL-1beta_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; CDK4/6_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Capmatinib + Spartalizumab; Ieramilimab + Spartalizumab; Ribociclib + Spartalizumab; Spartalizumab + canakinumab	CDK4/6_inhibitor + anti-PD-1_monoclonal_antibody; MET_inhibitor,type_1 + anti-PD-1_monoclonal_antibody; anti-IL-1beta_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-000610-38  CPDR001J2201	A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma	Melanoma	2145 - Westmead; 2060 - North Sydney	https://clinicaltrials.gov/ct2/show/NCT03484923
NCT03486873	MK-3475-587--3475-587	Unknown	Recruiting	WA, NZ, NSW, VIC, QLD, SA	3/04/2018	21/08/2018	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	MK-3475-587  3475-587	A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial	Solid Tumors	1023 - Auckland - Auckland City Hospital ( Site 1503); 2050 - Camperdown - Chris OBrien Lifehouse ( Site 3003); 2050 - Camperdown - Royal Prince Alfred Hospital-A.W. Morrow Gastroenterology and Liver Centre ( Site 3016); 2060 - North Sydney - Mater Hospital Sydney ( Site 3007); 2065 - Wollstonecraft - Melanoma Institute Australia ( Site 3001); 2109 - Macquarie University - Macquarie University ( Site 3010); 2145 - Westmead - Westmead Hospital ( Site 3000); 2298 - Waratah - Calvary Mater Newcastle ( Site 3005); 3000 - Melbourne - Peter MacCallum Cancer Centre ( Site 3008); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3004); 3168 - Clayton - Monash Health ( Site 3015); 3204 - Hamilton - Waikato Hospital ( Site 1502); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 3009); 4102 - Woolloongabba - Princess Alexandra Hospital ( Site 3002); 4120 - Brisbane - Gallipoli Medical Research Foundation ( Site 3011); 4215 - Southport - Tasman Oncology Research Pty Ltd ( Site 3012); 5000 - Adelaide - Royal Adelaide Hospital ( Site 3014); 6008 - Subiaco - St John of God Subiaco Hospital ( Site 3013); 6009 - Nedlands - Sir Charles Gairdner Hospital ( Site 3006); 6021 - Wellington - Capital &amp; Coast District Health Board - Wellington Hospital ( Site 1501); 8011 - Christchurch - Canterbury Regional Cancer &amp; Blood Service ( Site 1500)	https://clinicaltrials.gov/ct2/show/NCT03486873
NCT03497767	OUTRUN	Phase 2	Recruiting	WA, NSW, QLD, VIC, SA	13/04/2018	15/08/2019	Osimertinib	EGFR_inhibitor,third_generation	Osimertinib	EGFR_inhibitor,third_generation	TROG 17.02	A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Metastatic Non Small Cell Lung Cancer	2002 - Sydney - Liverpool Hospital; 2010 - Sydney - St. Vincents Hospital - (Not yet recruiting); 2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Hospital; 2217 - Sydney - St George Hospital; 2298 - Newcastle - Calvary Mater; 3002 - Melbourne - Peter MacCallum Cancer Center; 3175 - Melbourne - Monash Health; 4102 - Brisbane - Princess Alexandra Hospital; 4120 - Brisbane - ICON Cancer Centre Greenslopes; Adelaide - Royal Adelaide Hospital - (Not yet recruiting); Perth - Sir Charles Gairdner - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT03497767
NCT03498521	CUPISCO	Phase 2	Recruiting	NSW, QLD, VIC, SA	13/04/2018	10/07/2018	Alectinib; Atezolizumab; Bevacizumab; Carboplatin; Carboplatin + Cisplatin + Gemcitabine + Paclitaxel; Cisplatin; Cobimetinib; Entrectinib; Erlotinib; Gemcitabine; Ipatasertib; Ivosidenib; Olaparib; Paclitaxel; Pemigatinib; Pertuzumab; Trastuzumab; Vemurafenib; Vismodegib	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; taxane; SMO_inhibitor,first_generation; IDH1_R132_inhibitor; TRK_inhibitor,first_generation; FGFR1/2/3_inhibitor; ALK_inhibitor,second_generation; anti-VEGF_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor; MEK_inhibitor; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; EGFR_inhibitor,first_generation; anti-ERBB2_monoclonal_antibody; ALK_inhibitor,third_generation; BRAF_V600_inhibitor; ROS1_inhibitor; antimetabolite; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Gemcitabine + Paclitaxel	antimetabolite + platinum-based_antineoplastic_agent + taxane	2017-003040-20  MX39795	A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy	Cancer of Unknown Primary Site	2065 - St Leonards - Northern Cancer Institute; 2148 - Blacktown - Blacktown Hospital; 3002 - East Melbourne - Peter MacCallum Cancer Center - (Active, not recruiting); 4101 - South Brisbane - Icon Cancer Foundation - (Active, not recruiting); 5042 - Bedford Park - Flinders Medical Centre - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03498521
NCT03504397	Spotlight	Phase 3	Recruiting	NSW, QLD, VIC, SA	20/04/2018	21/06/2018	Fluorouracil; Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Zolbetuximab; Leucovorin; Oxaliplatin; Placebo; Zolbetuximab	folinic_acid; antimetabolite; platinum-based_antineoplastic_agent; placebo; antimetabolite + folinic_acid; anti-Claudin_18.2_monoclonal_antibody + antimetabolite + folinic_acid; anti-Claudin_18.2_monoclonal_antibody	Fluorouracil + Leucovorin; Fluorouracil + Leucovorin + Zolbetuximab	anti-Claudin_18.2_monoclonal_antibody + antimetabolite + folinic_acid; antimetabolite + folinic_acid	2017-002567-17  8951-CL-0301	A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma; Metastatic Gastric Adenocarcinoma or Cancer	2217 - Kogarah - Site AU61007; 3165 - East Bentleigh - Site AU61006; 4224 - Tugun - Site AU61011; 4814 - Douglas - Site AU61002; 5011 - Adelaide - Site AU61008	https://clinicaltrials.gov/ct2/show/NCT03504397
NCT03516981	KEYNOTE-495	Phase 2	Recruiting	NSW, QLD, WA	7/05/2018	1/10/2018	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	MK-3475-495  3475-495	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	Advanced Non-Small Cell Lung Cancer	2148 - Blacktown - Blacktown Hospital Western Sydney Local Health District ( Site 0200) - (Completed); 4120 - Brisbane - Gallipoli Medical Research Foundation ( Site 0202) - (Completed); 6150 - Murdoch - Fiona Stanley Hospital ( Site 0201)	https://clinicaltrials.gov/ct2/show/NCT03516981
NCT03522064	HiTeCH	Phase 2	Recruiting	NSW	11/05/2018	30/07/2018	Carboplatin; Testosterone Enanthate	platinum-based_antineoplastic_agent; testosterone	Carboplatin	platinum-based_antineoplastic_agent	HiTECH	High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer	Homologous Recombination Deficiency; Castration-resistant Prostate Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT03522064
NCT03529526	KN046-AUS-001	Phase 1	Unknown status	QLD	18/05/2018		KN046	bispecific_PD-L1/CTLA-4_antibody	KN046	bispecific_PD-L1/CTLA-4_antibody	KN046-AUS-001	An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	4125 - Southport - ICON Cancer Care	https://clinicaltrials.gov/ct2/show/NCT03529526
NCT03530397	D7980C00001	Phase 1	Recruiting	VIC, NSW	21/05/2018	24/04/2018	Carboplatin; Carboplatin + MEDI5752 + Pemetrexed; Carboplatin + Pembrolizumab + Pemetrexed; MEDI5752; Pembrolizumab; Pemetrexed	bispecific_PD-L1/CTLA-4_antibody; anti-PD-1_monoclonal_antibody; antimetabolite + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + MEDI5752 + Pemetrexed; Carboplatin + Pembrolizumab + Pemetrexed; MEDI5752	anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_PD-L1/CTLA-4_antibody + platinum-based_antineoplastic_agent; bispecific_PD-L1/CTLA-4_antibody	D7980C00001	A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.	Selected Advanced Solid Tumors	2031 - Randwick - Research Site - (Active, not recruiting); 3000 - Melbourne - Research Site - (Active, not recruiting); 3004 - Melbourne - Research Site - (Active, not recruiting); 3084 - Heidelberg - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03530397
NCT03537482	APG2575-001	Phase 0	Recruiting	VIC	25/05/2018	7/08/2018	Lisaftoclax	BCL2_inhibitor	Lisaftoclax	BCL2_inhibitor	APG2575-001	A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies	Hematologic Malignancies	Melbourne - St. Vincent Hospital	https://clinicaltrials.gov/ct2/show/NCT03537482
NCT03539536	2018-001772-38--M14-239	Phase 2	Recruiting	NSW, QLD, WA	29/05/2018	10/10/2018	Telisotuzumab Vedotin	anti-c-Met_antibody-drug_conjugate	Telisotuzumab Vedotin	anti-c-Met_antibody-drug_conjugate	2018-001772-38  M14-239	Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer	2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 207666; 2305 - Lambton Heights - Newcastle Private Hospital /ID# 206600; 2485 - Tweed Heads - The Tweed Hospital /ID# 206601; 4101 - South Brisbane - Mater Misericordiae Limited /ID# 229639; 6008 - Subiaco - St John Of God Subiaco Hospital /ID# 226943	https://clinicaltrials.gov/ct2/show/NCT03539536
NCT03549000	2018-000153-51--CNZV930X2101	Phase 1	Recruiting	VIC	7/06/2018	18/07/2018	NIR178; NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab; Spartalizumab	adenosine_A2A_receptor_antagonist; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody	NIR178 + NZV930; NIR178 + NZV930 + Spartalizumab; NZV930; NZV930 + Spartalizumab	adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody; adenosine_A2A_receptor_antagonist + anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-000153-51  CNZV930X2101	A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.	Metastatic Castration Resistant Prostate Cancer (mCRPC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer Microsatellite Stable (MSS); Ovarian Cancer; Non-small Cell Lung Cancer (NSCLC); Triple Negative Breast Cancer (TNBC); Renal Cell Carcinoma (RCC)	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT03549000
NCT03551626	COMBI-APlus	Phase 3	NOT_RECRUITING	QLD	11/06/2018	29/08/2018	Dabrafenib; Dabrafenib + Trametinib; Trametinib	BRAF_V600_inhibitor + MEK_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor	Dabrafenib + Trametinib	BRAF_V600_inhibitor + MEK_inhibitor	2018-000168-27  CDRB436F2410	COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Pyrexia AE-management Algorithm (Plus)	Malignant Melanoma	QLD 4870 - Cairns; 4102 - Woolloongabba	https://clinicaltrials.gov/ct2/show/NCT03551626
NCT03555149	2017-004566-99--CO39612	Phase 1/Phase 2	Recruiting	VIC	13/06/2018	27/09/2018	Atezolizumab; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib; Bevacizumab; Etrumadenant; Idasanutlin; Isatuximab; PGG Beta-Glucan; Regorafenib; Selicrelumab	anti-PD-L1_monoclonal_antibody + pan-FGFR_inhibitor; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-L1_monoclonal_antibody; dectin_receptor_agonist; PDGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; RET_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; RET_inhibitor; anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; anti-CD38_monoclonal_antibody; pan-FGFR_inhibitor; anti-VEGF_monoclonal_antibody; anti-CD40_agonist_antibody; KIT_inhibitor,first_generation + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; KIT_inhibitor,first_generation + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor; adenosine_A2aR_and_A2bR_antagonist; anti-CD40_agonist_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody + pan-FGFR_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist	Atezolizumab; Atezolizumab + Bevacizumab + PGG Beta-Glucan; Atezolizumab + Bevacizumab + Selicrelumab; Atezolizumab + Etrumadenant + Regorafenib; Atezolizumab + Idasanutlin; Atezolizumab + Isatuximab; Atezolizumab + Regorafenib; Regorafenib	KIT_inhibitor,first_generation; KIT_inhibitor,first_generation + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; KIT_inhibitor,first_generation + anti-PD-L1_monoclonal_antibody; MDM2_inhibitor + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; PDGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor; RET_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor; VEGFR_inhibitor + adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-L1_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist + anti-PD-L1_monoclonal_antibody + pan-FGFR_inhibitor; anti-CD38_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-CD40_agonist_antibody + anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + dectin_receptor_agonist; anti-PD-L1_monoclonal_antibody + pan-FGFR_inhibitor; pan-FGFR_inhibitor	2017-004566-99  CO39612	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	Colorectal Cancer	3002 - East Melbourne - Peter MacCallum Cancer Center - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03555149
NCT03557619	M16-185	Phase 1	Recruiting	VIC, NSW	15/06/2018	30/07/2019	Venetoclax	BCL2_inhibitor	Venetoclax	BCL2_inhibitor	M16-185	A Study to Assess the Effect of Venetoclax on the Pharmacokinetics of Ethinyl Estradiol/Levonorgestrel in Female Subjects With Hematologic Malignancies	Hematologic Malignancies	2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 225248 - (Not yet recruiting); 3002 - East Melbourne - Peter MacCallum Cancer Centre-East Melbourne /ID# 225247	https://clinicaltrials.gov/ct2/show/NCT03557619
NCT03588650	HLX20	Phase 1	Unknown status	NSW, QLD, VIC, SA	17/07/2018	7/08/2018	HLX20	anti-PD-1_monoclonal_antibody	HLX20	anti-PD-1_monoclonal_antibody	HLX20-001	A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting Programmed Death Ligand 1 (PD-L1) Protein in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst - Kinghorn cancer centre - (Not yet recruiting); 2109 - Darlinghurst - Macquarie University - (Not yet recruiting); 3144 - Melbourne - Cabrini Hospital - (Active, not recruiting); 4000 - Brisbane - Sunshine Coast University Hospital - (Active, not recruiting); 4215 - Southport - Gold Coast Hospital - (Not yet recruiting); 5000 - Adelaide - CMAX Clinical research	https://clinicaltrials.gov/ct2/show/NCT03588650
NCT03600883	NCT03600883	Phase 1/Phase 2	Recruiting	QLD, VIC, SA, NSW	26/07/2018	27/08/2018	Midazolam; Midazolam + Sotorasib; Sotorasib	benzodiazepam; KRAS_G12C_inhibitor + benzodiazepam; KRAS_G12C_inhibitor	Midazolam + Sotorasib; Sotorasib	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + benzodiazepam	20170543	A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)	KRAS p.G12C Mutant Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research Ltd; 3050 - Parkville - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT03600883
NCT03611868	Keynote-MK-3475-B66--APG-115-US-002	Phase 1/Phase 2	Recruiting	NSW, QLD, SA	2/08/2018	29/08/2018	Alrizomadlin; Alrizomadlin + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor; MDM2_inhibitor; MDM2_inhibitor + anti-PD-1_monoclonal_antibody; p53-HDM2_interaction_inhibitor	Alrizomadlin + Pembrolizumab	MDM2_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + p53-HDM2_interaction_inhibitor	Keynote MK-3475-B66  APG-115-US-002	A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors	STK11 Gene Mutation; Urothelial Carcinoma; Cutaneous Melanoma; MDM2 Gene Mutation; Non Small Cell Lung Cancer; ATM Gene Mutation; Malignant Peripheral Nerve Sheath Tumors; Liposarcoma; P53 Mutation; Uveal Melanoma; MPNST; Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Mucosal Melanoma; Melanoma	4101 - South Brisbane - Queensland Children's Hospital; 5042 - Bedford Park - Flinders Medical Centre; Brisbane - Metro South Hospital and Health Services via Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT03611868
NCT03628677	AB154CSP0001	Phase 1	Recruiting	NSW, VIC, QLD	14/08/2018	12/09/2018	Domvanalimab; Domvanalimab + Zimberelimab; Zimberelimab	anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Domvanalimab; Domvanalimab + Zimberelimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	AB154CSP0001	A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Solid Tumor, Unspecified, Adult	2010 - Darlinghurst - The Kinghorn Cancer Centre; 2031 - Randwick - Scientia Clinical Research; 2050 - Camperdown - Principal Investigator - (Completed); 2480 - Tweed Heads - Principal Investigator - (Completed); 2640 - Albury - Albury, Australia - (Completed); 3084 - Heidelberg - Olivia Newton-John Cancer Research Institute - (Completed); 4101 - South Brisbane - Principal Investigator - (Completed)	https://clinicaltrials.gov/ct2/show/NCT03628677
NCT03656718	2018-001585-42--CA209-8KX	Phase 1/Phase 2	Recruiting	NZ	4/09/2018	24/09/2018	Nivolumab; Nivolumab + rHuPH20; rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase; recombinant_human_hyaluronidase	Nivolumab; Nivolumab + rHuPH20	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + recombinant_human_hyaluronidase	2018-001585-42  CA209-8KX	Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy	Neoplasms by Site	Wellington; Tauranga; Dunedin	https://clinicaltrials.gov/ct2/show/NCT03656718
NCT03674567	KEYNOTE-877--FLX475-02	Phase 1/Phase 2	Recruiting	VIC, WA	17/09/2018	25/09/2018	FLX475; FLX475 + Pembrolizumab; Pembrolizumab	CCR4_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; CCR4_inhibitor	FLX475; FLX475 + Pembrolizumab	CCR4_inhibitor; CCR4_inhibitor + anti-PD-1_monoclonal_antibody	KEYNOTE-877  FLX475-02	Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer	Advanced Cancer	3084 - Heidelberg - Austin Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT03674567
NCT03682068	NILE	Phase 3	Recruiting	NSW, SA, VIC, QLD, WA	24/09/2018	27/09/2018	Carboplatin; Cisplatin; Durvalumab; Durvalumab + Tremelimumab; Gemcitabine; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent; anti-CTLA-4_monoclonal_antibody	Durvalumab; Durvalumab + Tremelimumab	anti-CTLA-4_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	D933SC00001	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.	Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer	2109 - Macquarie University - Research Site - (Active, not recruiting); 2217 - Kogarah - Research Site - (Terminated); 2800 - Orange - Research Site - (Active, not recruiting); 3021 - St Albans - Research Site - (Active, not recruiting); 3128 - Box Hill - Research Site - (Active, not recruiting); 4101 - South Brisbane - Research Site - (Terminated); 5112 - Elizabeth Vale - Research Site - (Active, not recruiting); 6150 - Murdoch - Research Site - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03682068
NCT03685448	UNICAB	Phase 2	Recruiting	SA, QLD, VIC, NSW	26/09/2018	11/04/2019	Cabozantinib	ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; KIT_inhibitor; RET_inhibitor; AXL_inhibitor; VEGFR2_inhibitor; MET_inhibitor,type_2	Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor	ANZUP1802	A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)	Xp11.2 Translocation-Related Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 1; Renal Cell Carcinoma; Papillary Renal Cell Carcinoma Type 2	2109 - Macquarie Park - Macquarie University Hospital; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 2560 - Campbelltown - Campbelltown Hospital; 3128 - Box Hill - Box Hill Hospital - Eastern Health; 3630 - Shepparton - Goulburn Valley Health, as a satellite site under the supervision of Border Medical Oncology Research Unit, via the Tele-trial model; 5037 - Kurralta Park - Adelaide Cancer Centre / Ashford Cancer Centre Research / Cancer Care SA; 5042 - Bedford Park - Flinders Medical Centre; Clayton - Monash Medical Centre; Herston - Royal Brisbane &amp; Women's Hospital; Kogarah - St George Hospital; Newcastle - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT03685448
NCT03690154	FN-1501-UP1	Phase 1	Recruiting	VIC	1/10/2018	23/07/2018	FN-1501	CDK2/4/6/FLT3_inhibitor	FN-1501	CDK2/4/6/FLT3_inhibitor	FN-1501-UP1	A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)	Acute Myeloid Leukemia Refractory; Advanced Cancer; Acute Myeloid Leukemia, in Relapse; Solid Tumors	3144 - Malvern - Cabrini Malvern Hospital	https://clinicaltrials.gov/ct2/show/NCT03690154
NCT03706365	CYCLONE-2	Phase 2/Phase 3	Recruiting	NSW, VIC	16/10/2018	26/11/2018	Abemaciclib; Abemaciclib + Abiraterone + Prednisone; Abiraterone; Abiraterone + Prednisone; Placebo; Prednisone	CYP17A1_inhibitor; glucocorticoid; CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid; CDK4/6_inhibitor; placebo	Abemaciclib + Abiraterone + Prednisone; Abiraterone + Prednisone	CDK4/6_inhibitor + CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid	I3Y-MC-JPCM  16598	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2031 - Randwick - Prince of Wales Hospital - (Active, not recruiting); 2050 - Camperdown - Chris O'Brien Lifehouse - (Active, not recruiting); 2109 - Macquarie Park - Macquarie University Hospital - (Active, not recruiting); 2228 - Kogarah - Southside Cancer Care Centre - (Active, not recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre; 3065 - Melbourne - St. Vincent's Hospital - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03706365
NCT03708328	2018-000982-35--NP40435	Phase 1	Recruiting	NZ	17/10/2018	15/10/2018	RO7121661	bispecific_PD-1/TIM-3_antibody	RO7121661	bispecific_PD-1/TIM-3_antibody	2018-000982-35  NP40435	An Open Label, Multicenter, Dose Escalation and Expansion, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors	Non-small Cell Lung Cancer (NSCLC); Solid Tumors; Metastatic Melanoma; Small Cell Lung Cancer (SCLC)	Auckland	https://clinicaltrials.gov/ct2/show/NCT03708328
NCT03719690	AIM-HN-SEQ-HN	Phase 2	Recruiting	VIC, NSW	25/10/2018	5/11/2018	Tipifarnib	farnesyltransferase_inhibitor	Tipifarnib	farnesyltransferase_inhibitor	KO-TIP-007	A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)	HRAS Gene Mutation; HNSCC	2065 - Saint Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03719690
NCT03729596	CP-MGC018-01	  Phase 1/Phase 2	Recruiting	VIC, QLD, NSW	2/11/2018	21/11/2018	MGC018; MGC018 + Retifanlimab; Retifanlimab	anti-B7-H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody; anti-B7-H3_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody	MGC018; MGC018 + Retifanlimab	anti-B7-H3_antibody-drug_conjugate; anti-B7-H3_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	CP-MGC018-01	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors	Non Small Cell Lung Cancer; Melanoma; Metastatic Castrate Resistant Prostate Cancer; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer; Advanced Solid Tumor, Adult	2010 - Darlinghurst - St Vincent's Health Network (Kinghorn Cancer Centre); 2298 - Waratah - Calvary Mater NewCastle; 3084 - Heidelberg - Austin Health - Olivia Newton John Cancer Center; 4105 - Woolloongabba - The University of Queensland - Princess Alexandra Hospital (PAH)	https://clinicaltrials.gov/ct2/show/NCT03729596
NCT03735121	BP40657	Phase 1/Phase 2	Recruiting	NZ	8/11/2018	27/12/2018	Atezolizumab; Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20; Bevacizumab; Carboplatin; Paclitaxel; rHuPH20	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase; recombinant_human_hyaluronidase; anti-VEGF_monoclonal_antibody; platinum-based_antineoplastic_agent; taxane; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Atezolizumab + rHuPH20	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + recombinant_human_hyaluronidase	BP40657	A Two-Part Phase Ib/II Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous in Patients With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	Christchurch	https://clinicaltrials.gov/ct2/show/NCT03735121
NCT03739710	NCT03739710	Phase 1/Phase 2	Recruiting	VIC, NSW, TAS	9/11/2018	24/01/2019	Docetaxel; Docetaxel + GSK3359609; GSK3359609	anti-ICOS_agonist_antibody; anti-ICOS_agonist_antibody + taxane; taxane	Docetaxel; Docetaxel + GSK3359609	anti-ICOS_agonist_antibody + taxane; taxane	205801	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	Neoplasms	2500 - Wollongong; 2250 - Gosford; 3350 - Ballarat; 7000 - Hobart; 3004 - Melbourne; 3199 - Frankston; 3168 - Clayton; 2050 - Camperdown; 3630 - Shepparton	https://clinicaltrials.gov/ct2/show/NCT03739710
NCT03742895	MK-7339-002--7339-002	Phase 2	Recruiting	WA, NSW	15/11/2018	12/12/2018	Olaparib	PARP_inhibitor	Olaparib	PARP_inhibitor	MK-7339-002  7339-002	A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	Advanced Solid Neoplasms	2010 - Darlinghurst - Kinghorn Cancer Centre ( Site 2200); 2444 - Port Macquarie - MNCCI Port Macquarie Base Hospital ( Site 2201); 6009 - Nedlands - Linear Clinical Research Ltd ( Site 2202)	https://clinicaltrials.gov/ct2/show/NCT03742895
NCT03744468	BGB-900-102	Phase 1/Phase 2	Recruiting	VIC, WA	16/11/2018	13/11/2018	BGB-A425; BGB-A425 + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody; anti-TIM3_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BGB-A425 + Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIM3_monoclonal_antibody	BGB-900-102	Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Locally Advanced or Metastatic Solid Tumors for Phase 1 HNSCC, NSCLC and RCC for Phase 2	Melbourne - Peter MacCallum Cancer Centre - (Active, not recruiting); Melbourne - Sunshine Western Health Melbourne; Perth - Hollywood Private Hospital - (Not yet recruiting); Perth - Linear Clinical Research - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03744468
NCT03746431	FPX-01-01	Phase 1	Recruiting	VIC, SA	19/11/2018	17/01/2019	FPI-1175; FPI-1547	IGF1R-radionucleotide_conjugate	FPI-1175	IGF1R-radionucleotide_conjugate	FPX-01-01	A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients With Advanced Solid Tumours	Radioimmunoconjugate; Actinium-225; Targeted Alpha Therapy; Antineoplastic Agents; Advanced Solid Tumours	3084 - Heidelberg - Austin Hospital; 5000 - Adelaide - Royal Adelaide Hospital - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03746431
NCT03748134	ORIENT-15	Phase 3	Recruiting	VIC, SA, NSW, WA	20/11/2018	24/12/2018	Cisplatin; Fluorouracil; Paclitaxel; Placebo; Sintilimab	anti-PD-1_monoclonal_antibody; taxane; platinum-based_antineoplastic_agent; antimetabolite; placebo	Sintilimab	anti-PD-1_monoclonal_antibody	CIBI308A301	A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)	Esophageal Squamous Cell Carcinoma	2640 - East Albury - Border Medical Oncology; 3079 - Heidelberg - Austin Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital; 6008 - Subiaco - St John of God Subiaco Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT03748134
NCT03755791	COSMIC-312	Phase 3	Recruiting	WA, NZ, NSW, SA, VIC, QLD	28/11/2018	10/12/2018	Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Sorafenib	anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor; KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; ROS1_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; FLT3_inhibitor; PDGFR_inhibitor; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2; VEGFR_inhibitor; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cabozantinib; Sorafenib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CRAF/FLT3/KIT/PDGFR/VEGFR_inhibitor; CRAF_inhibitor; FLT3_inhibitor; KIT_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR_inhibitor	XL184-312	A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy	Hepatocellular Carcinoma	1023 - Grafton - Exelixis Clinical Site #60 - (Active, not recruiting); 2010 - Darlinghurst - Exelixis Clinical Site #165 - (Active, not recruiting); 2050 - Camperdown - Exelixis Clinical Site #78 - (Active, not recruiting); 2145 - Westmead - Exelixis Clinical Site #155 - (Active, not recruiting); 2217 - Kogarah - Exelixis Clinical Site #126 - (Active, not recruiting); 2747 - Kingswood - Exelixis Clinical Site #171 - (Active, not recruiting); 3050 - Parkville - Exelixis Clinical Site #72 - (Active, not recruiting); 3084 - Heidelberg - Exelixis Clinical Site #166 - (Active, not recruiting); 3128 - Box Hill - Exelixis Clinical Site #107 - (Active, not recruiting); 4120 - Greenslopes - Exelixis Clinical Site #142 - (Active, not recruiting); 6009 - Nedlands - Exelixis Clinical Site #190 - (Active, not recruiting); 6021 - Newton - Exelixis Clinical Site #62 - (Active, not recruiting); Kurralta Park - Exelixis Clinical Site #17 - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03755791
NCT03773302	2018-004004-19--QBGJ398-301	Phase 3	Recruiting	WA, NSW, VIC, SA	12/12/2018	27/12/2019	Cisplatin; Cisplatin + Gemcitabine + Infigratinib; Gemcitabine; Infigratinib	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent	Cisplatin + Gemcitabine + Infigratinib; Infigratinib	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + antimetabolite + platinum-based_antineoplastic_agent	2018-004004-19  QBGJ398-301	A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial	FGFR2 Gene Mutation; Advanced Cholangiocarcinoma	Adelaide - Royal Adelaide Hospital; Bentleigh East - Monash Medical Centre; Camperdown - Chris O'Brien Lifehouse Hospital; Darlinghurst - Blacktown Hospital; Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; Subiaco - St John of God Hospital Subiaco	https://clinicaltrials.gov/ct2/show/NCT03773302
NCT03778957	EMERALD-1	Phase 3	Recruiting	NSW, VIC, QLD	19/12/2018	30/11/2018	Bevacizumab; Bevacizumab + Durvalumab; Durvalumab; Placebo	anti-PD-L1_monoclonal_antibody; placebo; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	Bevacizumab + Durvalumab; Durvalumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody	2018-002134-20  D933GC00001	A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)	Hepatocellular Carcinoma	2050 - Camperdown - Research Site - (Active, not recruiting); 2145 - Westmead - Research Site - (Withdrawn); 2170 - Liverpool - Research Site - (Completed); 3004 - Melbourne - Research Site - (Active, not recruiting); 3065 - Fitzroy - Research Site - (Withdrawn); 3128 - Box Hill - Research Site - (Active, not recruiting); 3168 - Clayton - Research Site - (Active, not recruiting); 4029 - Herston - Research Site - (Active, not recruiting); 4217 - Benowa - Research Site - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03778957
NCT03783403	U1111-1224-8251--CC-95251-ST-001	Phase 1	Recruiting	NSW, VIC	21/12/2018	1/02/2019	CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab; Cetuximab; Rituximab	anti-EGFR_monoclonal_antibody; anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-CD20_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody	CC-95251; CC-95251 + Cetuximab; CC-95251 + Rituximab	anti-CD20_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-SIRPa_monoclonal_antibody; anti-SIRPa_monoclonal_antibody	U1111-1224-8251  CC-95251-ST-001	A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers	Neoplasms	2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT03783403
NCT03792841	NCT03792841	Phase 1	Recruiting	VIC, NSW	3/01/2019	5/02/2019	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	20180101	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer	Metastatic Castration-resistant Prostate Cancer; Prostate Cancer	2031 - Randwick - Scientia Clinical Research Ltd; 2050 - Camperdown - Chris OBrien Lifehouse; 3050 - Parkville - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03792841
NCT03798626	2018-003952-19--CVPM087A2101	Phase 1	Recruiting	VIC, SA, South AustrailiaVIC	10/01/2019	22/05/2019	Bevacizumab; Bevacizumab + Gevokizumab; Cabozantinib; Cabozantinib + Gevokizumab; Gevokizumab; Gevokizumab + Paclitaxel + Ramucirumab; Paclitaxel; Ramucirumab	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; anti-VEGF_monoclonal_antibody; KIT_inhibitor + anti-IL-1beta_antibody; KIT_inhibitor; RET_inhibitor; anti-VEGFR2_monoclonal_antibody; ROS1_inhibitor; VEGFR2_inhibitor + anti-IL-1beta_antibody; MET_inhibitor,type_2 + anti-IL-1beta_antibody; anti-IL-1beta_antibody + anti-VEGFR2_monoclonal_antibody + taxane; taxane; MET_inhibitor,type_2; RET_inhibitor + anti-IL-1beta_antibody; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-IL-1beta_antibody; ROS1_inhibitor + anti-IL-1beta_antibody; AXL_inhibitor; anti-IL-1beta_antibody + anti-VEGF_monoclonal_antibody; AXL_inhibitor + anti-IL-1beta_antibody; VEGFR2_inhibitor; anti-IL-1beta_antibody	Bevacizumab + Gevokizumab; Cabozantinib + Gevokizumab; Gevokizumab + Paclitaxel + Ramucirumab	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-IL-1beta_antibody; AXL_inhibitor + anti-IL-1beta_antibody; KIT_inhibitor + anti-IL-1beta_antibody; MET_inhibitor,type_2 + anti-IL-1beta_antibody; RET_inhibitor + anti-IL-1beta_antibody; ROS1_inhibitor + anti-IL-1beta_antibody; VEGFR2_inhibitor + anti-IL-1beta_antibody; anti-IL-1beta_antibody + anti-VEGFR2_monoclonal_antibody + taxane; anti-IL-1beta_antibody + anti-VEGF_monoclonal_antibody	2018-003952-19  CVPM087A2101	Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma	Colorectal Cancer; Renal Cell Carcinoma; Gastroesophageal Cancer	3000 - Melbourne - Novartis Investigative Site; 5011 - Woodville - Novartis Investigative Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT03798626
NCT03811652	D8540C00002	Phase 1	NOT_RECRUITING	VIC	21/01/2019	20/12/2018	Abiraterone; Abiraterone + Enzalutamide; Capecitabine; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur; Enzalutamide; Fluorouracil; Irinotecan; MEDI7247; Oxaliplatin; Raltitrexed; Tegafur	platinum-based_antineoplastic_agent; antimetabolite; antimetabolite + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; antiandrogen,nonsteroidal,second_generation; anti-ASCT2_antibody-drug_conjugate; topoisomerase_inhibitor; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor	Abiraterone + Enzalutamide; Capecitabine + Fluorouracil + Irinotecan + Oxaliplatin + Raltitrexed + Tegafur	CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation; antimetabolite + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	D8540C00002	A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors	Small Cell Lung Cancer (SCLC); Non Small Cell Lung Cancer Squamous (NSCLC-Sq); Pancreatic Ductal Adenocarcinoma (PDAC); Head and Neck Squamous Cell Carcinoma (HNSCC); Metastatic Castration-resistant Prostate Cancer (mCRPC); Colorectal Cancer (CRC)	3084 - Heidelberg	https://clinicaltrials.gov/ct2/show/NCT03811652
NCT03816163	2018-002551-15--8951-CL-5201	Phase 2	Recruiting	SA, VIC, NSW, WA	25/01/2019	15/03/2019	Gemcitabine; Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab; Nab-paclitaxel; Zolbetuximab	taxane; anti-Claudin_18.2_monoclonal_antibody; antimetabolite; anti-Claudin_18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane	Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel + Zolbetuximab	anti-Claudin_18.2_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane	2018-002551-15  8951-CL-5201	A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma	Metastatic Pancreatic Cancer; Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma	5006 - North Adelaide - Site AU61002 - (Withdrawn); 5XRF+WX - Fitzroy - Site AU61005; HVGM+3C - Wollongong - Site AU61007; NSW 2250 - Gosford - Site AU61008; VIC 3280 - Warrnambool - Site AU61006	https://clinicaltrials.gov/ct2/show/NCT03816163
NCT03821233	ZWI-ZW49-101	Phase 1	Recruiting	SA	29/01/2019	15/04/2019	ZW49	anti-ERBB2_antibody-drug_conjugate	ZW49	anti-ERBB2_antibody-drug_conjugate	ZWI-ZW49-101	A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers	HER2-expressing Cancers	5042 - Adelaide - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT03821233
NCT03821935	2018-004303-40--M19-345	Phase 1	Recruiting	QLD, NSW	30/01/2019	21/02/2019	ABBV-151; ABBV-151 + Budigalimab; Budigalimab	anti-PD-1_monoclonal_antibody; anti-GARP_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ABBV-151; ABBV-151 + Budigalimab	anti-GARP_monoclonal_antibody; anti-GARP_monoclonal_antibody + anti-PD-1_monoclonal_antibody	2018-004303-40  M19-345	A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors Cancer	2050 - Camperdown - Chris O'Brien Lifehouse /ID# 213236; 4101 - South Brisbane - Icon Cancer Centre /ID# 224961	https://clinicaltrials.gov/ct2/show/NCT03821935
NCT03834493	KEYNOTE-641	Phase 3	Recruiting	NSW, SA, VIC, QLD, WA, NZ	8/02/2019	28/07/2019	Enzalutamide; Enzalutamide + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; placebo; antiandrogen,nonsteroidal,second_generation	Enzalutamide; Enzalutamide + Pembrolizumab	anti-PD-1_monoclonal_antibody + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation	2018-004117-40  3475-641	A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)	Prostatic Neoplasms	1023 - Auckland - Auckland City Hospital ( Site 0193); 2010 - Darlinghurst - St. Vincent's Hospital ( Site 0158); 2109 - Macquarie University - Macquarie University ( Site 0151); 2217 - Kogarah - St George Hospital ( Site 0157); 2298 - Waratah - Calvary Mater Newcastle ( Site 0148) - (Completed); 2444 - Port Macquarie - Port Macquarie Base Hospital ( Site 0153); 3112 - Tauranga - Tauranga Hospital ( Site 0215); 3168 - Clayton - Monash Health-Monash Medical Centre ( Site 0147); 4120 - Greenslopes - Gallipoli Medical Research Foundation ( Site 0149); 4215 - Southport - Gold Coast University Hospital ( Site 0150) - (Completed); 5000 - Adelaide - Royal Adelaide Hospital ( Site 0154) - (Active, not recruiting); 6150 - Perth - Fiona Stanley Hospital ( Site 0162) - (Active, not recruiting); 8011 - Christchurch - Canterbury Regional Cancer &amp; Blood Service ( Site 0195)	https://clinicaltrials.gov/ct2/show/NCT03834493
NCT03843359	GSK3745417-208850	Phase 1	Recruiting	VIC	18/02/2019	12/03/2019	Dostarlimab; Dostarlimab + GSK3745417; GSK3745417	anti-PD-1_monoclonal_antibody; STING_agonist; STING_agonist + anti-PD-1_monoclonal_antibody	Dostarlimab + GSK3745417; GSK3745417	STING_agonist; STING_agonist + anti-PD-1_monoclonal_antibody	208850	A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors	Neoplasms	3000 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT03843359
NCT03844048	2018-004356-38--M19-388	Phase 3	Recruiting	NZ, WA, VIC, NSW	18/02/2019	6/09/2019	Venetoclax	BCL2_inhibitor	Venetoclax	BCL2_inhibitor	2018-004356-38  M19-388	An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Acute Lymphoblastic Leukemia; Cancer; Non-Hodgkin's Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia	0622 - Takapuna - North Shore Hospital /ID# 225597; 2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 241675; 2025 - Papatoetoe - Middlemore Clinical Trials /ID# 225596; 2050 - Camperdown - Royal Prince Alfred Hospital /ID# 239557; 2170 - Liverpool - Liverpool Hospital /ID# 225591; 2217 - Kogarah - St George Hospital /ID# 225589; 3000 - Melbourne - Peter MacCallum Cancer Ctr /ID# 210559; 6009 - Nedlands - Perth Blood Institute Ltd /ID# 225592; 6021 - Newtown - Wellington Regional Hospital /ID# 225593; 6150 - Murdoch - Fiona Stanley Hospital /ID# 239480	https://clinicaltrials.gov/ct2/show/NCT03844048
NCT03850795	HC1119-CS-03	Phase 3	Recruiting	SA, QLD, WA	22/02/2019	15/03/2021	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	HC1119-CS-03	PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Castration-resistant Prostate Cancer; Prostate Cancer Metastatic	4215 - Southport - Icon Cancer Care Gold Coast; 5037 - Kurralta Park - Ashford Cancer Centre Research; 6009 - Nedlands - Affinity Clinical Research	https://clinicaltrials.gov/ct2/show/NCT03850795
NCT03856099	PMC-TTAC-0001-03	Phase 2	Recruiting	VIC	27/02/2019	13/11/2019	Bevacizumab; Olinvacimab	anti-VEGFR2_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Olinvacimab	anti-VEGFR2_monoclonal_antibody	PMC_TTAC-0001_03	A Multicenter, Open-Label, Phase ? Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy	Recurrent Glioblastoma	3084 - Heidelberg - Austin Hospital	https://clinicaltrials.gov/ct2/show/NCT03856099
NCT03874884	LuPARP	Phase 1	Recruiting	NSW, VIC	14/03/2019	9/07/2019	Lutetium-177-PSMA-617; Lutetium-177-PSMA-617 + Olaparib; Olaparib	177Lu-PSMA-radioconjugate + PARP_inhibitor; PARP_inhibitor; 177Lu-PSMA-radioconjugate	Lutetium-177-PSMA-617 + Olaparib	177Lu-PSMA-radioconjugate + PARP_inhibitor	Peter Mac project no.18/216	177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer	Metastatic Castration Resistant Prostate Cancer (mCRPC)	2010 - Sydney - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT03874884
NCT03875079	2018-003872-11--BP41054	Phase 1	NOT_RECRUITING	VIC, NSW	14/03/2019	24/06/2019	Pembrolizumab; Pembrolizumab + RO-6874281; RO-6874281	anti-PD-1_monoclonal_antibody; anti-FAP/interleukin-2_fusion_protein; anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody	Pembrolizumab + RO-6874281	anti-FAP/interleukin-2_fusion_protein + anti-PD-1_monoclonal_antibody	2018-003872-11  BP41054	An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-? (FAP), In Combination With Pembrolizumab (Anti-PD-1), In Participants With Advanced Or Metastatic Melanoma	Metastatic Melanoma	2060 - North Sydney; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT03875079
NCT03878719	C4221011--ARRAY-162-115	Phase 1	Recruiting	NZ, VIC, NSW	18/03/2019	13/08/2020	Binimetinib; Binimetinib + Encorafenib; Encorafenib	BRAF_V600_inhibitor; MEK_inhibitor; BRAF_V600_inhibitor + MEK_inhibitor	Binimetinib + Encorafenib	BRAF_V600_inhibitor + MEK_inhibitor	C4221011  ARRAY-162-115	A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Melanoma	3168 - Clayton; Wellington; 2145 - Westmead; 2031 - Sydney	https://clinicaltrials.gov/ct2/show/NCT03878719
NCT03893955	2019-000478-45--M19-037	Phase 1	Recruiting	QLD	28/03/2019	21/05/2019	ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel; Budigalimab; Carboplatin; Nab-paclitaxel	anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonist_antibody + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; anti-CD40_agonist_antibody + taxane; anti-CD40_agonist_antibody; taxane; anti-PD-1_monoclonal_antibody	ABBV-927; ABBV-927 + Budigalimab; ABBV-927 + Budigalimab + Carboplatin; ABBV-927 + Carboplatin; ABBV-927 + Nab-paclitaxel	anti-CD40_agonist_antibody; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonist_antibody + platinum-based_antineoplastic_agent; anti-CD40_agonist_antibody + taxane	2019-000478-45  M19-037	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors	Advanced Solid Tumors; Cancer; Metastatic Solid Tumors; Triple-Negative Breast Cancer (TNBC); Non-small-cell-lung-cancer (NSCLC)	4101 - South Brisbane - Icon Cancer Centre /ID# 224084	https://clinicaltrials.gov/ct2/show/NCT03893955
NCT03900442	PTX-100-PD-012017	Phase 1	Recruiting	VIC	3/04/2019	1/09/2019	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100	geranylgeranyl_transferase_inhibitor	PTX-100-PD-012017	Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies	Advanced Cancer	3121 - Melbourne - Epworth Healthcare; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT03900442
NCT03900884	PALVEN	Phase 1	Recruiting	VIC	3/04/2019	25/09/2019	Letrozole; Letrozole + Palbociclib + Venetoclax; Palbociclib; Venetoclax	BCL2_inhibitor; CDK4/6_inhibitor; aromatase_inhibitor; BCL2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor	Letrozole + Palbociclib + Venetoclax	BCL2_inhibitor + CDK4/6_inhibitor + aromatase_inhibitor	18/028	A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer	Breast Neoplasm Female	3000 - Melbourne - Peter MacCallum Cancer Centre; 3052 - Melbourne - Royal Melbourne Hospital; 3084 - Melbourne - Austin Health - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT03900884
NCT03905148	BGB-283-PD-0325901-AU-001	Phase 1/Phase 2	Recruiting	WA, VIC, NSW	5/04/2019	1/05/2019	Lifirafenib; Lifirafenib + Mirdametinib; Mirdametinib	EGFR/RAF_dimer_inhibitor; EGFR/RAF_dimer_inhibitor + MEK_inhibitor; MEK_inhibitor	Lifirafenib + Mirdametinib	EGFR/RAF_dimer_inhibitor + MEK_inhibitor	BGB-283/PD-0325901-AU-001	A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors	Solid Tumor, Adult	2031 - Randwick - The Prince of Wales Private Hospital - Specialist Medical Randwick; 2148 - Blacktown - Blacktown Cancer and Haematology Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT03905148
NCT03906331	Selpercatinib-EAP--17494		Available	NZ, WA, VIC, QLD, NSW	8/04/2019		Selpercatinib	RET_inhibitor	Selpercatinib	RET_inhibitor	Selpercatinib EAP  17494	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Colon Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Breast Cancer; Other Solid Tumors With Evidence of Activating RET Alteration; Medullary Thyroid Cancer; Non Small Cell Lung Cancer	2050 - Camperdown - NSW Health - Sydney Local Health District - (Available); 2065 - St. Leonards - Royal North Shore Hospital - (Available); 3000 - Melbourne - Peter MacCallum Cancer Centre - (Available); 4032 - Chermside - Queensland Health - Metro North Hospital and Health Service - (Available); 6009 - Nedlands - Linear Clinical Research Ltd - (Available); 91346 - Auckland - University of Auckland - (Available)	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03918278	MK-0482-001--0482-001	Phase 1	Recruiting	VIC, NSW	17/04/2019	19/06/2019	Carboplatin; Carboplatin + Pembrolizumab + Pemetrexed; Gemcitabine; Gemcitabine + Nab-paclitaxel + Pembrolizumab; Nab-paclitaxel; Paclitaxel; Paclitaxel + Pembrolizumab; Pembrolizumab; Pemetrexed	anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody + antimetabolite + taxane	Carboplatin + Pembrolizumab + Pemetrexed; Gemcitabine + Nab-paclitaxel + Pembrolizumab; Paclitaxel + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anti-PD-1_monoclonal_antibody + taxane	MK-0482-001  0482-001	A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.	Neoplasms	2109 - Macquarie University - Macquarie University ( Site 0033); 3004 - Melbourne - Alfred Health ( Site 0031)	https://clinicaltrials.gov/ct2/show/NCT03918278
NCT03933761	PRECISE	Phase 2	Recruiting	WA, NSW, QLD, VIC	1/05/2019	29/07/2019	Pamiparib	PARP_inhibitor	Pamiparib	PARP_inhibitor	ANZGOG 1721/2018	A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion	Ovarian Cancer; Carcinosarcoma		https://clinicaltrials.gov/ct2/show/NCT03933761
NCT03947385	IDE196-001	Phase 1/Phase 2	Recruiting	NSW	13/05/2019	28/06/2019	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Darovasertib	MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1; MEK_inhibitor; PKC_inhibitor; ALK_inhibitor,first_generation; ALK_inhibitor,first_generation + PKC_inhibitor; MET_inhibitor,type_1 + PKC_inhibitor; ROS1_inhibitor; PKC_inhibitor + ROS1_inhibitor	Binimetinib; Binimetinib + Darovasertib; Crizotinib; Crizotinib + Darovasertib; Darovasertib	ALK_inhibitor,first_generation; ALK_inhibitor,first_generation + PKC_inhibitor; MEK_inhibitor; MEK_inhibitor + PKC_inhibitor; MET_inhibitor,type_1; MET_inhibitor,type_1 + PKC_inhibitor; PKC_inhibitor; PKC_inhibitor + ROS1_inhibitor; ROS1_inhibitor	IDE196-001	A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors	Sydney - Westmead Hospital	https://clinicaltrials.gov/ct2/show/NCT03947385
NCT03948763	V941-001--V941-001	Phase 1	Recruiting	NZ, NSW, VIC, SA	14/05/2019	26/06/2019	Pembrolizumab; Pembrolizumab + mRNA-5671; mRNA-5671	anti-PD-1_monoclonal_antibody; mRNA-derived_KRAS-targeting_vaccine; anti-PD-1_monoclonal_antibody + mRNA-derived_KRAS-targeting_vaccine	Pembrolizumab + mRNA-5671; mRNA-5671	anti-PD-1_monoclonal_antibody + mRNA-derived_KRAS-targeting_vaccine; mRNA-derived_KRAS-targeting_vaccine	V941-001  V941-001	A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma	Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms	1023 - Auckland - Auckland City Hospital ( Site 6500); 2010 - Darlinghurst - Kinghorn Cancer Centre ( Site 6000); 3168 - Clayton - Monash Health-Monash Medical Centre ( Site 6001); 5042 - Bedford Park - Southern Oncology Clinical Research Unit SOCRU ( Site 6002); 8011 - Christchurch - New Zealand Clinical Research (Christchurch) ( Site 6501)	https://clinicaltrials.gov/ct2/show/NCT03948763
NCT03974022	DZ2019E0001	Phase 1/Phase 2	Recruiting	NSW, VIC, WA	4/06/2019	9/07/2019	DZD9008	ERBB2_inhibitor,exon_20_selective; EGFR_inhibitor,exon_20_selective	DZD9008	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective	DZ2019E0001	A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation	NonSmall Cell Lung Cancer	Blacktown - Blacktown Hospital; Heidelberg - Austin Hospital; Kogarah - St George Hospital; North Melbourne - Peter MacCallum Cancer Centre - East Melbourne - (Not yet recruiting); Perth - Linear Cancer trials; Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT03974022
NCT03975647	SGNTUC-016	Phase 3	Recruiting	NSW, VIC, WA, Othe	5/06/2019	2/10/2019	Placebo; Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib; Tucatinib	placebo; ERBB2_inhibitor,third_generation; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate	Trastuzumab Emtansine; Trastuzumab Emtansine + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate	SGNTUC-016	Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)	HER2-positive Breast Cancer	2060 - Sydney - Mater Hospital - (Active, not recruiting); 2145 - Westmead - Westmead Hospital - (Active, not recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre - (Active, not recruiting); 3084 - Melbourne - Austin Health - (Active, not recruiting); 6009 - Nedlands - Breast Cancer Research Centre - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT03975647
NCT03976375	LEAP-008	Phase 3	Recruiting	NSW, VIC, QLD, SA	6/06/2019	26/06/2019	Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody	Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; taxane	MK-7902-008  7902-008	A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)	Metastatic Non-Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital ( Site 0005); 2148 - Blacktown - Blacktown Hospital ( Site 0004); 2444 - Port Macquarie - Port Macquarie Base Hospital ( Site 0003); 2500 - Wollongong - Southern Medical Day Care Centre ( Site 0001); 3552 - Bendigo - Bendigo Cancer Centre ( Site 0008); 4102 - Woolloongabba - Princess Alexandra Hospital - Division of Cancer Services ( Site 0002); 5112 - Elizabeth Vale - Calvary Central Districts Hospital ( Site 0007)	https://clinicaltrials.gov/ct2/show/NCT03976375
NCT03994393	ILLUMINATE	Phase 2	Recruiting	TAS, NSW, SA, QLD, VIC	21/06/2019	23/10/2018	Durvalumab; Tremelimumab	anti-PD-L1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody			ALTG 16/009  CTC 0209	A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs)	EGFR Mutant Advanced Non Small Cell Lung Cancer	Bankstown - Bankstown Hospital; Bedford Park - Flinders Medical Centre - (Not yet recruiting); Chermside - The Prince Charles Hospital; Clayton - Monash Medical Centre - Clayton; Gosford - Gosford Hospital; Hobart - Royal Hobart Hospital; Kogarah - St George Hospital; Liverpool - Liverpool Hospital; Melbourne - Peter MacCallum Cancer Centre; Melbourne - St Vincent's Hospital (Melbourne); Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT03994393
NCT03995472	SHR-1501-I-101	Phase 1	Recruiting	NSW, QLD	24/06/2019	14/02/2020	SHR-1316; SHR-1316 + SHR-1501; SHR-1501	anti-PD-L1_monoclonal_antibody; anti-IL15_agonistic_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-IL15_agonistic_monoclonal_antibody	SHR-1316 + SHR-1501	anti-IL15_agonistic_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	SHR-1501-I-101	A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Efficacy of SHR-1501 in Combination With SHR-1316 in Patients With Advanced Malignancies	Advanced Malignancies	2031 - Randwick - Scientia Clinical Research; 2170 - Liverpool - Sydney Southwest Private Hospital; 4101 - South Brisbane - Icon Cancer Centre South Brisbane - (Not yet recruiting); 4224 - Tugun - John Flynn Private Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT03995472
NCT04000529	CTNO155B12101	Phase 1	Recruiting	NSW	27/06/2019	30/07/2019	Ribociclib; Ribociclib + TNO155; Spartalizumab; Spartalizumab + TNO155; TNO155	CDK4/6_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody; SHP2_inhibitor; anti-PD-1_monoclonal_antibody; CDK4/6_inhibitor + SHP2_inhibitor	Ribociclib + TNO155; Spartalizumab + TNO155	CDK4/6_inhibitor + SHP2_inhibitor; SHP2_inhibitor + anti-PD-1_monoclonal_antibody	CTNO155B12101	A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies	Gastrointestinal Stromal Tumors; Non-small Cell Lung Carcinoma; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Esophageal SCC	2145 - Westmead - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04000529
NCT04008030	CheckMate-8HW	Phase 3	Recruiting	SA, QLD, VIC, NSW	5/07/2019	29/07/2019	Bevacizumab; Cetuximab; Fluorouracil; Ipilimumab; Ipilimumab + Nivolumab; Irinotecan; Leucovorin; Nivolumab; Oxaliplatin	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody; folinic_acid; antimetabolite; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-000040-26  CA209-8HW	A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	2145 - Westmead - Westmead Hospital; 3084 - Heidelberg - Warringal Private Hospital; 3168 - Clayton - Local Institution; 4102 - Woolloongabba - Local Institution; 5112 - Elizabeth Vale - Calvary Central Districts Hospital	https://clinicaltrials.gov/ct2/show/NCT04008030
NCT04032704	SGNLVA-005	Phase 2	Recruiting	TAS, Othe, SA, QLD, VIC, NSW	25/07/2019	9/10/2019	Ladiratuzumab Vedotin	anti-LIV-1_antibody-drug_conjugate	Ladiratuzumab Vedotin	anti-LIV-1_antibody-drug_conjugate	SGNLVA-005	Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors	Gastric Adenocarcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous; Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer, Non-squamous; Gastroesophageal Junction Adenocarcinoma; Prostate Cancer; Melanoma	2010 - Sydney - St Vincents Hospital Sydney; 2250 - Gosford - Central Coast Local Health District (Gosford and Wyong Hospitals); 3144 - Malvern - Cabrini; 3199 - Frankston - Peninsula and South East Oncology; 4814 - Douglas - The Townsville Hospital; 5042 - Bedford Park - Flinders Medical Centre; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT04032704
NCT04035434	CRSP-ONC-001	Phase 1	Recruiting	VIC, NSW	29/07/2019	22/07/2019	CTX110	CD19-directed_CAR_T_cell	CTX110	CD19-directed_CAR_T_cell	CRSP-ONC-001	A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)	B-cell Malignancy; B-cell Lymphoma; Adult B Cell ALL; Non-Hodgkin Lymphoma	2050 - Sydney - Royal Prince Alfred Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04035434
NCT04045613	FIDES-02	Phase 1/Phase 2	Recruiting	NSW, VIC, QLD, NZ	5/08/2019	25/07/2019	Atezolizumab; Atezolizumab + Derazantinib; Derazantinib	anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor	Atezolizumab + Derazantinib; Derazantinib	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody	2019-000359-15  DZB-CS-201	An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations	Urothelial Carcinoma	2065 - Canberra - Canberra Hospital and Health Services; 2145 - Westmead - Westmead Hospital; 3355 - Wendouree - Ballarat Oncology &amp; Haematology Services; 4224 - Tugun - John Flynn Private Hospital; 4575 - Birtinya - Coastal Cancer Care	https://clinicaltrials.gov/ct2/show/NCT04045613
NCT04047290	AK112-101	Phase 1	Recruiting	VIC, QLD, SA, NSW	6/08/2019		AK112	bispecific_PD-1_VEGF_monoclonal_antibody	AK112	bispecific_PD-1_VEGF_monoclonal_antibody	AK112-101	A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors	Neoplasms Malignant	Albury - Border Medical Oncology - (Completed); Clayton - Monash Health; Kurralta Park - Adelaide Cancer Centre; Melbourne - Peter MacCallum Cancer Centre - (Not yet recruiting); Randwick - Scientia Clinical Research Ltd; South Brisbane - ICON Cancer Foundation; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT04047290
NCT04047862	BGB-900-105	Phase 1	Recruiting	NSW, SA, QLD, VIC, WA, TAS, NZ	7/08/2019	26/08/2019	Capecitabine; Capecitabine + Cisplatin + Fluorouracil + Ociperlimab + Tislelizumab; Carboplatin; Cisplatin; Cisplatin + Fluorouracil + Ociperlimab + Paclitaxel + Tislelizumab; Etoposide; Etoposide + Ociperlimab + Tislelizumab; Fluorouracil; Nab-paclitaxel; Nab-paclitaxel + Ociperlimab + Paclitaxel + Tislelizumab; Ociperlimab; Ociperlimab + Pemetrexed + Tislelizumab; Ociperlimab + Tislelizumab; Oxaliplatin; Paclitaxel; Pemetrexed; Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor; taxane; antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; platinum-based_antineoplastic_agent; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	Capecitabine + Cisplatin + Fluorouracil + Ociperlimab + Tislelizumab; Cisplatin + Fluorouracil + Ociperlimab + Paclitaxel + Tislelizumab; Etoposide + Ociperlimab + Tislelizumab; Nab-paclitaxel + Ociperlimab + Paclitaxel + Tislelizumab; Ociperlimab + Pemetrexed + Tislelizumab; Ociperlimab + Tislelizumab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + topoisomerase_inhibitor	BGB-900-105	Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Locally Advanced and Metastatic Solid Tumors	1023 - Auckland - Auckland City Hospital - (Not yet recruiting); 2050 - Camperdown - Chris O'Brien Lifehouse; 2146 - Blacktown - Blacktown Hospital; 3168 - Clayton - Monash Hospital; 4101 - South Brisbane - Icon Cancer Foundation; 4102 - Woolloongabba - Metro South Health, Cancer Trials Unit Division of Cancer Services - PAH; 5037 - Adelaide - Tennyson Centre Day Hospital; 5042 - Bedford Park - Southern Oncology Clinical Research Unit - (Not yet recruiting); 5087 - Adelaide - Adelaide Cancer Centre (Ashford Cancer Centre (ACC)) - 480 Specialist Centre; 6008 - Subiaco - St John of God - Subiaco Hospital - Bendat Family Comprehensive Cancer Centre (BFCCC); 6009 - Perth - Linear Clinical Research; 7000 - Hobart - Royal Hobart Hospital (RHH); 8140 - Christchurch - Christchurch Clinical Studies	https://clinicaltrials.gov/ct2/show/NCT04047862
NCT04049617	GS-US-494-5484	Phase 1/Phase 2	Recruiting	NZ	8/08/2019	26/08/2019	GS-4224	anti-PD-L1_monoclonal_antibody	GS-4224	anti-PD-L1_monoclonal_antibody	GS-US-494-5484	A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	Auckland	https://clinicaltrials.gov/ct2/show/NCT04049617
NCT04050436	CERPASS	Phase 2	Recruiting	SA, VIC, QLD, NSW, TAS, WA	8/08/2019	8/10/2019	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	RPL-002-18	A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma	Camperdown - Chris O'Brien Lifehouse; Clayton - Monash Medical Centre; Melbourne - Peter MacCallum Cancer Centre; Melbourne - The Alfred Hospital; Nedlands - Sir Charles Gairdner Hospital; Southport - Tasman Oncology Research Ltd; Wollongong - Southern Medical Day Care Centre	https://clinicaltrials.gov/ct2/show/NCT04050436
NCT04052971	ABN401-001	Phase 1/Phase 2	Recruiting	WA, NSW	12/08/2019	1/08/2019	ABN401	MET_inhibitor,type_1	ABN401	MET_inhibitor,type_1	ABN401-001	A Phase 1-2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2031 - Randwick - Scientia Clinical Research; 2170 - Liverpool - Sydney Southwest Private Hospital; 2217 - Kogarah - ST George Private Hospital; 6009 - Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04052971
NCT04059484	AMEERA-3	Phase 2	Recruiting	QLD, WA	16/08/2019	22/10/2019	Amcenestrant; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen	selective_estrogen_receptor_degrader; aromatase_inhibitor; selective_estrogen_receptor_modulator	Amcenestrant; Fulvestrant	selective_estrogen_receptor_degrader	2018-004593-98  ACT16105	An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies	Breast Cancer Metastatic	4101 - South Brisbane - Investigational Site Number :0360003 - (Completed); 4102 - Woolloongabba - Investigational Site Number :0360002 - (Active, not recruiting); 6009 - Nedlands - Investigational Site Number :0360001 - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04059484
NCT04064060	U1111-1235-8123--ACE-536-LTFU-001	Phase 3	Recruiting	NSW, SA, VIC, QLD	21/08/2019	12/08/2019	Luspatercept	recombinant_human_ActRIIb_fusion_protein	Luspatercept	recombinant_human_ActRIIb_fusion_protein	U1111-1235-8123  ACE-536-LTFU-001	A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials.	Beta-thalassemia; Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis; Myelodysplastic Syndromes (MDS)	2031 - Randwick - Prince of Wales Hospital - (Not yet recruiting); 2050 - Camperdown - Royal Prince Alfred Hospital; 3168 - Clayton - Monash Medical Centre; 4101 - South Brisbane - Mater Hospital Brisbane; 5000 - Adelaide - Royal Adelaide Hospital	https://clinicaltrials.gov/ct2/show/NCT04064060
NCT04083976	2019-002113-19--CR108661	Phase 2	Recruiting	WA, NSW, SA, VIC, QLD	10/09/2019	20/11/2019	Erdafitinib	pan-FGFR_inhibitor	Erdafitinib	pan-FGFR_inhibitor	2019-002113-19  CR108661	A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations	Advanced Solid Tumor	2010 - Darlinghurst - St. Vincent's Hospital Sydney; 2050 - Camperdown - Chris O'Brien Lifehouse; 3065 - Melbourne - St Vincents Hospital Melbourne; 4101 - South Brisbane - Intergrated Clinical Oncology Network Pty Ltd (ICON) - (Suspended); 5042 - Adelaide - Flinders Centre for Innovation in Cancer; 6150 - Murdoch - Fiona Stanley Hospital - (Completed)	https://clinicaltrials.gov/ct2/show/NCT04083976
NCT04100018	CheckMate-7DX	Phase 3	Recruiting	NSW, SA, VIC, QLD, NZ	23/09/2019	6/02/2020	Docetaxel; Docetaxel + Nivolumab + Prednisone; Docetaxel + Prednisone; Nivolumab; Placebo; Prednisone	placebo; glucocorticoid; glucocorticoid + taxane; taxane; anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; anti-PD-1_monoclonal_antibody	Docetaxel + Nivolumab + Prednisone; Docetaxel + Prednisone	anti-PD-1_monoclonal_antibody + glucocorticoid + taxane; glucocorticoid + taxane	2019-002030-36  CA209-7DX	A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer	Prostate Cancer	2076 - Wahroonga - Adventist HealthCare; 2145 - Westmead - Westmead Hospital; 2250 - Gosford - Gosford Hospital; 2480 - Lismore - Lismore Base hospital; 3112 - Tauranga - Local Institution; 3144 - Malvern - Cabrini Haematology and Oncology Centre; 3199 - Frankston - Psehog Pty Ltd; 3204 - Hamilton - Local Institution; 3350 - Ballarat - Ballarat Base Hospital; 4101 - South Brisbane - Integrated Clinical Oncology Network Pty Ltd (ICON); 4102 - Woolloongabba - Princess Alexandra Hospital; 4410 - Palmerston North - Local Institution; 5006 - North Adelaide - Adelaide Oncology and Haematology	https://clinicaltrials.gov/ct2/show/NCT04100018
NCT04106219	J1O-MC-JZHD--17295	Phase 1	Recruiting	WA, NSW, VIC	26/09/2019	11/06/2020	Cyclophosphamide; Cyclophosphamide + LY3295668 + Topotecan; LY3295668; Topotecan	AURKA_inhibitor + alkylating_agent + topoisomerase_inhibitor; alkylating_agent; AURKA_inhibitor; topoisomerase_inhibitor	Cyclophosphamide + LY3295668 + Topotecan; LY3295668	AURKA_inhibitor; AURKA_inhibitor + alkylating_agent + topoisomerase_inhibitor	J1O-MC-JZHD  17295	A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma	Neuroblastoma	2145 - Westmead - The Sydney Children's Hospitals Network; 3052 - Parkville - Royal Children's Hospital; 6009 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT04106219
NCT04106492	2020-0185--SQ3370-001	Phase 1	Recruiting	SA, NSW	27/09/2019	1/08/2020	SQ3370	anthracycline			2020-0185  SQ3370-001	A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors	Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - Sydney - Royal North Shore Hospital; 5000 - Adelaide - Cancer Research Institute	https://clinicaltrials.gov/ct2/show/NCT04106492
NCT04113616	KRT-232-104	Phase 1/Phase 2	Recruiting	WA, NSW, SA	3/10/2019	25/09/2019	Cytarabine; Decitabine; Decitabine + KRT-232; KRT-232	DNA_methyltransferase_inhibitor + MDM2_inhibitor; MDM2_inhibitor; DNA_methyltransferase_inhibitor; antimetabolite	Decitabine + KRT-232; KRT-232	DNA_methyltransferase_inhibitor + MDM2_inhibitor; MDM2_inhibitor	KRT-232-104	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)	Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN); Relapsed or Refractory Acute Myeloid Leukemia (AML)	6005 - West Perth - Perth Blood Institute; Clayton - Monash Health; Kogarah - St. George Hospital	https://clinicaltrials.gov/ct2/show/NCT04113616
NCT04122339	Maxinovel-10181-001	Phase 1	Recruiting	WA	10/10/2019	11/02/2020	MAX-10181	PD-L1_inhibitor,oral	MAX-10181	PD-L1_inhibitor,oral	Maxinovel-10181-001	A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor	Solid Tumor	6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04122339
NCT04123366	2019-001745-40--7339-007	Phase 2	Recruiting	WA, VIC, QLD, NSW	10/10/2019	18/11/2019	Olaparib; Olaparib + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; PARP_inhibitor; PARP_inhibitor + anti-PD-1_monoclonal_antibody	Olaparib + Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody	2019-001745-40  7339-007	A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer	Solid Tumors	2148 - Blacktown - Blacktown Hospital ( Site 2202); 3168 - Clayton - Monash Health-Monash Medical Centre ( Site 2205); 4215 - Southport - Tasman Oncology Research Pty Ltd ( Site 2203); 6009 - Nedlands - Linear Clinical Research Ltd ( Site 2206)	https://clinicaltrials.gov/ct2/show/NCT04123366
NCT04129502	NL20191212--TAK-788-3001	Phase 3	Recruiting	TAS, SA, QLD, NSW	16/10/2019	6/01/2020	Carboplatin; Carboplatin + Cisplatin + Pemetrexed; Cisplatin; Mobocertinib; Pemetrexed	ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent; EGFR_inhibitor,exon_20_selective; antimetabolite; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pemetrexed; Mobocertinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,exon_20_selective; antimetabolite + platinum-based_antineoplastic_agent	NL20191212  TAK-788-3001	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	2065 - St Leonards - GenesisCare North Shore; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 7000 - Hobart - Royal Hobart Hospital	https://clinicaltrials.gov/ct2/show/NCT04129502
NCT04135261	4003.1	Phase 1	Recruiting	VIC, NSW	22/10/2019	24/09/2019	HBM4003	anti-CTLA-4_monoclonal_antibody			4003.1	A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2109 - Macquarie - Macquarie University, 2 Technology Place; 2217 - Kogarah - St. George Private Hospital, 1 South Street; 3004 - Melbourne - The Alfred Hospital, Commercial Road; 3168 - Clayton - Monash Health, Monash Medical Centre, 246 Clayton Road	https://clinicaltrials.gov/ct2/show/NCT04135261
NCT04154956	CARMEN-LC03	Phase 3	Recruiting	NSW, QLD	7/11/2019	6/02/2020	Docetaxel; SAR408701	anti-CEACAM5_antibody-drug_conjugate; taxane	Docetaxel; SAR408701	anti-CEACAM5_antibody-drug_conjugate; taxane	2019-001273-81  EFC15858	Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors	Non-small Cell Lung Cancer Metastatic	2148 - Blacktown - Investigational Site Number :0360002; 2298 - Waratah - Investigational Site Number :0360003; 4102 - Woolloongabba - Investigational Site Number :0360001	https://clinicaltrials.gov/ct2/show/NCT04154956
NCT04161885	VIALE-T	Phase 3	Recruiting	NSW, SA, VIC	13/11/2019	26/02/2020	Azacitidine; Azacitidine + Venetoclax; Venetoclax	BCL2_inhibitor; DNA_methyltransferase_inhibitor; BCL2_inhibitor + DNA_methyltransferase_inhibitor; antimetabolite; BCL2_inhibitor + antimetabolite	Azacitidine + Venetoclax	BCL2_inhibitor + DNA_methyltransferase_inhibitor; BCL2_inhibitor + antimetabolite	2019-002621-30  M19-063	A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T)	Acute Myeloid Leukemia (AML); Cancer	2010 - Darlinghurst - The Kinghorn Cancer Centre /ID# 214660; 3000 - Melbourne - Peter MacCallum Cancer Ctr /ID# 214653 - (Not yet recruiting); 3004 - Melbourne - Alfred Health /ID# 240931 - (Not yet recruiting); 5000 - Adelaide - Royal Adelaide Hospital /ID# 215678	https://clinicaltrials.gov/ct2/show/NCT04161885
NCT04163900	2019-001025-28--NuTide	Phase 3	Recruiting	WA, NSW, VIC, QLD	15/11/2019	24/12/2019	Cisplatin; Cisplatin + Fosgemcitabine Palabenamide; Cisplatin + Gemcitabine; Fosgemcitabine Palabenamide; Gemcitabine	antimetabolite + platinum-based_antineoplastic_agent; gemcitabine-phosphoramidate; gemcitabine-phosphoramidate + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent	Cisplatin + Fosgemcitabine Palabenamide; Cisplatin + Gemcitabine	antimetabolite + platinum-based_antineoplastic_agent; gemcitabine-phosphoramidate + platinum-based_antineoplastic_agent	2019-001025-28  NuTide:121	A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer	Biliary Tract Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital; 2305 - Newcastle - Newcastle Private Hospital; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Warringal Medical Centre; 4814 - Townsville - Townsville Cancer Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT04163900
NCT04164199	2019-002554-23--BGB-A317-290-LTE1	Phase 3	Recruiting	SA, QLD, VIC, NSW, NZ	15/11/2019	19/12/2019	Capecitabine; Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed; Pemetrexed + Tislelizumab; Temozolomide; Tislelizumab	antimetabolite; PARP_inhibitor + anti-PD-1_monoclonal_antibody; alkylating_agent; PARP_inhibitor; PARP_inhibitor + alkylating_agent; anti-PD-1_monoclonal_antibody + antimetabolite; anti-PD-1_monoclonal_antibody	Capecitabine + Tislelizumab; Pamiparib; Pamiparib + Temozolomide; Pamiparib + Tislelizumab; Pemetrexed + Tislelizumab; Tislelizumab	PARP_inhibitor; PARP_inhibitor + alkylating_agent; PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite	2019-002554-23  BGB-A317-290-LTE1	An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies	Advanced Malignancies	2031 - Randwick - Prince of Wales Hospital; 2065 - Saint Leonards - Northern Cancer Institute; 2298 - Waratah - Calvary Mater Newcastle; 3168 - Clayton - Monash Health; 4101 - Brisbane - Icon Cancer Care; 5011 - Woodville - The Queen Elizabeth Hospital; Auckland - Auckland City Hospital; East Melbourne - Peter MacCallum Cancel Centre	https://clinicaltrials.gov/ct2/show/NCT04164199
NCT04170283	BGB-3111-LTE1	Phase 3	Recruiting	TAS, NZ, WA, QLD, VIC, SA, NSW	20/11/2019	21/01/2020	Tislelizumab; Tislelizumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor; anti-PD-1_monoclonal_antibody; BTK_inhibitor + anti-PD-1_monoclonal_antibody	Tislelizumab + Zanubrutinib; Zanubrutinib	BTK_inhibitor; BTK_inhibitor + anti-PD-1_monoclonal_antibody	BGB-3111-LTE1	An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies	B-cell Malignancies	0620 - Auckland - North Shore Hospital (NZ); 1023 - Auckland - Auckland City Hospital; 3004 - Melbourne - The Alfred Hospital; 3065 - Fitzroy - St. Vincent's Hospital Melbourne; 3144 - Malvern - Cabrini Hospital; 3220 - Geelong - Barwon Health, University Hospital Geelong; 4120 - Greenslopes - Brisbane Clinic for Lymphoma, Myeloma and Leukaemia; 4224 - Tugun - John Flynn Private Hospital; 5037 - Kurralta Park - Ashford Cancer Centre Research; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital; Adelaide - Royal Adelaide Hospital; Clayton - Monash Health; Concord - Concord Repatriation General Hospital; Frankston - Peninsula Private Hospital; Geelong - Geelong University Hospital; Hobart - Royal Hobart Hospital; Kogarah - St George Hospital; Malvern - Cabrini Hospital; Melbourne - Peter MacCallum Cancer Center; Melbourne - St Vincent's Hospital; Perth - Royal Perth Hospital; Sydney - St George Hospital; Westmead - Westmead Hospital; Wodonga - Border Medical Oncology; Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04170283
NCT04171141	GUCY2C--C3861001	Phase 1	Recruiting	VIC	20/11/2019	19/11/2019	Bevacizumab	anti-VEGF_monoclonal_antibody	Bevacizumab	anti-VEGF_monoclonal_antibody	GUCY2C  C3861001	A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS	Esophageal Adenocarcinomas; Gastric Adenocarcinomas; Colorectal Adenocarcinomas; Gastrointestinal Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre - (Not yet recruiting); 3050 - Parkville - The Royal Melbourne Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04171141
NCT04176757	ZN-c5-002	Phase 1	Recruiting	QLD, VIC, NSW	25/11/2019	3/01/2020	ZN-C5	selective_estrogen_receptor_degrader	ZN-C5	selective_estrogen_receptor_degrader	ZN-c5-002	A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer	Breast Cancer	2109 - Sydney - Site 9; 2170 - Liverpool - Site 11; 3121 - Richmond - Site 8; 4870 - Cairns - Site 10	https://clinicaltrials.gov/ct2/show/NCT04176757
NCT04186637	NEON-1	Phase 1	Recruiting	WA, NedlandsVIC, VIC	5/12/2019	2/06/2020	ALPN-202	dual_PD-L1/CTLA-4_inhibitor; CD28_agonist	ALPN-202	CD28_agonist; dual_PD-L1/CTLA-4_inhibitor	AIS-B01	An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)	Lymphoma; Advanced Solid Tumor	3004 - Melbourne - Nucleus Network Pty Ltd - (Active, not recruiting); 3004 - Melbourne - The Alfred; 6009 - Perth - Linear Research	https://clinicaltrials.gov/ct2/show/NCT04186637
NCT04188548	EMBER	Phase 1	Recruiting	WA, PerthSA, SA, NSW	6/12/2019	10/12/2019	Abemaciclib; Abemaciclib + Anastrozole + Exemestane + LY3484356 + Letrozole; Abemaciclib + LY3484356 + Trastuzumab; Alpelisib; Alpelisib + LY3484356; Anastrozole; Everolimus; Everolimus + LY3484356; Exemestane; LY3484356; LY3484356 + Pertuzumab + Trastuzumab; Letrozole; Pertuzumab; Trastuzumab	MTORC1_inhibitor; aromatase_inhibitor; CDK4/6_inhibitor; CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; MTORC1_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader	Abemaciclib + Anastrozole + Exemestane + LY3484356 + Letrozole; Abemaciclib + LY3484356 + Trastuzumab; Alpelisib + LY3484356; Everolimus + LY3484356; LY3484356; LY3484356 + Pertuzumab + Trastuzumab	CDK4/6_inhibitor + anti-ERBB2_monoclonal_antibody + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; MTORC1_inhibitor + selective_estrogen_receptor_degrader; PI3K_alpha_inhibitor + selective_estrogen_receptor_degrader; anti-ERBB2_monoclonal_antibody + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	J2J-MC-JZLA  17502	EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers	Advanced Breast Cancer; Endometrial Cancer; Breast Cancer; Metastatic Breast Cancer	2010 - Darlinghurst - St Vincent's Hospital; 2298 - Waratah - Calvary Mater Newcastle; 5037 - Kurralta Park - Ashford Cancer Centre Research; 6009 - Nedlands - Breast Cancer Research Centre-WA; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT04188548
NCT04191499	2019-002455-42--WO41554	Phase 2/Phase 3	Recruiting	NZ, NSW, QLD, VIC	9/12/2019	29/01/2020	Fulvestrant; Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib; Inavolisib; Palbociclib; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; PI3K_inhibitor; CDK4/6_inhibitor + PI3K_inhibitor + selective_estrogen_receptor_degrader; placebo; CDK4/6_inhibitor	Fulvestrant + Inavolisib + Palbociclib; Fulvestrant + Palbociclib	CDK4/6_inhibitor + PI3K_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	2019-002455-42  WO41554	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer	Breast Cancer	1023 - Auckland - Auckland City Hospital; Clinical Oncology; 2109 - Macquarie Park - Macquarie University Hospital; 2500 - Wollongong - Southern Medical Day Care Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology; 3065 - Fitzroy - Western Health; 3084 - Heidelberg - Austin Health; Cancer Clinical Trial Centre; 3199 - Frankston - Peninsula and South Eastern Haematology and Oncology Group; 3240 - Hamilton - Waikato Hospital; Dept of Medical Oncology; 4101 - South Brisbane - Mater Adult Hospital; Oncology; 4102 - Woolloongabba - Princess Alexandra Hospital; Cancer Trials Unit; 4442 - Palmerston North - Palmerston North Hospital; Regional Cancer Treatment Service; 4810 - Townsville - Townsville Hospital; Haematology and Oncology; 4870 - Cairns - Cairns Base Hospital; Cancer Care Centre; 8011 - Christchurch - Christchurch Hospital NZ	https://clinicaltrials.gov/ct2/show/NCT04191499
NCT04194944	LIBRETTO-431	Phase 3	Recruiting	NSW, VIC, QLD	11/12/2019	17/02/2020	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Pembrolizumab; Pemetrexed; Selpercatinib	anti-PD-1_monoclonal_antibody; RET_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Selpercatinib	RET_inhibitor; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	J2G-MC-JZJC  17479	LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2145 - Westmead - Westmead Hospital; 2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3065 - Melbourne - St. Vincent's Hospital; 3149 - Frankston - Slade Pharmacy - (Not yet recruiting); 3168 - Clayton - Monash Medical Centre; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04194944
NCT04199104	LEAP-10	Phase 3	Recruiting	NSW, SA	13/12/2019	5/02/2020	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	placebo; anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor	Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody	MK-7902-010  7902-010	A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).	Head and Neck Squamous Cell Carcinoma	2050 - Camperdown - Chris OBrien Lifehouse ( Site 1002); 2217 - Kogarah - St George Hospital ( Site 1001); 5000 - Adelaide - Royal Adelaide Hospital ( Site 1004)	https://clinicaltrials.gov/ct2/show/NCT04199104
NCT04200404	CS1001-Regorafenib-101	Phase 1/Phase 2	Recruiting	SA	16/12/2019	13/12/2019	Regorafenib; Sugemalimab	anti-PD-L1_monoclonal_antibody; RET_inhibitor; pan-FGFR_inhibitor; VEGFR_inhibitor; KIT_inhibitor,first_generation; PDGFR_inhibitor			CS1001/Regorafenib-101	A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors	Advanced Refractory Solid Tumors	5037 - Kurralta Park - Ashford Cancer Centre Research	https://clinicaltrials.gov/ct2/show/NCT04200404
NCT04205227	MK3475-951	Phase 1/Phase 2	Recruiting	NSW	19/12/2019	18/02/2020	ENB003; ENB003 + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; ETBR_inhibitor; ETBR_inhibitor + anti-PD-1_monoclonal_antibody	ENB003 + Pembrolizumab	ETBR_inhibitor + anti-PD-1_monoclonal_antibody	ENB-003-101 (MK3475-951)	A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Solid Tumor; Pancreatic Cancer; Melanoma; Cancer; Ovary Cancer	2010 - Darlinghurst - Kinghorn-St Vincent's Hospital; 2148 - Blacktown - Blacktown Oncology; 2640 - Albury - Border Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT04205227
NCT04209855	MIRASOL	Phase 3	Recruiting	NSW, VIC, SA	24/12/2019	31/12/2019	Mirvetuximab Soravtansine; Paclitaxel; Pegylated liposomal doxorubicin; Topotecan	anti-FR-alpha_antibody-drug_conjugate; taxane; topoisomerase_inhibitor; anthracycline	Mirvetuximab Soravtansine; Paclitaxel	anti-FR-alpha_antibody-drug_conjugate; taxane	2019-003509-80  IMGN853-0416	MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer	2031 - Randwick - Prince of Wales Hospital; 2065 - Saint Leonards - Royal North Shore Hospital; 2305 - New Lambton Heights - Newcastle Private Hospital; 3144 - Malvern - Oncology Clinics Victoria (OCV) - Cabrini Malvern Hospital Location; 3168 - Clayton - Monash Health; 5065 - Toorak Gardens - Burnside War Memorial Hospital - The Brian Fricker Oncology Centre	https://clinicaltrials.gov/ct2/show/NCT04209855
NCT04211337	LIBRETTO-531	Phase 3	Recruiting	VIC, NSW, WA	26/12/2019	11/02/2020	Cabozantinib; Cabozantinib + Vandetanib; Selpercatinib; Vandetanib	EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + RET_inhibitor; MET_inhibitor,type_2; AXL_inhibitor + EGFR_inhibitor,second_generation; RET_inhibitor + ROS1_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; VEGFR2_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + RET_inhibitor; AXL_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; RET_inhibitor; RET_inhibitor + VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; KIT_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; ROS1_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; KIT_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + MET_inhibitor,type_2	Cabozantinib + Vandetanib; Selpercatinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; VEGFR2_inhibitor	J2G-MC-JZJB  17478	A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	Medullary Thyroid Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St. Leonards - Royal North Shore Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT04211337
NCT04215978	BGB-A317-A445-101	Phase 1	Recruiting	NSW, VIC, WA, NZ	2/01/2020	30/01/2020	BGB-A445; BGB-A445 + Tislelizumab; Tislelizumab	anti-OX40_agonistic_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agonistic_monoclonal_antibody; anti-PD-1_monoclonal_antibody	BGB-A445; BGB-A445 + Tislelizumab	anti-OX40_agonistic_monoclonal_antibody; anti-OX40_agonistic_monoclonal_antibody + anti-PD-1_monoclonal_antibody	BGB-A317-A445-101	Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	1023 - Grafton - Auckland City Hospital; 2146 - Blacktown - Blacktown Hospital; 3004 - Melbourne - Monash Health; 3004 - Melbourne - Nucleus Network; 6009 - Perth - Linear Clinical Research; Melbourne - Peter MacCallum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT04215978
NCT04221542	NCT04221542	Phase 1	Recruiting	NSW, VIC	9/01/2020	4/03/2020	AMG 509	bispecific_STEAP1/CD3_antibody	AMG 509	bispecific_STEAP1/CD3_antibody	20180146	A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04221542
NCT04222972	AcceleRET-Lung	Phase 3	Recruiting	NSW, SA	10/01/2020	24/07/2020	Carboplatin; Cisplatin; Gemcitabine; Nab-paclitaxel; Paclitaxel; Pembrolizumab; Pemetrexed; Pralsetinib	RET_inhibitor; antimetabolite; platinum-based_antineoplastic_agent; taxane; anti-PD-1_monoclonal_antibody	Pembrolizumab; Pralsetinib	RET_inhibitor; anti-PD-1_monoclonal_antibody	2019-002463-10  BO42864	A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer	Neoplasms; Adenocarcinoma; RET-fusion Non Small Cell Lung Cancer; Lung Diseases; Neoplasms, Nerve Tissue; Neoplasms by Histologic Type; Thoracic Neoplasms; Respiratory Tract Disease; Bronchial Diseases; Neoplasms by Site; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Head and Neck Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Respiratory Tract Neoplasms; Lung Neoplasm	2065 - St Leonards - Royal North Shore Hospital; Department of Medical Oncology; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04222972
NCT04223856	EV-302	Phase 3	Recruiting	NSW, QLD, VIC, SA	10/01/2020	30/03/2020	Carboplatin; Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Cisplatin; Enfortumab Vedotin; Enfortumab Vedotin + Pembrolizumab; Gemcitabine; Pembrolizumab	anti-Nectin-4_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent; anti-Nectin-4_antibody; anti-Nectin-4_antibody + anti-PD-1_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Enfortumab Vedotin + Pembrolizumab; Carboplatin + Cisplatin + Gemcitabine; Enfortumab Vedotin + Pembrolizumab	anti-Nectin-4_antibody + anti-PD-1_monoclonal_antibody; anti-Nectin-4_antibody + anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2019-004542-15  SGN22E-003	An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer	Urothelial Cancer	2109 - Macquarie Park - Site AUS61002; 3084 - Heidelberg - Site AUS61004; 3128 - Box Hill - Site AU61003; 4101 - South Brisbane - Site AU61005; 4814 - Douglas - Site AUS61001; 5112 - South Australia - Site AUS61006	https://clinicaltrials.gov/ct2/show/NCT04223856
NCT04233060	CS3005-101	Phase 1	Recruiting	NSW	18/01/2020	10/01/2020	CS3005	adenosine_A2A_receptor_antagonist	CS3005	adenosine_A2A_receptor_antagonist	CS3005-101	A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2031 - Sydney - Scientia Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT04233060
NCT04242199	INCB-99280-112	Phase 1	Recruiting	WA, NSW, VIC	27/01/2020	20/08/2020					INCB 99280-112	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors	Nasopharyngeal Carcinoma; Small-cell Lung Cancer; PD-L1 Amplified Tumor (9p24.1); Urothelial Carcinoma; HepatoCellular Carcinoma; MSI-H/dMMR Tumors; Mesothelioma; Advanced Solid Tumor; Cervical Cancer; Esophageal Squamous Cell Carcinoma; Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma	02050 - Camperdown - Chris Obrien Lifehouse; 03004 - Melbourne - Nucleus Network Pty Ltd - (Completed); Heidelberg - Austin Hospital; Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04242199
NCT04246177	LEAP-012	Phase 3	Recruiting	WA, NZ, NSW, VIC, QLD	29/01/2020	22/05/2020	Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; placebo	Lenvatinib + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2019-002345-37  7902-012	A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)	Carcinoma, Hepatocellular	1023 - Auckland - Auckland City Hospital ( Site 0459); 2217 - Kogarah - St George Hospital ( Site 0005); 3004 - Melbourne - Alfred Health ( Site 0004); 3084 - Heidelberg - Austin Health ( Site 0008); 4102 - Brisbane - Princess Alexandra Hospital ( Site 0006); 6000 - Perth - Royal Perth Hospital ( Site 0002)	https://clinicaltrials.gov/ct2/show/NCT04246177
NCT04249843	BGB-3245-AU-001	Phase 1	Recruiting	NSW	31/01/2020	17/02/2020	BGB-3245	RAF_dimer_inhibitor	BGB-3245	RAF_dimer_inhibitor	BGB-3245-AU-001	A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors	B-Raf Mutation-Related Tumors; Solid Tumor	2010 - Melbourne - Peter MacCallum Cancer Centre; 2010 - Sydney - The Kinghorn Cancer Centre, St Vincent Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT04249843
NCT04250155	GO41596	Phase 1	Recruiting	VIC	31/01/2020	9/03/2020	Atezolizumab; Atezolizumab + XmAb24306; XmAb24306	anti-PD-L1_monoclonal_antibody; IL15/IL15R_Fc-fusion_protein; IL15/IL15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	Atezolizumab + XmAb24306; XmAb24306	IL15/IL15R_Fc-fusion_protein; IL15/IL15R_Fc-fusion_protein + anti-PD-L1_monoclonal_antibody	GO41596	A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors	Solid Tumors	3002 - East Melbourne - Peter Mac Callum Cancer Center	https://clinicaltrials.gov/ct2/show/NCT04250155
NCT04251117	GT-30	Phase 1/Phase 2	Recruiting	NZ	31/01/2020		GNOS-PV02; GNOS-PV02 + INO-9012 + Pembrolizumab; INO-9012; Pembrolizumab	DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine; personalized_neoantigen_vaccine; DNA_plasmid_encoding_IL-12; anti-PD-1_monoclonal_antibody	GNOS-PV02 + INO-9012 + Pembrolizumab	DNA_plasmid_encoding_IL-12 + anti-PD-1_monoclonal_antibody + personalized_neoantigen_vaccine	GT-30	An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) in Combination With Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma	HCC	Auckland	https://clinicaltrials.gov/ct2/show/NCT04251117
NCT04251533	EPIK-B3	Phase 3	Recruiting	VIC, NSW, WA	5/02/2020	8/06/2020	Alpelisib; Alpelisib + Nab-paclitaxel; Nab-paclitaxel; Placebo	PI3K_alpha_inhibitor + taxane; placebo; PI3K_alpha_inhibitor; taxane	Alpelisib + Nab-paclitaxel; Nab-paclitaxel	PI3K_alpha_inhibitor + taxane; taxane	2019-002637-11  CBYL719H12301	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation	Triple Negative Breast Neoplasms	2010 - Darlinghurst - Novartis Investigative Site; 3000 - Melbourne - Novartis Investigative Site; 6009 - Nedlands - Novartis Investigative Site; 6150 - Murdoch - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04251533
NCT04262856	ARC-7	Phase 2	Recruiting	NSW, SA	10/02/2020	28/05/2020	Domvanalimab; Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab; Etrumadenant; Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; adenosine_A2aR_and_A2bR_antagonist; anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	Domvanalimab + Etrumadenant + Zimberelimab; Domvanalimab + Zimberelimab; Zimberelimab	adenosine_A2aR_and_A2bR_antagonist + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	AB154CSP0002	A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer	Squamous Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Lung Cancer; Non Small Cell Lung Cancer	2450 - Coffs Harbour - Coffs Harbour Health Campus; 2485 - Tweed Heads - Tweed Hospital; 2500 - Nowra - Shoalhaven Cancer Care Centre; 2640 - Albury - Border Medical Oncology; 5112 - Elizabeth Vale - Adelaide Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04262856
NCT04269200	DUO-E	Phase 3	Recruiting	WA, NSW, SA, VIC	13/02/2020	21/05/2020	Carboplatin; Durvalumab; Durvalumab + Olaparib; Olaparib; Paclitaxel; Placebo	platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; placebo; PARP_inhibitor; taxane	Durvalumab + Olaparib	PARP_inhibitor + anti-PD-L1_monoclonal_antibody	2019-004112-60  D9311C00001	A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	Endometrial Neoplasms	2217 - Kogarah - Research Site; 2444 - Port Macquarie - Research Site - (Withdrawn); 2560 - Campbelltown - Research Site - (Not yet recruiting); 3000 - Melbourne - Research Site; 3144 - Malvern - Research Site; 3168 - Clayton - Research Site; 5042 - Bedford Park - Research Site; 5042 - Bedford Park - Research Site - (Withdrawn); 6009 - Nedlands - Research Site; NSW 2145 - Sydney - Research Site	https://clinicaltrials.gov/ct2/show/NCT04269200
NCT04277637	BGB-11417-101	Phase 1	Recruiting	WA, NZ, NSW, SA, VIC, QLD	20/02/2020	24/03/2020	BGB-11417; BGB-11417 + Zanubrutinib; Zanubrutinib	BCL2_inhibitor + BTK_inhibitor; BCL2_inhibitor; BTK_inhibitor	BGB-11417; BGB-11417 + Zanubrutinib	BCL2_inhibitor; BCL2_inhibitor + BTK_inhibitor	BGB-11417-101	A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies	Mature B-Cell Malignancies	2010 - Darlinghurst - St Vincent's Hospital Sydney (Kinghorn); 2139 - Concord - Concord Repatriation General Hospital; 2800 - Orange - Orange Health Service; 3000 - Melbourne - Peter McCallum Cancer Center; 3002 - East Melbourne - St Vincent's Hospital Melbourne; 3168 - Clayton - Monash Medical Centre; 4217 - Benowa - Pindara Private Hospital; 4224 - Tugun - John Flynn Private Hospital; 5042 - Adelaide - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research; 6021 - Newtown - Wellington Hospital; Adelaide - Royal Adelaide Hospital; Grafton - Auckland City Hospital; Takapuna - North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT04277637
NCT04282018	BGB-A317-3111-10188-101	Phase 1/Phase 2	Recruiting	WA, NSW, SA, VIC	24/02/2020	25/05/2020	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib; Tislelizumab; Zanubrutinib	BTK_inhibitor + PI3K_delta_inhibitor; BTK_inhibitor; anti-PD-1_monoclonal_antibody; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody; PI3K_delta_inhibitor	BGB-10188; BGB-10188 + Tislelizumab; BGB-10188 + Zanubrutinib	BTK_inhibitor + PI3K_delta_inhibitor; PI3K_delta_inhibitor; PI3K_delta_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-3111-10188-101	A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kd) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors	Marginal Zone Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Non-small Cell Lung Cancer; Small Lymphocytic Lymphoma; Advanced Solid Tumor; Metastatic Melanoma	2148 - Blacktown - Blacktown Hospital; 4029 - Herston - Royal Brisbane and Women's Hospital; 5000 - Adelaide - a) Hematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital,; Clayton - Monash Hospital - Hematology; Darlinghurst - St. Vincent Hospital - Sydney - Hematology/Oncology; Heidelberg - Austin Hospital - Hematology; West Perth - Perth Blood Institute	https://clinicaltrials.gov/ct2/show/NCT04282018
NCT04284761	Biolen-PC	Phase 1	Recruiting	NSW, VIC, NZ	26/02/2020	11/10/2020	Bicalutamide	antiandrogen,nonsteroidal,first_generation	Bicalutamide	antiandrogen,nonsteroidal,first_generation	CP-001	A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer	Prostate Adenocarcinoma; Lower Urinary Tract Symptoms	2076 - Wahroonga - Australian Clinical Trials; 2500 - Wollongong - University of Wollongong; 3112 - Tauranga - Tauranga Urology Research; 3144 - Melbourne - Australian Urology Associates	https://clinicaltrials.gov/ct2/show/NCT04284761
NCT04293094	NCT04293094	Phase 1	Recruiting	SA, VIC	3/03/2020	11/03/2020	AMG 650	KIF18A_inhibitor	AMG 650	KIF18A_inhibitor	20190131	A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre; 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT04293094
NCT04294160	CADPT01C12101	Phase 1	Recruiting	NSW	3/03/2020	22/07/2020	Dabrafenib; Dabrafenib + LTT462; Dabrafenib + LTT462 + Naporafenib; Dabrafenib + LTT462 + Spartalizumab; Dabrafenib + LTT462 + TNO155; Dabrafenib + LTT462 + Trametinib; Dabrafenib + TNO155 + Trametinib; LTT462; Naporafenib; Spartalizumab; TNO155; Trametinib	anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + SHP2_inhibitor; SHP2_inhibitor; ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + ERK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + MEK_inhibitor; MEK_inhibitor; RAF_dimer_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + RAF_dimer_inhibitor; BRAF_V600_inhibitor	Dabrafenib + LTT462; Dabrafenib + LTT462 + Naporafenib; Dabrafenib + LTT462 + Spartalizumab; Dabrafenib + LTT462 + TNO155; Dabrafenib + LTT462 + Trametinib; Dabrafenib + TNO155 + Trametinib	BRAF_V600_inhibitor + ERK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + MEK_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + RAF_dimer_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + SHP2_inhibitor; BRAF_V600_inhibitor + ERK_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor + MEK_inhibitor + SHP2_inhibitor	CADPT01C12101	A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer	BRAF V600 Colorectal Cancer	2145 - Westmead - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04294160
NCT04294810	SKYSCRAPER-01	Phase 3	Recruiting	NSW, QLD, VIC	4/03/2020	4/03/2020	Atezolizumab; Atezolizumab + Tiragolumab; Placebo; Tiragolumab	placebo; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Atezolizumab; Atezolizumab + Tiragolumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-002925-31  GO41717	A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2010 - Darlinghurst - St Vincent's Hospital Sydney - (Active, not recruiting); 3000 - Melbourne - Peter Maccallum Cancer Centre; 3084 - Heidelberg - Austin Hospital Olivia Newton John Cancer Centre; 3199 - Frankston - Frankston Hospital; Oncology/Haematology - (Active, not recruiting); 4102 - Woolloongabba - Princess Alexandra Hospital - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04294810
NCT04300244	NIPU	Phase 2	Recruiting	WA	9/03/2020	4/05/2020	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Sargramostim	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; Granulocyte-Macrophage_Colony_Stimulating_Factor; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-7H4 NIPU	Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)	Cancer, Lung; Cancer of Lung; Mesothelioma; Lung; Pleura; Cancer; Mesotheliomas Pleural	Perth - University of Western Australia	https://clinicaltrials.gov/ct2/show/NCT04300244
NCT04305041	2019-003956-35--3475-02A	Phase 1/Phase 2	Recruiting	WA, QLD, NSW	12/03/2020	26/06/2020	Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab + Vibostolimab; Quavonlimab; Vibostolimab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; VEGF_inhibitor; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab + Quavonlimab + Vibostolimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-003956-35  3475-02A	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A	Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia ( Site 1402); 2298 - Waratah - Calvary Mater Newcastle-Medical Oncology ( Site 1404); 4215 - Southport - Tasman Oncology Research Pty Ltd ( Site 1403); 6150 - Murdoch - Fiona Stanley Hospital ( Site 1401)	https://clinicaltrials.gov/ct2/show/NCT04305041
NCT04305054	2019-003977-24--3475-02B	Phase 1/Phase 2	Recruiting	NSW, QLD, WA	12/03/2020	1/07/2020	Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab; Quavonlimab; Vibostolimab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody	Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Pembrolizumab + Vibostolimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-003977-24  3475-02B	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B	Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia ( Site 2402); 2298 - Waratah - Calvary Mater Newcastle-Medical Oncology ( Site 2404); 4120 - Southport - Tasman Oncology Research Pty Ltd ( Site 2403) - (Suspended); 6150 - Murdoch - Fiona Stanley Hospital ( Site 2401)	https://clinicaltrials.gov/ct2/show/NCT04305054
NCT04305249	ERASER	Phase 1	Recruiting	NSW, VIC	12/03/2020	15/08/2020	ATG-017	ERK_inhibitor	ATG-017	ERK_inhibitor	ATG-017-001	A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies	Solid Tumor; Hematological Malignancy	3002 - East Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Hospital; 3084 - Heidelberg - Austin Hospital; Randwick - Scientia Clinical Research; Sydney - Chris O'Brien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT04305249
NCT04305496	CAPItello-291	Phase 3	Recruiting	NSW, QLD, VIC, SA	12/03/2020	16/04/2020	Capivasertib; Capivasertib + Fulvestrant; Fulvestrant; Placebo	selective_estrogen_receptor_degrader; pan-AKT_inhibitor; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; placebo	Capivasertib + Fulvestrant; Fulvestrant	pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	D3615C00001	A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor	Locally Advanced (Inoperable) or Metastatic Breast Cancer	2060 - North Sydney - Research Site - (Active, not recruiting); 2139 - Concord - Research Site - (Active, not recruiting); 2298 - Waratah - Research Site - (Active, not recruiting); 2640 - East Albury - Research Site - (Withdrawn); 2800 - Orange - Research Site - (Active, not recruiting); 3128 - Box Hill - Research Site - (Active, not recruiting); 3135 - Ringwood East - Research Site - (Active, not recruiting); 3350 - Ballarat - Research Site - (Active, not recruiting); 3355 - Wendouree - Research Site - (Active, not recruiting); 4101 - South Brisbane - Research Site - (Active, not recruiting); 4575 - Birtinya - Research Site - (Active, not recruiting); 5000 - Adelaide - Research Site - (Active, not recruiting); 5037 - Kurralta Park - Research Site - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04305496
NCT04311710	CheckMate-76U	Phase 1/Phase 2	Recruiting	VIC, NZ	17/03/2020	22/06/2020	Ipilimumab; Nivolumab; rHuPH20	recombinant_human_hyaluronidase; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody			CA209-76U	A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab	Tumor	3144 - Malvern; Auckland	https://clinicaltrials.gov/ct2/show/NCT04311710
NCT04322318	NCI-2020-01561--AREN1921	Phase 2	Recruiting	VIC, QLD, WA, NZ	26/03/2020	18/09/2020	Carboplatin; Carboplatin + Etoposide + Ifosfamide; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Topotecan; Vincristine	doxorubicin; anthracycline; alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; vinca_alkaloid; alkylating_agent; platinum-based_antineoplastic_agent	Carboplatin + Etoposide + Ifosfamide	alkylating_agent + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	NCI-2020-01561  AREN1921	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)	Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor; Recurrent Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Anaplastic Kidney Wilms Tumor	1145 - Grafton - Starship Children's Hospital; 3052 - Parkville - Royal Children's Hospital - (Suspended); 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT04322318
NCT04322539	FRESCO-2	Phase 3	Recruiting	WA, SA, VIC, QLD	26/03/2020	10/07/2020	Fruquintinib; Placebo	VEGFR1/2/3_inhibitor; placebo	Fruquintinib	VEGFR1/2/3_inhibitor	2019-013-GLOB1	A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer	Metastatic Colorectal Cancer; Metastatic Colon Cancer	3021 - Melbourne - Western Health; 3084 - Melbourne - Austin Hopistal Medical Oncology Unit; 3168 - Melbourne - Monash Health; 4001 - Brisbane - Integrated Clinical Oncology Network Pty Ltd (Icon); 5011 - Adelaide - The Queen Elizabeth Hospital; 5042 - Adelaide - Flinders Medical Centre; 6009 - Perth - Affinity Clinical Research Services	https://clinicaltrials.gov/ct2/show/NCT04322539
NCT04324814	SHR-1701-001AUS	Phase 1	Recruiting	WA, QLD, NSW	27/03/2020	31/03/2020	SHR-1701	PD-L1/TGF-beta_fusion_protein	SHR-1701	PD-L1/TGF-beta_fusion_protein	SHR-1701-001AUS	A Phase 1, Open-Label, Multi-Center, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SHR-1701 in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	4101 - South Brisbane - Icon Cancer Care Centre; Perth - Linear Clinical Research; Sydney - Scientia Clinical research; Sydney - Sydney South West Private	https://clinicaltrials.gov/ct2/show/NCT04324814
NCT04334759	DREAM3R	Phase 3	Recruiting	QLD, VIC, SA, NSW, TAS, NZ, WA	6/04/2020	18/02/2021	Durvalumab	anti-PD-L1_monoclonal_antibody	Durvalumab	anti-PD-L1_monoclonal_antibody	PrE0506  DREAM3R	DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial	Pleural Mesothelioma; Mesothelioma; Malignant Pleural Mesothelioma	1023 - Grafton - Auckland City Hospital; 2065 - Saint Leonards - Northern Cancer Institute (GenesisCare); 2145 - Westmead - Westmead Hospital; 2148 - Blacktown - Blacktown Hospital; 2170 - Liverpool - Liverpool Hospital; 2250 - Gosford - Gosford Hospital; 2259 - Hamlyn Terrace - Wyong Hospital; 2298 - Waratah - Calvary Mater Newcastle; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2747 - Kingswood - Nepean Hospital; 2800 - Orange - Orange Health Service; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3021 - Saint Albans - Sunshine Hospital (Western Health); 3084 - Heidelberg - Austin Hospital; 3121 - Richmond - Epworth HealthCare - Richmond; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; 3630 - Shepparton - Goulburn Valley Health; 4032 - Chermside - Icon Cancer Care Chermside; 4032 - Chermside - The Prince Charles Hospital; 4066 - Auchenflower - Icon Cancer Care Wesley; 4101 - South Brisbane - Icon Cancer Care South Brisbane; 4102 - Woolloongabba - Princess Alexandra Hospital; 4575 - Birtinya - Sunshine Coast University Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital (SCGH); 7000 - Hobart - Royal Hobart Hospital; 7250 - Launceston - Launceston General Hospital	https://clinicaltrials.gov/ct2/show/NCT04334759
NCT04338269	CONTACT-03	Phase 3	Recruiting	QLD, VIC, NSW	8/04/2020	28/07/2020	Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib	VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor; KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; ROS1_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody	Atezolizumab + Cabozantinib; Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; KIT_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	WO41994	A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	2109 - Macquarie Park - Macquarie University Hospital - (Active, not recruiting); 2800 - Orange - Orange Hospital - (Active, not recruiting); 3128 - Box Hill - Box Hill Hospital; Oncology - (Active, not recruiting); 3550 - Bendigo - Bendigo Cancer Centre; 4101 - South Brisbane - Icon Cancer Foundation	https://clinicaltrials.gov/ct2/show/NCT04338269
NCT04343885	UpFrontPSMA	Phase 2	Recruiting	NSW, QLD, VIC, SA	13/04/2020	21/04/2020	Docetaxel; Docetaxel + Lutetium-177-PSMA-617; Lutetium-177-PSMA-617	177Lu-PSMA-radioconjugate; 177Lu-PSMA-radioconjugate + taxane; taxane	Docetaxel + Lutetium-177-PSMA-617	177Lu-PSMA-radioconjugate + taxane	19/195	UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer	Metastatic Hormone Naive Prostate Cancer	2010 - Sydney - St Vincent's Hospital Sydney; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Melbourne - Austin Health; 4029 - Brisbane - Royal Brisbane and Women's Hospital; 5000 - Adelaide - Royal Adelaide Hospital	https://clinicaltrials.gov/ct2/show/NCT04343885
NCT04349969	AK117-101	Phase 1	Not yet recruiting	WA, NSW, SA, VIC, QLD	16/04/2020		AK117	anti-CD47_monoclonal_antibody	AK117	anti-CD47_monoclonal_antibody	AK117-101	A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas	Neoplasms Malignant	3084 - Heidelberg - Austin Health; 4101 - South Brisbane - ICON Cancer Foundation; 5037 - Kurralta Park - Adelaide Cancer Centre; 6009 - Nedlands - Linear Clinical Research/Sir Charles Gairdner Hospital; Sydney - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT04349969
NCT04353102	YH002002	Phase 1	Recruiting	NSW, VIC	20/04/2020	22/04/2020	YH002	anti-OX40_agnostic_monoclonal_antibody	YH002	anti-OX40_agnostic_monoclonal_antibody	YH002002	A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies	Advanced Solid Malignancies	2162 - Macquarie - Macquarie University; 2217 - Kogarah - St George Private Hospital; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT04353102
NCT04357756	YH001002	Phase 1	Recruiting	VIC, NSW	22/04/2020	21/04/2020	Toripalimab; Toripalimab + YH001; YH001	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Toripalimab + YH001	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	YH001002	A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors	Advanced Solid Tumor	2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre; 2217 - Kogarah - St George Private Hospital; 3199 - Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group	https://clinicaltrials.gov/ct2/show/NCT04357756
NCT04362748	NCT04362748	Phase 1	Recruiting	VIC, NSW	27/04/2020	15/09/2020	AMG 256	anti-PD-1_x_IL21_mutein	AMG 256	anti-PD-1_x_IL21_mutein	20180144	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2010 - Darlinghurst - St Vincents Hospital Sydney; 2050 - Camperdown - Chris OBrien Lifehouse; 3168 - Clayton - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04362748
NCT04380805	AK104-201-AU	Phase 2	Recruiting	NSW, SA, VIC, WA, NZ	8/05/2020	15/07/2020	AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody	AK104-201-AU	A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer	Metastatic Cervical Cancer; Recurrent Cervical Cancer	Adelaide - Adelaide Cancer Centre; Blacktown - Blacktown Hospital; Brisbane - ICON Cancer Centre; Clayton - Monash Health; Grafton - Auckland City Hospital - (Not yet recruiting); Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT04380805
NCT04383210	ELVCAP-001-01	Phase 2	Recruiting	VIC	12/05/2020	29/09/2020	Seribantumab	anti-ERBB3_monoclonal_antibody			ELVCAP-001-01	CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors	Pancreatic Cancer; Esophageal Cancer; Ovarian Cancer; Breast Cancer; Lung Cancer; Kidney Cancer; Metastatic Solid Tumor; Uterine Cancer; Locally Advanced Solid Tumor; Colorectal Cancer; Sarcoma; Bile Duct Cancer; Gallbladder Cancer; Prostate Cancer; Cholangiocarcinoma; Bladder Cancer; Head and Neck Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04383210
NCT04385277	NCI-2020-02950--ANBL19P1	Phase 2	Recruiting	WA, NZ, NSW, QLD, VIC	12/05/2020	30/11/2020	Dinutuximab; Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide; Irinotecan; Isotretinoin; Sargramostim; Temozolomide	anti-GD2_monoclonal_antibody; topoisomerase_inhibitor; 13-cis-retinoic_acid; 13-cis-retinoic_acid + Granulocyte-Macrophage_Colony_Stimulating_Factor + alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor; Granulocyte-Macrophage_Colony_Stimulating_Factor; alkylating_agent	Dinutuximab + Irinotecan + Isotretinoin + Sargramostim + Temozolomide	13-cis-retinoic_acid + Granulocyte-Macrophage_Colony_Stimulating_Factor + alkylating_agent + anti-GD2_monoclonal_antibody + topoisomerase_inhibitor	NCI-2020-02950  ANBL19P1	A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma	High Risk Neuroblastoma; Ganglioneuroblastoma, Nodular	1145 - Grafton - Starship Children's Hospital; 2145 - Westmead - The Children's Hospital at Westmead; 3052 - Parkville - Royal Children's Hospital; 4101 - South Brisbane - Queensland Children's Hospital; 6009 - Perth - Perth Children's Hospital	https://clinicaltrials.gov/ct2/show/NCT04385277
NCT04390763	daNIS-1	Phase 2	Recruiting	NSW, VIC	18/05/2020	16/10/2020	Gemcitabine; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel; NIS793; Nab-paclitaxel; Spartalizumab	taxane; anti-PD-1_monoclonal_antibody; anti-TGF-beta_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane; antimetabolite	Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + NIS793 + Nab-paclitaxel + Spartalizumab; Gemcitabine + Nab-paclitaxel	anti-PD-1_monoclonal_antibody + anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane	2020-000349-14  CNIS793B12201	A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Metastatic Pancreatic Ductal Adenocarcinoma	2145 - Westmead; 3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04390763
NCT04402073	PersoMed-I	Phase 2	Not yet recruiting		20/05/2020		Cisplatin; Lomustine; Radiotherapy; Sonidegib; Vincristine	platinum-based_antineoplastic_agent; vinca_alkaloid; alkylating_agent; radiotherapy; SMO_inhibitor,first_generation	Radiotherapy	radiotherapy	1634	Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)	Medulloblastoma		https://clinicaltrials.gov/ct2/show/NCT04402073
NCT04416516	ASN-002-003	Phase 2	Recruiting	QLD	4/06/2020	16/07/2020	Gusacitinib; Gusacitinib + Vismodegib; Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SMO_inhibitor,first_generation; SYK/JAK_inhibitor	Gusacitinib; Gusacitinib + Vismodegib	SMO_inhibitor,first_generation + SYK/JAK_inhibitor; SYK/JAK_inhibitor	ASN-002-003	A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients	Basal Cell Nevus Syndrome; Basal Cell Carcinoma	4000 - Brisbane - Central Brisbane Dermatology	https://clinicaltrials.gov/ct2/show/NCT04416516
NCT04417621	2020-000873-26--CLXH254C12201	Phase 2	Recruiting	NSW, QLD, WA	4/06/2020	30/10/2020	LTT462; LTT462 + Naporafenib; Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib; Ribociclib; Trametinib	RAF_dimer_inhibitor; CDK4/6_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor; CDK4/6_inhibitor + RAF_dimer_inhibitor	LTT462 + Naporafenib; Naporafenib + Ribociclib; Naporafenib + Trametinib	CDK4/6_inhibitor + RAF_dimer_inhibitor; ERK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor	2020-000873-26  CLXH254C12201	A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma	Melanoma	2060 - North Sydney; 6008 - Subiaco; 4102 - Wooloongabba	https://clinicaltrials.gov/ct2/show/NCT04417621
NCT04418661	U1111-1244-2555--TCD16210	Phase 1	Recruiting	NSW, VIC, QLD	5/06/2020	16/06/2020	Pembrolizumab; RMC-4630	SHP2_inhibitor; anti-PD-1_monoclonal_antibody	RMC-4630	SHP2_inhibitor	U1111-1244-2555  TCD16210	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies	Metastatic Neoplasm	2031 - Randwick - Investigational Site Number :0360002; 3081 - Heidelberg West - Investigational Site Number :0360003; 4102 - Woolloongabba - Investigational Site Number :0360001	https://clinicaltrials.gov/ct2/show/NCT04418661
NCT04419402	ENZA-p	Phase 2	Recruiting	NSW, SA, VIC, QLD, WA	5/06/2020	17/08/2020	Enzalutamide	antiandrogen,nonsteroidal,second_generation	Enzalutamide	antiandrogen,nonsteroidal,second_generation	ANZUP 1901	ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901)	Metastatic Castration-Resistant Prostate Cancer	2010 - Darlinghurst - St Vincents Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - Sydney - Northern Cancer Institute; 2170 - Liverpool - Liverpool Hospital; 2298 - Newcastle - Calvary Mater Newcastle; 3002 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Health; 3168 - Clayton - Monash Health; 4029 - Brisbane - Royal Brisbane and Women's Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6150 - Perth - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT04419402
NCT04427072	GeoMETry-III	Phase 3	Recruiting	VIC	11/06/2020	25/09/2020	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	Capmatinib; Docetaxel	MET_inhibitor,type_1; taxane	CINC280A2301	A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14).	Carcinoma, Non-Small-Cell Lung	3000 - Melbourne - Novartis Investigative Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04427072
NCT04428151	LEAP-009	Phase 2	Recruiting	NSW, QLD, VIC	11/06/2020	6/08/2020	Capecitabine; Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Cetuximab; Docetaxel; Lenvatinib; Lenvatinib + Pembrolizumab; Paclitaxel; Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + antimetabolite + taxane; taxane; anti-PD-1_monoclonal_antibody; antimetabolite	Capecitabine + Cetuximab + Docetaxel + Paclitaxel; Lenvatinib; Lenvatinib + Pembrolizumab	VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-EGFR_monoclonal_antibody + antimetabolite + taxane	LEAP-009  7902-009	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)	Squamous Cell Carcinoma of Head and Neck	2148 - Blacktown - Blacktown Hospital ( Site 0101); 2444 - Port Macquarie - Mid North Coast Cancer Institute ( Site 0109); 3168 - Clayton - Monash Health ( Site 0102); 4120 - Brisbane - Gallipoli Medical Research Foundation-GMRF CTU ( Site 0105); 4814 - Douglas - The Townsville Hospital ( Site 0107)	https://clinicaltrials.gov/ct2/show/NCT04428151
NCT04430842	QBS-72S-1001	Phase 1	Recruiting	NSW	12/06/2020	20/07/2020	QBS10072S	amino_acid_analogue,LAT1_targeting	QBS10072S	amino_acid_analogue,LAT1_targeting	QBS-72S-1001	A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma	Colorectal Cancer; Tongue Cancer; Cervical Cancer; Melanoma; Head and Neck Cancer; Cholangiocarcinoma; Bladder Cancer; Prostate Cancer; Thymic Carcinoma; Sarcoma; Ovarian Cancer; Brain Metastases; Pancreatic Cancer; Pleural Mesothelioma; Gastric Cancer; Esophagus Cancer; Liver Cancer; Brain Cancer; Kidney Cancer; Lung Cancer; Breast Cancer; Astrocytoma; Urinary Tract Cancer	2170 - Liverpool - Sydney Southwest Private Hospital; 2217 - Kogarah - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04430842
NCT04432207	IMU.201.101	Phase 1	Recruiting	VIC, NSW	16/06/2020	30/11/2020	IMU-201	B_cell_immunotherapy	IMU-201	B_cell_immunotherapy	IMU.201.101	An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1 Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer Stage IIIB; Non Small Cell Lung Cancer; Large Cell Carcinoma Lung; Adenocarcinoma Lung; Squamous Non-small-cell Lung Cancer; Non-small Cell Lung Cancer Stage IV	2050 - Camperdown - Chris O'Brien Lifehouse; 2109 - Macquarie - Macquarie University; 3000 - Melbourne - Cabrini Malvern Hospital	https://clinicaltrials.gov/ct2/show/NCT04432207
NCT04434482	IMP4297-106	Phase 1	Recruiting	NSW, VIC	17/06/2020	7/08/2020	IMP4297; IMP4297 + Temozolomide; Temozolomide	PARP_inhibitor + alkylating_agent; alkylating_agent; PARP_inhibitor	IMP4297 + Temozolomide	PARP_inhibitor + alkylating_agent	IMP4297-106	A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer	Small Cell Lung Cancer; Advanced Solid Tumours	2148 - Blacktown - Blacktown Hospital; 2640 - Albury - Border Medical Centre; 2800 - Orange - Orange Hospital; 3199 - Frankston - Peninsula Health - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04434482
NCT04438083	CRSP-ONC-003	Phase 1	Recruiting	VIC	18/06/2020	16/06/2020	Cyclophosphamide	alkylating_agent	Cyclophosphamide	alkylating_agent	CRSP-ONC-003	A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation	Renal Cell Carcinoma	3000 - Melbourne	https://clinicaltrials.gov/ct2/show/NCT04438083
NCT04446117	CONTACT-02	Phase 3	Recruiting	NSW, VIC, SA, ACT, TAS	24/06/2020	30/06/2020	Abiraterone; Abiraterone + Enzalutamide + Prednisone; Atezolizumab; Atezolizumab + Cabozantinib; Cabozantinib; Enzalutamide; Prednisone	ROS1_inhibitor; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; glucocorticoid; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; RET_inhibitor; antiandrogen,nonsteroidal,second_generation; KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor; MET_inhibitor,type_2	Abiraterone + Enzalutamide + Prednisone; Atezolizumab + Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + anti-PD-L1_monoclonal_antibody; AXL_inhibitor + anti-PD-L1_monoclonal_antibody; CYP17A1_inhibitor + antiandrogen,nonsteroidal,second_generation + glucocorticoid; KIT_inhibitor + anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_2 + anti-PD-L1_monoclonal_antibody; RET_inhibitor + anti-PD-L1_monoclonal_antibody; ROS1_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR2_inhibitor + anti-PD-L1_monoclonal_antibody	XL184-315	A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Adenocarcinoma; Metastatic Prostate Cancer	2065 - Saint Leonards - Exelixis Clinical Site #175; 2109 - Sydney - Exelixis Clinical Site # 189; 2500 - Wollongong - Exelixis Site #162; 2605 - Garran - Exelixis Clinical Site #151; 3000 - Melbourne - Exelixis Clinical Site #53; 3128 - Box Hill - Exelixis Clinical Site #149; 3199 - Frankston - Exelixis Clinical Site #95; 3350 - Ballarat - Exelixis Clinical Site #79; 5000 - Adelaide - Exelixis Clinical Site #115; 7250 - Launceston - Exelixis Clinical Site #103	https://clinicaltrials.gov/ct2/show/NCT04446117
NCT04446260	SHR-A1811-I-101	Phase 1	Recruiting	NSW, VIC, SA	24/06/2020	3/09/2020	SHR-A1811	anti-ERBB2_antibody-drug_conjugate			SHR-A1811-I-101	A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects	Advanced Solid Tumors	2109 - Macquarie - Macquarie University Hospital; 3004 - Melbourne - Alfred Hospital; 3004 - Melbourne - Nucleus Network - (Active, not recruiting); 3199 - Frankston - Peninsula and South Eastern Haematology &amp; Oncology Group; 5042 - Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04446260
NCT04447118	PYRAMID-1	Phase 3	Recruiting	Saint Leonard, WA, SA, VIC, NSW	25/06/2020	11/09/2020	Docetaxel; Pyrotinib	taxane; ERBB2_inhibitor,second_generation; EGFR_inhibitor,exon_20_selective	Docetaxel; Pyrotinib	EGFR_inhibitor,exon_20_selective; ERBB2_inhibitor,second_generation; taxane	HR-BLTN-III-NSCLC	A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy	Non-squamous NSCLC; HER2 Exon 20 Mutation	Albury - Border Medical Oncology; Fitzroy - St Vincent's Hospital Melbourne; Nedlands - Sir Charles Gairdner Hospital; North Adelaide - Calvary North Adelaide Hospital; St Leonards - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT04447118
NCT04449874	2020-000084-22--GO42144	Phase 1	Recruiting	NSW, VIC, WA, NZ	29/06/2020	29/07/2020	Atezolizumab; Atezolizumab + GDC-6036; Bevacizumab; Bevacizumab + GDC-6036; Cetuximab; Cetuximab + GDC-6036; Erlotinib; Erlotinib + GDC-6036; GDC-6036; GDC-6036 + RLY-1971; RLY-1971	EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; anti-VEGF_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; EGFR_inhibitor,first_generation; anti-EGFR_monoclonal_antibody; SHP2_inhibitor; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody	Atezolizumab + GDC-6036; Bevacizumab + GDC-6036; Cetuximab + GDC-6036; Erlotinib + GDC-6036; GDC-6036; GDC-6036 + RLY-1971	EGFR_inhibitor,first_generation + KRAS_G12C_inhibitor; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + anti-EGFR_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-L1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-VEGF_monoclonal_antibody	2020-000084-22  GO42144	A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	Non-Small Cell Lung Cancer; Advanced Solid Tumors; Colorectal Cancer	1023 - Auckland - Auckland City Hospital - (Not yet recruiting); 2010 - Darlinghurst - St Vincent's Hospital Sydney - (Not yet recruiting); 3002 - East Melbourne - Peter MacCallum Cancer Center; 3004 - Melbourne - Alfred Health; 6009 - Nedlands - Linear Clinical Research Limited; 8011 - Christchurch - Christchurch Clinical Studies Trust Ltd - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04449874
NCT04450732	GQ1001X2101	Phase 1	Recruiting	NSW, VIC	29/06/2020	7/07/2020	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001	anti-ERBB2_antibody-drug_conjugate	GQ1001X2101	A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors	HER2-positive Gastric Cancer; Advanced Solid Tumor; HER2-positive Breast Cancer	2031 - Randwick - Scientia Clinical Research Limited; 3050 - Melbourne - Cabrini Institute in Melbourne, Australia	https://clinicaltrials.gov/ct2/show/NCT04450732
NCT04450901	YBL006C101	Phase 1	Recruiting	NSW	30/06/2020	1/07/2020	YBL006	anti-PD-1_monoclonal_antibody	YBL006	anti-PD-1_monoclonal_antibody	YBL006C101	A Phase 1, Open-Label, Multicenter, Single Arm, Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors	Advanced Solid Tumors	2109 - Macquarie - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04450901
NCT04455503	EVX-02-001	Phase 1/Phase 2	Recruiting	WA, NSW, VIC, SA	2/07/2020	13/07/2020	Nivolumab	anti-PD-1_monoclonal_antibody	Nivolumab	anti-PD-1_monoclonal_antibody	EVX-02-001	A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence	Melanoma Stage IV; Melanoma Stage III	2170 - Goulburn - Liverpool Hospital; 3000 - Melbourne - Peter Maccallum Cancer Centre; 3168 - Clayton - Monash Medical Centre; 3350 - Drummond - Ballarat Health Services; 5042 - Adelaide - Flinders Medical Centre; 6009 - Nedlands - Linear Cancer Trials	https://clinicaltrials.gov/ct2/show/NCT04455503
NCT04456699	MK-7339-003--7339-003	Phase 3	Recruiting	NSW, VIC, QLD, SA	2/07/2020	19/08/2020	Bevacizumab; Bevacizumab + Capecitabine; Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Olaparib; Capecitabine; Fluorouracil; Leucovorin; Olaparib	anti-VEGF_monoclonal_antibody + antimetabolite + folinic_acid; PARP_inhibitor; anti-VEGF_monoclonal_antibody; folinic_acid; antimetabolite; anti-VEGF_monoclonal_antibody + antimetabolite; PARP_inhibitor + anti-VEGF_monoclonal_antibody	Bevacizumab + Capecitabine; Bevacizumab + Fluorouracil + Leucovorin; Bevacizumab + Olaparib; Olaparib	PARP_inhibitor; PARP_inhibitor + anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite; anti-VEGF_monoclonal_antibody + antimetabolite + folinic_acid	MK-7339-003  7339-003	A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction (LYNK-003)	Metastatic Colorectal Cancer	2170 - Liverpool - Liverpool Hospital ( Site 0055); 2217 - Kogarah - St George Hospital ( Site 0052); 3168 - Clayton - Monash Health ( Site 0050); 3199 - Frankston - Peninsula Health Frankston Hospital ( Site 0056); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 0054); 5011 - Woodville South - Queen Elizabeth Hospital ( Site 0053)	https://clinicaltrials.gov/ct2/show/NCT04456699
NCT04460456	SBT6050-101	Phase 1	Recruiting	VIC, NSW, WA	7/07/2020	27/07/2020	Cemiplimab; Cemiplimab + SBT6050; Pembrolizumab; Pembrolizumab + SBT6050; SBT6050	anti-PD-1_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	Cemiplimab + SBT6050; Pembrolizumab + SBT6050; SBT6050	anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-1_monoclonal_antibody	SBT6050-101	A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2	HER2 Positive Solid Tumors	2109 - Sydney - Macquarie University Hospital Clinical Trials Unit; 3000 - Melbourne - Peter MacCallum Cancer Centre - (Active, not recruiting); 6009 - Nedlands - Breast Cancer Research Centre - WA	https://clinicaltrials.gov/ct2/show/NCT04460456
NCT04464226	2019-003618-15--20321	Phase 3	Recruiting	SA	9/07/2020	20/10/2020	Darolutamide	antiandrogen,nonsteroidal,second_generation	Darolutamide	antiandrogen,nonsteroidal,second_generation	2019-003618-15  20321	An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies	Cancer	5037 - Kurralta Park - Adelaide Cancer Centre Research Pty Ltd	https://clinicaltrials.gov/ct2/show/NCT04464226
NCT04468607	GO41751	Phase 1	Recruiting	VIC	13/07/2020	31/08/2020					GO41751	A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer	Colorectal Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT04468607
NCT04472429	INCMGA-0012-303	Phase 3	Recruiting	QLD, VIC, SA	15/07/2020	9/11/2020	Carboplatin; Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Retifanlimab; Paclitaxel; Placebo; Retifanlimab	taxane; anti-PD-1_monoclonal_antibody; placebo; platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane	Carboplatin + Paclitaxel; Carboplatin + Paclitaxel + Retifanlimab	anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + taxane; platinum-based_antineoplastic_agent + taxane	INCMGA 0012-303	A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)	Squamous Cell Carcinoma of the Anal Canal	03168 - Clayton - Monash Medical Centre Clayton; 04102 - Woolloongabba - Princess Alexandra Hospital Australia; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04472429
NCT04475939	ZEAL-1L	Phase 3	Recruiting	VIC, NSW, TAS	17/07/2020	26/10/2020	Niraparib; Niraparib + Pembrolizumab; Pembrolizumab; Placebo	anti-PD-1_monoclonal_antibody; PARP_inhibitor + anti-PD-1_monoclonal_antibody; placebo; PARP_inhibitor	Niraparib + Pembrolizumab; Pembrolizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	213400	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)	Lung Cancer, Non-Small Cell	2148 - Blacktown - GSK Investigational Site; 3084 - Heidelberg - GSK Investigational Site; 3350 - Ballarat - GSK Investigational Site; 7000 - Hobart - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT04475939
NCT04482309	DPT02	Phase 2	Recruiting	NSW, VIC, QLD, WA	22/07/2020	18/08/2020	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate			D967VC00001	A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)	Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors	2031 - Randwick - Research Site - (Withdrawn); 2050 - Camperdown - Research Site; 3084 - Heidelberg - Research Site; 4066 - Auchenflower - Research Site; 6009 - Nedlands - Research Site; NSW 2217 - Kogarah - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04482309
NCT04487080	MARIPOSA	Phase 3	Recruiting	QLD, VIC, SA, NSW, WA	27/07/2020	30/09/2020	Amivantamab; Amivantamab + Lazertinib; Lazertinib; Lazertinib + Osimertinib; Osimertinib; Placebo	bispecific_c-Met_EGFR_monoclonal_antibody; placebo; EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody; EGFR_inhibitor,third_generation	Amivantamab + Lazertinib; Lazertinib + Osimertinib	EGFR_inhibitor,third_generation; EGFR_inhibitor,third_generation + bispecific_c-Met_EGFR_monoclonal_antibody	2020-000743-31  CR108856	A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Carcinoma, Non-Small-Cell Lung	2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital - (Withdrawn); 2500 - Wollongong - Southern Medical Day Care Centre; 3084 - Heidelberg - Austin Hospital; 3144 - Malvern - Cabrini Medical Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital; 6150 - Murdoch - St John of God Hospital Murdoch; 6150 - Murdoch - St John of God Hospital Murdoch - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04487080
NCT04493853	CAPItello-281	Phase 3	Recruiting	NSW, QLD, VIC	30/07/2020	13/07/2020	Abiraterone; Abiraterone + Capivasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone; Capivasertib; Placebo; Prednisolone; Prednisone	glucocorticoid; CYP17A1_inhibitor + glucocorticoid; placebo; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor; pan-AKT_inhibitor; CYP17A1_inhibitor	Abiraterone + Capivasertib + Prednisolone + Prednisone; Abiraterone + Prednisolone + Prednisone	CYP17A1_inhibitor + glucocorticoid; CYP17A1_inhibitor + glucocorticoid + pan-AKT_inhibitor	D361BC00001	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.	Hormone-Sensitive Prostate Cancer	2010 - Darlinghurst - Research Site; 2500 - Wollongong - Research Site - (Withdrawn); 2747 - Kingswood - Research Site; 2747 - Kingswood - Research Site - (Suspended); 2800 - Orange - Research Site; 3121 - Richmond - Research Site - (Withdrawn); 4101 - South Brisbane - Research Site; 4575 - Birtinya - Research Site	https://clinicaltrials.gov/ct2/show/NCT04493853
NCT04494425	DB-06	Phase 3	Recruiting	TAS, WA, VIC, QLD, SA, NSW	31/07/2020	24/07/2020	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel; Trastuzumab Deruxtecan	taxane; anti-ERBB2_antibody-drug_conjugate; antimetabolite + taxane; antimetabolite	Capecitabine + Nab-paclitaxel + Paclitaxel; Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate; antimetabolite + taxane	D9670C00001	A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)	Advanced or Metastatic Breast Cancer	2010 - Darlinghurst - Research Site; 2065 - St Leonards - Research Site - (Suspended); 2139 - Concord - Research Site - (Withdrawn); 2298 - Waratah - Research Site; 3004 - Melbourne - Research Site - (Withdrawn); 3065 - Fitzroy - Research Site - (Withdrawn); 3199 - Frankston - Research Site - (Withdrawn); 4066 - Auchenflower - Research Site - (Withdrawn); 4101 - South Brisbane - Research Site; 4575 - Birtinya - Research Site; 5000 - Adelaide - Research Site - (Withdrawn); 6150 - Murdoch - Research Site; 7000 - Hobart - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04494425
NCT04497844	AMPLITUDE	Phase 3	Recruiting	VIC, QLD, SA, NSW, NZ, TAS, WA	4/08/2020	23/09/2020	Abiraterone; Abiraterone + Niraparib + Prednisone; Niraparib; Niraparib + Prednisone; Placebo; Prednisone	glucocorticoid; CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; placebo; PARP_inhibitor; PARP_inhibitor + glucocorticoid; CYP17A1_inhibitor	Abiraterone + Niraparib + Prednisone; Niraparib + Prednisone	CYP17A1_inhibitor + PARP_inhibitor + glucocorticoid; PARP_inhibitor + glucocorticoid	2020-002209-25  CR108852	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Metastatic Castrate Sensitive Prostate Cancer	1023 - Auckland - Auckland City Hospital; 2010 - Darlinghurst - St. Vincent's Hospital Sydney; 2109 - North Ryde - Macquarie University Hospital; 2170 - Liverpool - Liverpool Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3112 - Tauranga - Tauranga Hospital; 4029 - Herston - Royal Brisbane and Women's Hospital; 4101 - South Brisbane - ICON Cancer Care; 5037 - Kurralta Park - Ashford Cancer Centre; 6008 - Subiaco - St John of God Subiaco Hospital; 6150 - Murdoch - Fiona Stanley Hospital; 7000 - Hobart - Royal Hobart Hospital; 8013 - Christchurch - Canterbury Urology Research Trust; 9016 - Dunedin Central - Dunedin Hospital; Birtinya - Sunshine Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT04497844
NCT04499352	2019-004749-33--1381-0011	Phase 2	Recruiting	NSW	5/08/2020	14/09/2020	BI836880; Ezabenlimab	VEGF/Ang2-blocking_nanobody; anti-PD-1_monoclonal_antibody			2019-004749-33  1381-0011	An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal	Anal Canal Squamous Cell Carcinoma	2031 - Randwick	https://clinicaltrials.gov/ct2/show/NCT04499352
NCT04501276	ADG116-1003	Phase 1	Recruiting	NSW, SA	6/08/2020	23/09/2020	ADG116	anti-CTLA-4_monoclonal_antibody	ADG116	anti-CTLA-4_monoclonal_antibody	ADG116-1003	A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors	Advanced/Metastatic Solid Tumors	Kurralta Park - Ashford Cancer Centre Research; Malvern - Cabrini Hospital; Sydney - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT04501276
NCT04505826	OP-1250-001	Phase 1/Phase 2	Recruiting	NSW, SA, QLD, VIC	10/08/2020	13/08/2020	OP-1250	complete_estrogen_receptor_antagonist	OP-1250	complete_estrogen_receptor_antagonist	OP-1250-001	A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer	Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer	2109 - Sydney - Macquarie University; 2145 - Westmead - Westmead - (Not yet recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre - (Not yet recruiting); 4066 - Auchenflower - ICON Cancer Centre - (Not yet recruiting); 5000 - Adelaide - Cancer Research South Australia - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04505826
NCT04513925	SKYSCRAPER-03	Phase 3	Recruiting	NZ, WA, SA, QLD, VIC, NSW	14/08/2020	24/08/2020	Atezolizumab; Atezolizumab + Tiragolumab; Durvalumab; Tiragolumab	anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + Tiragolumab; Durvalumab	anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2019-004773-29  GO41854	A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation	Non-small Cell Lung Cancer (NSCLC)	2148 - Blacktown - Blacktown Hospital; 2217 - Kogarah - St George Hospital; Cancer Care Centre; 2560 - Campbelltown - Macarthur Cancer Therapy Centre; 3143 - Tauranga - Tauranga Hospital; 3168 - Victoria - Monash Health Translational Precinct; Clinical Trials Centre, Level 3; 4102 - Woolloongabba - Princess Alexandra Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6149 - Bull Creek - Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit - (Active, not recruiting)	https://clinicaltrials.gov/ct2/show/NCT04513925
NCT04516447	ZN-c3-002	Phase 1	Recruiting	WA, VIC, QLD	18/08/2020	26/10/2020	Carboplatin; Carboplatin + ZN-C3; Gemcitabine; Gemcitabine + ZN-C3; Paclitaxel; Paclitaxel + ZN-C3; Pegylated liposomal doxorubicin; ZN-C3	WEE1_inhibitor + taxane; WEE1_inhibitor; anthracycline; taxane; antimetabolite; platinum-based_antineoplastic_agent; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent	Carboplatin + ZN-C3; Gemcitabine + ZN-C3; Paclitaxel + ZN-C3; ZN-C3	WEE1_inhibitor; WEE1_inhibitor + antimetabolite; WEE1_inhibitor + platinum-based_antineoplastic_agent; WEE1_inhibitor + taxane	ZN-c3-002	A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer	Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Solid Tumor	3144 - Melbourne - Site 2706; 4101 - South Brisbane - Site 2707; 4556 - Sunshine Coast - Site 2708; 6009 - Nedlands - Site 2705	https://clinicaltrials.gov/ct2/show/NCT04516447
NCT04521686	2020-002863-77--LOXO-IDH-20002	Phase 1	Recruiting	NSW	20/08/2020	16/10/2020	LY3410738	IDH1_R132_inhibitor,covalent; IDH1_R132_inhibitor	LY3410738	IDH1_R132_inhibitor; IDH1_R132_inhibitor,covalent	2020-002863-77  LOXO-IDH-20002	A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	Any Solid Tumor; Chondrosarcoma; Cholangiocarcinoma; Glioma	2010 - Darlinghurst - St Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT04521686
NCT04522323	D7980C00003	Phase 1	Recruiting	VIC, NSW	21/08/2020	5/08/2020	Axitinib; Axitinib + Lenvatinib + MEDI5752; Lenvatinib; Lenvatinib + MEDI5752; MEDI5752	VEGF_inhibitor; VEGFR/PDGFR_inhibitor; bispecific_PD-L1/CTLA-4_antibody; KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; KIT_inhibitor,ATP-competitive	Axitinib + Lenvatinib + MEDI5752; Lenvatinib + MEDI5752	KIT_inhibitor,ATP-competitive + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGFR/PDGFR_inhibitor + VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody; VEGF_inhibitor + bispecific_PD-L1/CTLA-4_antibody	D7980C00003	A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma	Advanced Renal Cell Carcinoma	2298 - Waratah - Research Site - (Not yet recruiting); 3000 - Melbourne - Research Site - (Not yet recruiting); 3199 - Frankston - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04522323
NCT04524689	CARMEN-LC05	Phase 2	Recruiting	VIC, NSW	24/08/2020	26/10/2020	Carboplatin; Carboplatin + Pembrolizumab; Carboplatin + Pembrolizumab + Pemetrexed; Cisplatin; Cisplatin + Pembrolizumab; Cisplatin + Pembrolizumab + Pemetrexed; Pembrolizumab; Pemetrexed; SAR408701	anti-CEACAM5_antibody-drug_conjugate; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	Carboplatin + Pembrolizumab; Carboplatin + Pembrolizumab + Pemetrexed; Cisplatin + Pembrolizumab; Cisplatin + Pembrolizumab + Pemetrexed; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent	U1111-1233-9798  ACT16146	Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	3081 - Heidelberg West; 2109 - Macquarie Park	https://clinicaltrials.gov/ct2/show/NCT04524689
NCT04526106	RLY-4008-101	Phase 1	Recruiting	NSW, QLD, WA	25/08/2020	2/09/2020	RLY-4008	FGFR2_inhibitor	RLY-4008	FGFR2_inhibitor	RLY-4008-101	A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors	Intrahepatic Cholangiocarcinoma; Gastric Cancer; Breast Cancer; FGFR2 Amplification; Solid Tumor, Adult; FGFR2 Gene Activation; Endometrial Cancer; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene Translocation; Cholangiocarcinoma	2010 - Darlinghurst - St. Vincent's Hosptial Sydney; 4101 - South Brisbane, - Icon Cancer Care South Brisbane; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT04526106
NCT04526509	NCT04526509	Phase 1	Recruiting	VIC	25/08/2020	21/12/2020	Cyclophosphamide; Fludarabine	antimetabolite; alkylating_agent			209012	Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors	Neoplasms	3000 - Melbourne - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT04526509
NCT04526899	2020-002195-12--BNT111-01	Phase 2	Recruiting	NSW	26/08/2020	19/05/2021	Cemiplimab	anti-PD-1_monoclonal_antibody	Cemiplimab	anti-PD-1_monoclonal_antibody	2020-002195-12  BNT111-01	Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma	Unresectable Melanoma; Melanoma Stage IV; Melanoma Stage III	2640 - East Albury - Border Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT04526899
NCT04527991	TROPiCS-04	Phase 3	Recruiting	SA, QLD, VIC, NSW, NZ, WA	27/08/2020	13/01/2021	Docetaxel; Docetaxel + Paclitaxel + Vinflunine; Paclitaxel; Sacituzumab Govitecan; Vinflunine	taxane + vinca_alkaloid; vinca_alkaloid; anti-Trop2_antibody-drug_conjugate; taxane	Docetaxel + Paclitaxel + Vinflunine; Sacituzumab Govitecan	anti-Trop2_antibody-drug_conjugate; taxane + vinca_alkaloid	2020-002964-29  IMMU-132-13	A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)	Locally Advanced or Metastatic Unresectable Urothelial Cancer	2145 - Westmead - Westmead Hospital; 2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health; 4066 - Auchenflower - Icon Cancer Centre Wesley; 5037 - Kurralta Park - Ashford Cancer Centre Research - ICON Cancer Centre Adelaide; 5042 - Bedford Park - Southern Adelaide Local Health Network Incorporated; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT04527991
NCT04538664	PAPILLON	Phase 3	Recruiting	WA, NSW, VIC	4/09/2020	13/10/2020	Amivantamab; Amivantamab + Carboplatin + Pemetrexed; Carboplatin; Carboplatin + Pemetrexed; Pemetrexed	bispecific_c-Met_EGFR_monoclonal_antibody; antimetabolite + platinum-based_antineoplastic_agent; antimetabolite + bispecific_c-Met_EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite; platinum-based_antineoplastic_agent	Amivantamab + Carboplatin + Pemetrexed; Carboplatin + Pemetrexed	antimetabolite + bispecific_c-Met_EGFR_monoclonal_antibody + platinum-based_antineoplastic_agent; antimetabolite + platinum-based_antineoplastic_agent	2020-000633-40  CR108850	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	2050 - Camperdown - Chris O'Brien Lifehouse; 2217 - Kogarah - St George Hospital; 3084 - Heidelberg - Austin Hospital - (Withdrawn); 3144 - Malvern - Cabrini Medical Centre; 6009 - Nedlands - Sir Charles Gairdner Hospital	https://clinicaltrials.gov/ct2/show/NCT04538664
NCT04538742	DB-07	Phase 1/Phase 2	Recruiting	VIC	4/09/2020	28/12/2020	Durvalumab; Durvalumab + Paclitaxel; Paclitaxel; Pertuzumab; Trastuzumab Deruxtecan; Tucatinib	anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; taxane; ERBB2_inhibitor,third_generation; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + taxane	Durvalumab; Durvalumab + Paclitaxel; Paclitaxel; Pertuzumab; Tucatinib	ERBB2_inhibitor,third_generation; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + taxane; taxane	D967JC00001	A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)	Metastatic Breast Cancer	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT04538742
NCT04546009	2020-000119-66--BO41843	Phase 3	Recruiting	NSW, SA, VIC, QLD, WA, NZ	11/09/2020	9/10/2020	Giredestrant; Giredestrant + Letrozole + Palbociclib; LHRH Agonist; Letrozole; Palbociclib; Placebo	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader; LHRH_agonist; selective_estrogen_receptor_degrader; aromatase_inhibitor; CDK4/6_inhibitor; placebo	Giredestrant + Letrozole + Palbociclib	CDK4/6_inhibitor + aromatase_inhibitor + selective_estrogen_receptor_degrader	2020-000119-66  BO41843	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	1023 - Auckland - Auckland City Hospital; Clinical Oncology; 2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2050 - Camperdown - Chris O'Brien Lifehouse; 2298 - Waratah - Calvary Mater Newcastle; Medical Oncology - (Active, not recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre-East Melbourne; 3021 - St Albans - Sunshine Hospital - (Active, not recruiting); 3084 - Heidelberg - Austin Health; Cancer Clinical Trial Centre; 3199 - Frankston - Frankston Hospital; 3240 - Hamilton - Waikato Breast Cancer Trust; 4101 - South Brisbane - Mater Hospital Brisbane; 4102 - Woolloongabba - Princess Alexandra Hospital; Division of Cancer Services; 5042 - Bedford Park - Flinders Medical Centre; Medical Oncology; 6150 - Murdoch - Fiona Stanley Hospital - Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT04546009
NCT04551352	2020-000793-18--BP42169	Phase 1	Recruiting	VIC	16/09/2020	28/10/2020	Obinutuzumab; Tocilizumab	anti-IL-6_monoclonal_antibody; anti-CD20_monoclonal_antibody			2020-000793-18  BP42169	An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma	Mucosal Melanoma; Uveal Melanoma; Cutaneous Melanoma	3000 - Melbourne - Peter Maccallum Cancer Institute; Clinical Trial Unit	https://clinicaltrials.gov/ct2/show/NCT04551352
NCT04551963	BGB-3111-113	Phase 1	Recruiting	WA, SA, VIC, QLD, NSW	16/09/2020	15/11/2020	Zanubrutinib	BTK_inhibitor	Zanubrutinib	BTK_inhibitor	BGB-3111-113	A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies	B-cell Malignancies	2139 - Concord - Concord General Repatriation Hospital; 3168 - Clayton - Monash Health; 3199 - Frankston - Peninsula Private Hospital; 4224 - Tugun - John Flynn Private Hospital; 5000 - Adelaide - Royal Adelaide Hospital; 5042 - Bedford Park - Flinders Medical Centre; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04551963
NCT04556773	DB-08	Phase 1	Recruiting	NSW, VIC	21/09/2020	17/12/2020	Anastrozole; Capecitabine; Capivasertib; Durvalumab; Durvalumab + Paclitaxel; Fulvestrant; Paclitaxel; Trastuzumab Deruxtecan	anti-PD-L1_monoclonal_antibody + taxane; anti-ERBB2_antibody-drug_conjugate; selective_estrogen_receptor_degrader; taxane; antimetabolite; aromatase_inhibitor; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor	Anastrozole; Capecitabine; Capivasertib; Durvalumab + Paclitaxel; Fulvestrant	anti-PD-L1_monoclonal_antibody + taxane; antimetabolite; aromatase_inhibitor; pan-AKT_inhibitor; selective_estrogen_receptor_degrader	D967JC00002	A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)	Metastatic Breast Cancer	2145 - Westmead - Research Site; 3002 - East Melbourne - Research Site; 3004 - Melbourne - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04556773
NCT04565275	ICP-CL-00303	Phase 1/Phase 2	Recruiting	NSW, VIC	25/09/2020	1/02/2021	Gunagratinib	pan-FGFR_inhibitor	Gunagratinib	pan-FGFR_inhibitor	ICP-CL-00303	A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations	Cholangiocarcinoma; Advanced Solid Tumors; Urothelial Carcinoma	2109 - Macquarie Park - Macquarie University Hospital; 3084 - Melbourne - Olivia Newton-John Cancer Research Institute; 3168 - Clayton - Monash Medical Centre; 3199 - Frankston - Peninsula &amp; South Eastern Haematology &amp; Oncology Group	https://clinicaltrials.gov/ct2/show/NCT04565275
NCT04567615	2018-003151-38--CA224-073	Phase 2	Recruiting	NZ, NSW	28/09/2020	4/02/2021	Nivolumab; Nivolumab + Relatlimab; Relatlimab	anti-LAG3_monoclonal_antibody; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Nivolumab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2018-003151-38  CA224-073	A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)	Liver Cancer, Adult; Liver Cell Carcinoma, Adult; Liver Cell Carcinoma; Hepatocellular Carcinoma; Hepatoma	1142 - Auckland - Local Institution; 2050 - Camperdown - Local Institution - (Not yet recruiting); 2050 - Camperdown - Local Institution - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04567615
NCT04572152	AK119-102	Phase 1	Recruiting	SA, QLD, VIC, NSW	1/10/2020	18/01/2021	AK104	bispecific_PD-1/CTLA-4_antibody	AK104	bispecific_PD-1/CTLA-4_antibody	AK119-102	A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.	Advanced or Metastatic Solid Tumors	2148 - Blacktown - Blacktown Cancer and Haematology Centre (Blacktown Hospital); 3004 - Melbourne - Alfred Health (The Alfred Hospital); 3168 - Clayton - Monash Health; 4101 - South Brisbane - ICON Cancer Centre; 5037 - Adelaide - Ashford Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04572152
NCT04585035	KEYNOTE-C15--D1553-101	Phase 1/Phase 2	Recruiting	WA, NSW, SA, VIC	14/10/2020	2/10/2020	D-1553	KRAS_G12C_inhibitor	D-1553	KRAS_G12C_inhibitor	KEYNOTE-C15  D1553-101	A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation	NSCLC; Solid Tumor, Adult; CRC	2148 - Blacktown - Research Site; 2217 - Kogarah - Research Site - (Not yet recruiting); 2298 - Waratah - Research Site - (Not yet recruiting); 2640 - East Albury - Research Site; 3065 - Fitzroy - Research Site; 3144 - Malvern - Research Site; 3199 - Frankston - Research Site - (Not yet recruiting); 5011 - Woodville South - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT04585035
NCT04585815	2020-002829-28--B8011011	Phase 1/Phase 2	Recruiting	NSW, VIC	14/10/2020	10/11/2020	Axitinib; Axitinib + Sasanlimab; Binimetinib; Binimetinib + Encorafenib + Sasanlimab; Encorafenib; Sasanlimab	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor; anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; BRAF_V600_inhibitor; KIT_inhibitor,ATP-competitive; MEK_inhibitor	Axitinib + Sasanlimab; Binimetinib + Encorafenib + Sasanlimab	BRAF_V600_inhibitor + MEK_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-1_monoclonal_antibody	2020-002829-28  B8011011	A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small-Cell Lung	2050 - Camperdown - Chris O'Brien Lifehouse; 2065 - St Leonards - North Shore Radiology and Nuclear Medicine; 2065 - St Leonards - Northern Cancer Institute; 2139 - Concord - Concord Hospital; 3084 - Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT04585815
NCT04586231	2020-002075-35--6482-011	Phase 3	Recruiting	SA, VIC	14/10/2020	25/02/2021	Belzutifan; Belzutifan + Lenvatinib; Cabozantinib; Lenvatinib	MET_inhibitor,type_2; HIF2a_inhibitor + VEGF_inhibitor; AXL_inhibitor; VEGFR2_inhibitor; VEGF_inhibitor; HIF2a_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; KIT_inhibitor; RET_inhibitor; ROS1_inhibitor	Belzutifan + Lenvatinib; Cabozantinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL_inhibitor; HIF2a_inhibitor + VEGF_inhibitor; KIT_inhibitor; MET_inhibitor,type_2; RET_inhibitor; ROS1_inhibitor; VEGFR2_inhibitor	2020-002075-35  6482-011	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy	Carcinoma, Renal Cell	3000 - Melbourne - Peter MacCallum Cancer Centre ( Site 4010); 3199 - Frankston - Peninsula Health Frankston Hospital ( Site 4001); 5112 - Elizabeth Vale - Lyell McEwin Hospital ( Site 4004)	https://clinicaltrials.gov/ct2/show/NCT04586231
NCT04586335	CYH33-G102	Phase 1	Recruiting	QLD	14/10/2020	28/09/2020	CYH33; CYH33 + Olaparib; Olaparib	PI3K_alpha_inhibitor; PARP_inhibitor + PI3K_alpha_inhibitor; PARP_inhibitor	CYH33 + Olaparib	PARP_inhibitor + PI3K_alpha_inhibitor	CYH33-G102	Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Ovarian Cancer; Breast Cancer; Solid Tumor; Endometrial Cancer; Prostate Cancer	4101 - Brisbane - Integrated Oncology Network PTY LTD	https://clinicaltrials.gov/ct2/show/NCT04586335
NCT04589845	2020-001847-16--BO41932	Phase 2	Recruiting	NZ, QLD, VIC, NSW	19/10/2020	18/01/2021	Alectinib; Atezolizumab; Belvarafenib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate; TRK_inhibitor,first_generation; ALK_inhibitor,second_generation; MDM2_inhibitor; ALK_inhibitor,third_generation; RET_inhibitor; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor; RAF_dimer_inhibitor; PI3K_inhibitor; ROS1_inhibitor	Alectinib; Atezolizumab; Belvarafenib; Entrectinib; Idasanutlin; Inavolisib; Ipatasertib; Pralsetinib; Trastuzumab Emtansine	ALK_inhibitor,second_generation; ALK_inhibitor,third_generation; MDM2_inhibitor; PI3K_inhibitor; RAF_dimer_inhibitor; RET_inhibitor; ROS1_inhibitor; TRK_inhibitor,first_generation; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody; pan-AKT_inhibitor	2020-001847-16  BO41932	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	Solid Tumors	1023 - Auckland - Auckland City Hospital, Cancer and Blood Research; 2010 - Darlinghurst - Kinghorn Cancer Centre; St Vincents Hospital; 2031 - Randwick - Sydney Children's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology - (Active, not recruiting); 3052 - Parkville - Royal Children's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital; Christchurch - Christchurch Hospital; Dept of Oncology - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04589845
NCT04590963	INTERLINK-1	Phase 3	Recruiting	QLD, VIC, SA, NSW	19/10/2020	2/10/2020	Cetuximab; Cetuximab + Monalizumab; Monalizumab; Placebo	anti-NKG2A_monoclonal_antibody; placebo; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody; anti-EGFR_monoclonal_antibody	Cetuximab; Cetuximab + Monalizumab	anti-EGFR_monoclonal_antibody; anti-EGFR_monoclonal_antibody + anti-NKG2A_monoclonal_antibody	D7310C00001	A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor	Squamous Cell Carcinoma of the Head and Neck	2050 - Camperdown - Research Site; 2298 - Waratah - Research Site - (Withdrawn); 3000 - Melbourne - Research Site; 3084 - Heidelberg - Research Site; 4102 - Woolloongabba - Research Site; 4102 - Woolloongabba - Research Site - (Withdrawn); 5112 - Elizabeth Vale - Research Site	https://clinicaltrials.gov/ct2/show/NCT04590963
NCT04597411	CAAA817A12101--PSMA-617-100	Phase 1	Recruiting	NSW	22/10/2020	1/04/2021	LHRH Agonist	LHRH_agonist	LHRH Agonist	LHRH_agonist	CAAA817A12101  PSMA-617-100	AcTION: A Phase I Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer and Extensive Skeletal Metastases	Prostatic Neoplasms, Castration-Resistant	Darlinghurst - St. Vincent's Hospital Research Office-Translational Research Center - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04597411
NCT04603001	2020-002830-33--LOXO-IDH-20001	Phase 1	Recruiting	VIC, WA	26/10/2020	1/12/2020	LY3410738	IDH1_R132_inhibitor; IDH1_R132_inhibitor,covalent			2020-002830-33  LOXO-IDH-20001	A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	Acute Myeloid Leukemia (AML); Myeloproliferative Neoplasms (MPNs); Chronic Myelomonocytic Leukemia (CMML); Myelodysplastic Syndrome (MDS)	3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04603001
NCT04604132	FIDES-03	Phase 1/Phase 2	Recruiting	VIC	27/10/2020	6/10/2020	Atezolizumab; Atezolizumab + Derazantinib; Derazantinib; Derazantinib + Paclitaxel + Ramucirumab; Paclitaxel; Paclitaxel + Ramucirumab; Ramucirumab	taxane; FGFR1/2/3_inhibitor + anti-VEGFR2_monoclonal_antibody + taxane; FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; anti-VEGFR2_monoclonal_antibody + taxane; anti-PD-L1_monoclonal_antibody; anti-VEGFR2_monoclonal_antibody	Atezolizumab + Derazantinib; Derazantinib; Derazantinib + Paclitaxel + Ramucirumab; Paclitaxel + Ramucirumab	FGFR1/2/3_inhibitor; FGFR1/2/3_inhibitor + anti-PD-L1_monoclonal_antibody; FGFR1/2/3_inhibitor + anti-VEGFR2_monoclonal_antibody + taxane; anti-VEGFR2_monoclonal_antibody + taxane	DZB-CS-202	A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations	Gastric Adenocarcinoma	3000 - Melbourne - Peter MacCallum Cancer Centre; 3168 - Clayton - Monash Medical Centre Clayton; 3181 - Prahran - The Alfred Hospital	https://clinicaltrials.gov/ct2/show/NCT04604132
NCT04607421	2020-001288-99--C4221015	Phase 3	Recruiting	NSW, VIC, QLD, SA, NZ	29/10/2020	21/12/2020	Bevacizumab; Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Capecitabine; Cetuximab; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin; Encorafenib; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin	anti-VEGF_monoclonal_antibody; anti-VEGF_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor; platinum-based_antineoplastic_agent; folinic_acid; antimetabolite; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent; topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + antimetabolite + folinic_acid + topoisomerase_inhibitor; anti-EGFR_monoclonal_antibody	Bevacizumab + Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin; Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin; Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin	BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; BRAF_V600_inhibitor + anti-EGFR_monoclonal_antibody + antimetabolite + folinic_acid + topoisomerase_inhibitor; anti-VEGF_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2020-001288-99  C4221015	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER	Neoplasms	1023 - Auckland - Auckland City Hospital - (Not yet recruiting); 2065 - St Leonards - GenesisCare - North Shore - (Not yet recruiting); 2065 - St Leonards - Northern Cancer Institute - (Not yet recruiting); 2080 - Mount Kuring-Gai - Slade Pharmacy - (Not yet recruiting); 2170 - Liverpool - Liverpool Hospital - (Not yet recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - The Alfred Hospital - (Not yet recruiting); 3112 - Tauranga - Tauranga Hospital - (Not yet recruiting); 3168 - Clayton - Monash Health; 4029 - Herston - Royal Brisbane &amp; Women's Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital - (Not yet recruiting); 5011 - Adelaide - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT04607421
NCT04612751	2021-000274-28--DS1062-A-U104	Phase 1	Recruiting	SA, NSW	3/11/2020	6/11/2020	Carboplatin; Cisplatin; Datopotamab deruxtecan; Datopotamab deruxtecan + Durvalumab; Durvalumab	anti-Trop2_antibody-drug_conjugate; platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	Datopotamab deruxtecan + Durvalumab	anti-PD-L1_monoclonal_antibody + anti-Trop2_antibody-drug_conjugate	2021-000274-28  DS1062-A-U104	A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Data-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Advanced or Metastatic NSCLC	5042 - Bedford Park; 2500 - Wollongong	https://clinicaltrials.gov/ct2/show/NCT04612751
NCT04618393	EMB02X101	Phase 1/Phase 2	Recruiting	VIC	5/11/2020	11/03/2021	EMB-02	bispecific_PD-1/LAG3_antibody	EMB-02	bispecific_PD-1/LAG3_antibody	EMB02X101	A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors	Advanced Solid Tumors	3199 - Frankston - Peninsula &amp; South Eastern Haematology &amp; Oncology Group (PASO)	https://clinicaltrials.gov/ct2/show/NCT04618393
NCT04619004	2020-000730-17--U31402-A-U201	Phase 2	Recruiting	NSW, VIC, QLD, WA	6/11/2020	2/02/2021	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	Patritumab Deruxtecan	anti-ERBB3_antibody-drug_conjugate	2020-000730-17  U31402-A-U201	HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)	Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor	2050 - Camperdown - The Chris O'Brien Lifehouse; 2148 - Blacktown - Blacktown Hosital; 2217 - Kogarah - St George Public Hospital - (Not yet recruiting); 3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 6008 - Subiaco - St John of God Subiaco Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04619004
NCT04623775	2020-004026-31--CA224-104	Phase 2	Recruiting	NSW, VIC, QLD, WA, NZ	10/11/2020	17/02/2021	Carboplatin; Cisplatin; Nab-paclitaxel; Nivolumab; Nivolumab + Relatlimab; Paclitaxel; Pemetrexed; Relatlimab	taxane; anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-LAG3_monoclonal_antibody; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite	Nivolumab; Nivolumab + Relatlimab	anti-LAG3_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2020-004026-31  CA224-104	A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Metastatic Non-small Cell Lung Cancer; Non-small Cell Lunch Cancer; Recurrent Non-small Cell Lung Cancer	2050 - Camperdown - The Chris OBrien Lifehouse; 2250 - Gosford - Gosford Hospital; 2340 - Tamworth - North West Cancer Centre in Tamworth; 3128 - Box Hill - Box Hill Hospital-Eastern Health; 3199 - Frankston - Frankston Hospital - peninsula Health; 3350 - Ballarat - Ballarat Health Services; 3550 - Bendigo - Local Institution; 4101 - South Brisbane - Icon Cancer Centre; 6009 - Nedlands - Hollywood Private Hospital; 6150 - Murdoch - St John of God Hospital - Murdoch; 8013 - Christchurch - Local Institution - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04623775
NCT04624204	MK-7339-013--7339-013	Phase 3	Recruiting	QLD, VIC, NSW	10/11/2020	8/12/2020	Dexamethasone; Etoposide; Etoposide + Olaparib + Pembrolizumab + Radiotherapy; Olaparib; Pembrolizumab; Placebo; Radiotherapy	PARP_inhibitor; placebo; glucocorticoid; PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; topoisomerase_inhibitor; radiotherapy	Etoposide + Olaparib + Pembrolizumab + Radiotherapy	PARP_inhibitor + anti-PD-1_monoclonal_antibody + radiotherapy + topoisomerase_inhibitor	MK-7339-013  7339-013	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	Small Cell Lung Cancer	2298 - Waratah - Calvary Mater Newcastle ( Site 3000); 2560 - Campbelltown - Campbelltown Hospital ( Site 3002); 2750 - Penrith - Nepean Hospital ( Site 3001); 3021 - St Albans - Western Health-Sunshine Hospital ( Site 3004); 3084 - Heidelberg - Austin Health-Austin Hospital ( Site 3006); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 3007); 4215 - Southport - Gold Coast University Hospital ( Site 3003)	https://clinicaltrials.gov/ct2/show/NCT04624204
NCT04626479	2019-003609-84--3475-03A	Phase 1/Phase 2	Recruiting	NZ, NSW, QLD, VIC	12/11/2020	16/12/2020	Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2019-003609-84  3475-03A	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A	Carcinoma, Renal Cell	2217 - Kogarah; 3084 - Heidelberg; 2148 - Blacktown; Auckland; 4029 - Herston	https://clinicaltrials.gov/ct2/show/NCT04626479
NCT04626518	2019-003610-13--3475-03B	Phase 1/Phase 2	Recruiting	NZ, VIC, QLD, NSW	12/11/2020	17/12/2020	Belzutifan; Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; HIF2a_inhibitor; VEGF_inhibitor; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor; anti-PD-1_monoclonal_antibody	Belzutifan + Lenvatinib; Belzutifan + Pembrolizumab; Lenvatinib + Pembrolizumab; Pembrolizumab; Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor; HIF2a_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2019-003610-13  3475-03B	A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B	Carcinoma, Renal Cell	4029 - Herston; Auckland; 2148 - Blacktown; 3084 - Melbourne; 2217 - Kogarah	https://clinicaltrials.gov/ct2/show/NCT04626518
NCT04630756	D8230C00002	Phase 1/Phase 2	Recruiting	WA, VIC	16/11/2020	17/02/2021	AZD4573; AZD4573 + Acalabrutinib; Acalabrutinib	BTK_inhibitor + CDK9_inhibitor; BTK_inhibitor; CDK9_inhibitor	AZD4573 + Acalabrutinib	BTK_inhibitor + CDK9_inhibitor	D8230C00002	A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies	Advanced Haematological Malignancies	3168 - Clayton - Research Site; 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT04630756
NCT04631601	2020-001305-23--20190505	Phase 1/Phase 2	Recruiting	NSW	17/11/2020	15/01/2021	AMG 404; Abiraterone; Enzalutamide	antiandrogen,nonsteroidal,second_generation; CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody	AMG 404; Abiraterone; Enzalutamide	CYP17A1_inhibitor; anti-PD-1_monoclonal_antibody; antiandrogen,nonsteroidal,second_generation	2020-001305-23  20190505	A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	Metastatic Castration-resistant Prostate Cancer	2010 - Darlinghurst - St Vincents Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT04631601
NCT04634825	CP-MGA271-06	Phase 2	Recruiting	NSW, QLD, VIC	18/11/2020	17/03/2021	Enoblituzumab; Enoblituzumab + Retifanlimab; Retifanlimab	anti-CD276_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CD276_monoclonal_antibody	Enoblituzumab; Enoblituzumab + Retifanlimab	anti-CD276_monoclonal_antibody; anti-CD276_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CP-MGA271-06	A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Head and Neck Squamous Cell Carcinoma; Head and Neck Neoplasms; Head and Neck Cancer	2065 - Sydney - Royal North Shore Hospital; 2170 - Liverpool - Liverpool Hospital; 2298 - Waratah - Calvary Mater Newcastle; 3168 - Ruse - Monash Health, Medical Oncology Department; 3220 - Geelong - Andrew Love Cancer Centre, Barwon Health; 4215 - Southport - Icon Cancer Centre Southport	https://clinicaltrials.gov/ct2/show/NCT04634825
NCT04642365	2020-003164-82--BP42595	Phase 1	Recruiting	VIC	24/11/2020	4/01/2021	Atezolizumab; Atezolizumab + RO7296682; RO7296682	Treg_cell_depleting_antibody + anti-PD-L1_monoclonal_antibody; Treg_cell_depleting_antibody; anti-PD-L1_monoclonal_antibody	Atezolizumab + RO7296682	Treg_cell_depleting_antibody + anti-PD-L1_monoclonal_antibody	2020-003164-82  BP42595	An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors	Solid Tumors	3000 - Melbourne - Peter Maccallum Cancer Institute; Clinical Trial Unit	https://clinicaltrials.gov/ct2/show/NCT04642365
NCT04644068	PETRA	Phase 1/Phase 2	Recruiting	VIC	25/11/2020	12/11/2020	AZD5305; AZD5305 + Carboplatin + Paclitaxel; AZD5305 + Paclitaxel; Carboplatin; Paclitaxel	platinum-based_antineoplastic_agent; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + taxane; PARP_inhibitor; taxane	AZD5305; AZD5305 + Carboplatin + Paclitaxel; AZD5305 + Paclitaxel	PARP_inhibitor; PARP_inhibitor + platinum-based_antineoplastic_agent + taxane; PARP_inhibitor + taxane	D9720C00001	A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies	Prostate Cancer; Breast Cancer; Ovarian Cancer; Pancreatic Cancer	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT04644068
NCT04644237	DESTINY-LUNG02	Phase 2	Recruiting	WA, QLD	25/11/2020	19/03/2021	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	DS8201-A-U206	A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Non-Small Cell Lung Cancer	4102 - Woolloongabba - Princess Alexandra Hospital; 4814 - Townsville - Townsville University Hospital - (Withdrawn); 6008 - Subiaco - St John of God Subiaco Hospital	https://clinicaltrials.gov/ct2/show/NCT04644237
NCT04645069	ADG126-1001	Phase 1	Recruiting	QLD, VIC, NSW	27/11/2020	15/03/2021	ADG126	anti-CTLA-4_monoclonal_antibody	ADG126	anti-CTLA-4_monoclonal_antibody	ADG126-1001	First-in-human (FIH), Open-Label, Phase I Dose Escalation Study of ADG126 in Patients With Advanced Malignancies	Advanced/Metastatic Tumors	2228 - Sydney - Southside Cancer Care Centre; 3144 - Melbourne - Cabrini Health Limited - (Not yet recruiting); 4575 - Sunshine Coast - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04645069
NCT04649385	BGB-A317-15025-101	Phase 1	Recruiting	NZ, WA, SA, VIC	2/12/2020	4/03/2021	BGB-15025; BGB-15025 + Tislelizumab; Tislelizumab	HPK1_inhibitor + anti-PD-1_monoclonal_antibody; HPK1_inhibitor; anti-PD-1_monoclonal_antibody	BGB-15025; BGB-15025 + Tislelizumab	HPK1_inhibitor; HPK1_inhibitor + anti-PD-1_monoclonal_antibody	BGB-A317-15025-101	A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors	Advanced Solid Tumor	1023 - Grafton - ADHB, Cancer &amp; Blood Research - Auckland Cancer Trials Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; 5037 - Windsor - Ashford Cancer Centre Research; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04649385
NCT04655976	COSTAR-Lung	Phase 2/Phase 3	Recruiting	SA, VIC, QLD, NSW, TAS	7/12/2020	8/12/2020	Docetaxel; Docetaxel + Dostarlimab; Dostarlimab	anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Docetaxel + Dostarlimab	anti-PD-1_monoclonal_antibody + taxane; taxane	2020-003433-37  213410	A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)	Lung Cancer, Non-Small Cell	2148 - Blacktown - GSK Investigational Site; 3004 - Melbourne - GSK Investigational Site; 3350 - Ballarat - GSK Investigational Site; 4101 - South Brisbane - GSK Investigational Site; 5037 - Kurralta Park - GSK Investigational Site; 7000 - Hobart - GSK Investigational Site	https://clinicaltrials.gov/ct2/show/NCT04655976
NCT04656652	2020-004643-80--DS1062-A-U301	Phase 3	Recruiting	NSW	7/12/2020	21/12/2020	DS-1062a; Docetaxel	taxane; anti-Trop2_antibody-drug_conjugate	DS-1062a; Docetaxel	anti-Trop2_antibody-drug_conjugate; taxane	2020-004643-80  DS1062-A-U301	Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)	Non-small Cell Lung Cancer	02109 - North Ryde - Macquarie Hospital; 02148 - Blacktown - Blacktown Hosital; 02500 - Wollongong - Southern Medical Day Care Centre; 03084 - Heidelberg - Austin Hospital; 04101 - South Brisbane - Icon Cancer Centre - (Withdrawn); 05042 - Bedford Park - Flinders Medical Centre; 2145 - Sydney - Crown Princess Mary Cancer Centre Westmead Hospital; 2217 - Kogarah - St George Public Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04656652
NCT04659629	NL201-101	Phase 1	Recruiting	VIC, NSW	9/12/2020	26/04/2021	NL-201	IL-2/IL-15_receptor_agonist	NL-201	IL-2/IL-15_receptor_agonist	NL201-101	A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer	Advanced Solid Tumor; Solid Tumor	2065 - Sydney - Melanoma Institute Australia; Heidelberg - Olivia Newton-John Cancer Wellness &amp; Research Centre; Sydney - St Vincents Hospital	https://clinicaltrials.gov/ct2/show/NCT04659629
NCT04662710	LEAP-015	Phase 3	Recruiting	WA, NSW, QLD	10/12/2020	30/12/2020	Capecitabine; Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab; Fluorouracil; Lenvatinib; Leucovorin; Oxaliplatin; Pembrolizumab	VEGF_inhibitor; anti-PD-1_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent; folinic_acid	Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody + antimetabolite + folinic_acid + platinum-based_antineoplastic_agent	2020-001990-53  7902-015	Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)	Advanced/Metastatic Gastroesophageal Adenocarcinoma	2500 - Wollongong - Wollongong Hospital ( Site 2307); 2747 - Kingswood - Nepean Hospital ( Site 2305); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 2304); 6009 - Nedlands - Hollywood Private Hospital-Medical Oncology ( Site 2308)	https://clinicaltrials.gov/ct2/show/NCT04662710
NCT04665206	VT3989-001	Phase 1	Recruiting	VIC, WA	11/12/2020	24/03/2021	VT3989	YAP-TEAD_inhibitor	VT3989	YAP-TEAD_inhibitor	VT3989-001	Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene	Solid Tumor, Adult; Mesothelioma	3000 - Melbourne - Peter MacCullum Cancer Centre; 3168 - Clayton - Monash Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04665206
NCT04670679	FLAGSHP-1	Phase 1	Recruiting	WA, VIC	17/12/2020	15/12/2020	Cetuximab; Cetuximab + ERAS-601; ERAS-601	anti-EGFR_monoclonal_antibody; SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	Cetuximab + ERAS-601; ERAS-601	SHP2_inhibitor; SHP2_inhibitor + anti-EGFR_monoclonal_antibody	ERAS-601-01	An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	Melbourne - Peter MacCallum Cancer Centre; Perth - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04670679
NCT04674683	HBI-8000-303	Phase 3	Recruiting	NSW, VIC, QLD, WA, NZ	19/12/2020	12/08/2021	Nivolumab; Placebo	anti-PD-1_monoclonal_antibody; placebo	Nivolumab	anti-PD-1_monoclonal_antibody	HBI-8000-303	A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors	Progressive Brain Metastasis; Unresectable or Metastatic Melanoma	3112 - Tauranga - Tauranga Hospital; 4556 - Buderim - University of the Sunshine Coast; Ballarat - Ballarat Health Services; Brisbane - Royal Brisband and Women's Hospital; Hamilton - Waikato Hospital; Liverpool - Liverpool Hospital; Nedlands - Affinity Clinical Research; Shepparton - Goulburn Valley Health; South Brisbane - Icon Cancer Centre Wesley; Tweed Heads - Tweed Hospital; Wahroonga - Sydney Adventist Hospital; Waratah - Calvary Mater Newcastle	https://clinicaltrials.gov/ct2/show/NCT04674683
NCT04675294	KEYNOTE-B87--AT148003	Phase 2	Recruiting	SA	19/12/2020	2/04/2021	Pembrolizumab	anti-PD-1_monoclonal_antibody	Pembrolizumab	anti-PD-1_monoclonal_antibody	KEYNOTE-B87  AT148003	A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma	5037 - Adelaide - Ashford Cancer Center	https://clinicaltrials.gov/ct2/show/NCT04675294
NCT04675333	KEYNOTE-B88--AT148004	Phase 2	Recruiting	SA	19/12/2020	10/05/2021	Carboplatin; Cisplatin; Fluorouracil; Pembrolizumab	anti-PD-1_monoclonal_antibody; antimetabolite; platinum-based_antineoplastic_agent	Pembrolizumab	anti-PD-1_monoclonal_antibody	KEYNOTE-B88  AT148004	A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma	5037 - Adelaide - Ashford Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04675333
NCT04677855	PCUR101-003	Phase 1	Recruiting	NSW, SA	21/12/2020	30/03/2021	Abiraterone; Abiraterone + PCUR-101 + Prednisone; PCUR-101; Prednisone	CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; CYP17A1_inhibitor; glucocorticoid; synthetic_plumbagin	Abiraterone + PCUR-101 + Prednisone; PCUR-101	CYP17A1_inhibitor + glucocorticoid + synthetic_plumbagin; synthetic_plumbagin	PCUR101-003	A Phase I Study of PCUR-101 in Combination With Androgen Directed Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	2170 - Liverpool - Sydney South West Private Hospital - (Not yet recruiting); 2217 - Kogarah - St. George Private Hospital; 5042 - Bedford Park - Southern Oncology Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04677855
NCT04684108	SG301-001	Phase 1	Not yet recruiting	VIC, QLD	24/12/2020		SG301	anti-CD38_monoclonal_antibody	SG301	anti-CD38_monoclonal_antibody	SG301-001	A First-in-human Phase 1 Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of SG301 in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies	Hematological Malignancy; Relapsed or Refractory Multiple Myeloma	3199 - Frankston - Peninsula and Southeast Oncology; 4224 - Tugun - John Flynn Private Hospital; 4558 - Maroochydore - University of Sunshine Coast	https://clinicaltrials.gov/ct2/show/NCT04684108
NCT04699188	CJDQ443A12101	Phase 1/Phase 2	Recruiting	VIC	7/01/2021	24/02/2021	JDQ443; JDQ443 + Spartalizumab; JDQ443 + Spartalizumab + TNO155; JDQ443 + TNO155; Spartalizumab; TNO155	SHP2_inhibitor; anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody	JDQ443; JDQ443 + Spartalizumab; JDQ443 + Spartalizumab + TNO155; JDQ443 + TNO155	KRAS_G12C_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor; KRAS_G12C_inhibitor + SHP2_inhibitor + anti-PD-1_monoclonal_antibody; KRAS_G12C_inhibitor + anti-PD-1_monoclonal_antibody	CJDQ443A12101	A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation	Pulmonary Cancer; Cancer of Lung; Carcinoma, Colorectal; Lung Cancer; Cancer of the Lung; KRAS G12C Mutant Solid Tumors; Neoplasms, Lung; Neoplasms, Pulmonary; Carcinoma, Non-Small-Cell Lung; Pulmonary Neoplasms	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04699188
NCT04700072	2020-003742-36--3475-02D	Phase 1/Phase 2	Recruiting	NSW	7/01/2021	3/05/2021	Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2020-003742-36  3475-02D	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D	Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia ( Site 4402); 2298 - Waratah - Calvary Mater Newcastle ( Site 4404)	https://clinicaltrials.gov/ct2/show/NCT04700072
NCT04702737	NCT04702737	Phase 1	Recruiting	NSW, VIC	11/01/2021	10/06/2021	AMG 757	bispecific_T_cell_engager_targeting_DLL3			20200040	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer	Neuroendocrine Prostate Cancer	2050 - Camperdown - Chris OBrien Lifehouse; 3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04702737
NCT04702880	2020-001863-10--CA001-050	Phase 2	Recruiting	WA, VIC, QLD, NSW	11/01/2021	17/03/2021	BMS-986012; BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin; Carboplatin + Etoposide + Nivolumab; Etoposide; Nivolumab	anti-fucosyl-GM1_monoclonal_antibody; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	BMS-986012 + Carboplatin + Etoposide + Nivolumab; Carboplatin + Etoposide + Nivolumab	anti-PD-1_monoclonal_antibody + anti-fucosyl-GM1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor; anti-PD-1_monoclonal_antibody + platinum-based_antineoplastic_agent + topoisomerase_inhibitor	2020-001863-10  CA001-050	A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	2145 - Westmead - Westmead Hospital-Department of Medical Oncology; 3144 - Malvern - Cabrini Hospital; 3350 - Ballarat - Local Institution - (Not yet recruiting); 4102 - Queensland - Gallipoli Medical Research Foundation-GMRF CTU; 6150 - Murdoch - St. John of God Murdoch Hospital-Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT04702880
NCT04713891	KFCS001	Phase 1	Recruiting	NSW	19/01/2021	9/03/2021	Atezolizumab; Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody; prostaglandin_EP4_receptor_inhibitor; anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor	Atezolizumab + KF-0210; KF-0210	anti-PD-L1_monoclonal_antibody + prostaglandin_EP4_receptor_inhibitor; prostaglandin_EP4_receptor_inhibitor	KFCS001	A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients With Advanced Solid Tumors	Advanced Solid Tumor; Colorectal Cancer; Bladder Cancer; Gastric Cancer; Squamous Cell Carcinoma of the Esophagus; Lung Cancer	2031 - Randwick - Scientia Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04713891
NCT04720768	CELEBRATE	Phase 1/Phase 2	Recruiting	VIC	22/01/2021	4/06/2020	Binimetinib; Encorafenib; Palbociclib	BRAF_V600_inhibitor; MEK_inhibitor; CDK4/6_inhibitor	Encorafenib	BRAF_V600_inhibitor	17/021	A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)	Melanoma; Metastasis	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04720768
NCT04721015	2020-004953-57--M20-111	Phase 1	Recruiting	VIC, NSW	22/01/2021	18/02/2021	Docetaxel; Osimertinib	taxane; EGFR_inhibitor,third_generation	Docetaxel; Osimertinib	EGFR_inhibitor,third_generation; taxane	2020-004953-57  M20-111	A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors	Advanced Solid Tumors Cancer; Non Small Cell Lung Cancer (NSCLC)	2500 - Wollongong - Wollongong Hospital /ID# 228350 - (Not yet recruiting); 3084 - Heidelberg - Austin Health /ID# 225638	https://clinicaltrials.gov/ct2/show/NCT04721015
NCT04721756	18F-LY3546117-01	Phase 0	Not yet recruiting	VIC	25/01/2021						18F-LY3546117-01	A Phase I Study Evaluating the Safety and Imaging Characteristics of 18F-LY3546117 Injection in Subjects Who Are Undergoing Treatment With Immune Checkpoint Inhibitors	Neoplasms; Neoplasms Malignant	Heidelberg - Olivia Newton-John Cancer Institute and Austin Health	https://clinicaltrials.gov/ct2/show/NCT04721756
NCT04725188	MK-7684A-002--7684A-002	Phase 2	Recruiting	QLD, ACT, WA	26/01/2021	20/04/2021	Docetaxel; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab; Pembrolizumab + Vibostolimab; Placebo; Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; anti-TIGIT_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody	Docetaxel; Docetaxel + Pembrolizumab + Vibostolimab; Pembrolizumab + Vibostolimab	anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody + taxane; taxane	MK-7684A-002  7684A-002	A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy	Metastatic Non Small Cell Lung Cancer	2605 - Canberra - Canberra Hospital ( Site 0104); 4215 - Southport - Gold Coast University Hospital-Clinical Trials Service ( Site 0106); 6150 - Murdoch - Fiona Stanley Hospital-Medical Oncology ( Site 0102)	https://clinicaltrials.gov/ct2/show/NCT04725188
NCT04726033	CUPID	Phase 0	Recruiting	WA	27/01/2021	4/08/2021	64Cu-TLX592	PSMA-targeting_antibody_radioimmunoconjugate	64Cu-TLX592	PSMA-targeting_antibody_radioimmunoconjugate	64Cu-TLX592-001	A Phase I, Single Centre, Open-label Study of TLX592 to Assess the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry in Patients Diagnosed With Prostate Cancer	Metastatic Prostate Cancer	6014 - Perth - Envision Medical Imaging; 6014 - Perth - GenesisCare Wembly	https://clinicaltrials.gov/ct2/show/NCT04726033
NCT04727554	NCT04727554	Phase 1	Recruiting	WA, VIC	27/01/2021	29/04/2021	AMG 404	anti-PD-1_monoclonal_antibody	AMG 404	anti-PD-1_monoclonal_antibody	20190136	A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	3168 - Clayton - Monash Medical Centre; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04727554
NCT04729387	CBYL719K12301	Phase 3	Recruiting	SA, VIC	28/01/2021	2/07/2021	Alpelisib; Alpelisib + Olaparib; Olaparib; Paclitaxel; Paclitaxel + Pegylated liposomal doxorubicin; Pegylated liposomal doxorubicin	anthracycline; taxane; PI3K_alpha_inhibitor; anthracycline + taxane; PARP_inhibitor + PI3K_alpha_inhibitor; PARP_inhibitor	Alpelisib + Olaparib; Paclitaxel + Pegylated liposomal doxorubicin	PARP_inhibitor + PI3K_alpha_inhibitor; anthracycline + taxane	CBYL719K12301	EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer	Ovarian Cancer	3630 - Shepparton - Novartis Investigative Site; 5041 - Bedford Park - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04729387
NCT04736199	ARANOTE	Phase 3	Recruiting	NZ, NSW, SA, VIC	3/02/2021	23/02/2021	Darolutamide; Placebo	placebo; antiandrogen,nonsteroidal,second_generation	Darolutamide	antiandrogen,nonsteroidal,second_generation	2020-003093-48  21140	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	Prostatic Neoplasms	2065 - St Leonards - Northern Cancer Institute; 2109 - Macquarie University - Macquarie University Hospital; 2751 - Sydney - Nepean Hospital; 3112 - Tauranga - Tauranga Urology Research Limited; 3199 - Frankston - Peninsula Oncology Centre; 3200 - Hamilton - Waikato Hospital - (Not yet recruiting); 3214 - Hamilton - Urology Waikato; 5000 - South Terrace - Cancer Research South Australia; 8013 - Christchurch - Canterbury Urology Research Trust; Heidelberg - Austin Health	https://clinicaltrials.gov/ct2/show/NCT04736199
NCT04736706	2020-002216-52--6482-012	Phase 3	Recruiting	WA, SA, VIC, NSW	3/02/2021	14/04/2021	Belzutifan; Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Quavonlimab	VEGF_inhibitor + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; VEGF_inhibitor; HIF2a_inhibitor; anti-PD-1_monoclonal_antibody; HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Belzutifan + Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab; Lenvatinib + Pembrolizumab + Quavonlimab	HIF2a_inhibitor + VEGF_inhibitor + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-PD-1_monoclonal_antibody	2020-002216-52  6482-012	An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	Carcinoma, Renal Cell	2109 - Macquarie Park - Macquarie University ( Site 4007); 2170 - Liverpool - Liverpool Hospital ( Site 4006); 3168 - Clayton - Monash Health ( Site 4008); 5112 - Elizabeth Vale - Lyell McEwin Hospital ( Site 4004); 6150 - Murdoch - Fiona Stanley Hospital ( Site 4009)	https://clinicaltrials.gov/ct2/show/NCT04736706
NCT04737122	LM061-01-102	Phase 1	Recruiting	NSW	3/02/2021	17/05/2021	LM-061	MET/VEGFR2/FLT3_inhibitor			LM061-01-102	A Phase I, First-in-Human, Open-Label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumors	Advanced Tumours	2217 - Kogarah - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04737122
NCT04739761	DESTINY-B12	Phase 3	Recruiting	WA, NSW, VIC, QLD	5/02/2021	22/06/2021	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate	D9673C00007	An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)	Breast Cancer	2065 - St Leonards - Research Site; 3084 - Heidelberg - Research Site; 3168 - Clayton - Research Site; 4066 - Auchenflower - Research Site; 6008 - Subiaco - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04739761
NCT04740918	KATE3	Phase 3	Recruiting	NSW, VIC, QLD	5/02/2021	7/06/2021	Atezolizumab; Atezolizumab + Trastuzumab Emtansine; Pertuzumab; Placebo; Trastuzumab; Trastuzumab Emtansine	anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody; placebo; anti-PD-L1_monoclonal_antibody; anti-ERBB2_monoclonal_antibody	Atezolizumab + Trastuzumab Emtansine	anti-ERBB2_antibody-drug_conjugate + anti-PD-L1_monoclonal_antibody	2020-002818-41  MO42319	A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3)	Metastatic Breast Cancer	2065 - St. Leonards - Royal North Shore Hospital; Oncology; 2290 - Gateshead - Lake Macquarie Private Hospital; 3002 - East Melbourne - Peter MacCallum Cancer Center; 3021 - St Albans - Sunshine Hospital; 4102 - Woolloongabba - Princess Alexandra Hospital	https://clinicaltrials.gov/ct2/show/NCT04740918
NCT04744831	DESTINY-CRC02	Phase 2	Recruiting	NSW, VIC, SA	9/02/2021	5/03/2021	Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate			2020-004782-39  DS8201-A-U207	A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)	Advanced Colorectal Cancer	Bedford Park - Flinders Medical Centre (FMC); Blacktown - Blacktown Hospital; Brisbane - Royal Brisbane &amp; Women's Hospital; Clayton - Monash Medical Centre; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04744831
NCT04745689	TAZMAN	Phase 2	Recruiting	NSW	9/02/2021	23/02/2021	Carboplatin; Cisplatin; Durvalumab; Etoposide	platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; topoisomerase_inhibitor	Durvalumab	anti-PD-L1_monoclonal_antibody	D6132C00001	A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer	Small-Cell Lung Cancer	2250 - North Gosford - Research Site - (Not yet recruiting); 2500 - Wollongong - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04745689
NCT04746612	HH30134-G101	Phase 1	Recruiting	NSW	10/02/2021	8/04/2021	HH30134	AXL/FLT3/NTRK_inhibitor	HH30134	AXL/FLT3/NTRK_inhibitor	HH30134-G101	A Phase I, Multi-centre, Open-Label, First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours	Advanced Solid Tumors	Blacktown - Blacktown Hospital - (Not yet recruiting); Randwick - Scientia Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04746612
NCT04746924	BGB-A317-A1217-302--AdvanTIG-302	Phase 3	Recruiting	WA, QLD, VIC, SA, NSW	10/02/2021	8/06/2021	Ociperlimab; Ociperlimab + Tislelizumab; Pembrolizumab; Placebo; Tislelizumab	anti-PD-1_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	Ociperlimab + Tislelizumab; Pembrolizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	BGB-A317-A1217-302  AdvanTIG-302	A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer; NSCLC	2065 - Saint Leonards - Northern Cancer Institute, Genesis Care; 2139 - Concord - Concord Repatriation General Hospital; 2298 - Waratah - Calvary Mater Newcastle, Medical Oncology Trial Unit, Edith Street; 3021 - St Albans - Western Health - Sunshine Hospital; 3168 - Clayton - Monash Health - (Not yet recruiting); 3350 - Ballarat - Ballarat Health Services; 4032 - Chermside - The Prince Charles Hospital - (Not yet recruiting); 4101 - South Brisbane - Mater Cancer Care Centre - (Not yet recruiting); 4224 - Tugun - John Flynn Private Hospital; 5112 - Elizabeth Vale - Lyell McEwin Hospital; 6150 - Murdoch - St John of God, Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT04746924
NCT04760288	AcceleRET-MTC	Phase 3	Not yet recruiting	VIC, SA, NSW	18/02/2021		Cabozantinib; Cabozantinib + Vandetanib; Pralsetinib; Vandetanib	KIT_inhibitor + RET_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; ROS1_inhibitor; EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; AXL_inhibitor + VEGFR2_inhibitor; RET_inhibitor + VEGFR2_inhibitor; RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; KIT_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; RET_inhibitor + ROS1_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor; AXL_inhibitor + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; EGFR_inhibitor,second_generation + RET_inhibitor; MET_inhibitor,type_2	Cabozantinib + Vandetanib; Pralsetinib	AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + EGFR_inhibitor,second_generation; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + RET_inhibitor; AXL/MET/RET/VEGFR/ROS1/KIT_inhibitor + VEGFR2_inhibitor; AXL_inhibitor + EGFR_inhibitor,second_generation; AXL_inhibitor + RET_inhibitor; AXL_inhibitor + VEGFR2_inhibitor; EGFR_inhibitor,second_generation + KIT_inhibitor; EGFR_inhibitor,second_generation + MET_inhibitor,type_2; EGFR_inhibitor,second_generation + RET_inhibitor; EGFR_inhibitor,second_generation + ROS1_inhibitor; EGFR_inhibitor,second_generation + VEGFR2_inhibitor; KIT_inhibitor + RET_inhibitor; KIT_inhibitor + VEGFR2_inhibitor; MET_inhibitor,type_2 + RET_inhibitor; MET_inhibitor,type_2 + VEGFR2_inhibitor; RET_inhibitor; RET_inhibitor + ROS1_inhibitor; RET_inhibitor + VEGFR2_inhibitor; ROS1_inhibitor + VEGFR2_inhibitor; VEGFR2_inhibitor	2020-005269-15  CO42865	A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.	Thyroid Cancer	2065 - St. Leonards - Royal North Shore Hospital; 2109 - Macquarie Park - Macquarie University Hospital; 3004 - Melbourne - The Alfred Hospital;Clinical Trial Pharmacy; 5037 - Kurralta Park - Ashford Cancer Center Research	https://clinicaltrials.gov/ct2/show/NCT04760288
NCT04771130	BGB-11417-103	Phase 1/Phase 2	Recruiting	WA, NZ, NSW, VIC, QLD	25/02/2021	24/05/2021	Azacitidine; Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole; BGB-11417; Posaconazole	BCL2_inhibitor + antimetabolite; antimetabolite; azole_antifungal; BCL2_inhibitor + antimetabolite + azole_antifungal; BCL2_inhibitor + DNA_methyltransferase_inhibitor; BCL2_inhibitor; BCL2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; DNA_methyltransferase_inhibitor	Azacitidine + BGB-11417; Azacitidine + BGB-11417 + Posaconazole	BCL2_inhibitor + DNA_methyltransferase_inhibitor; BCL2_inhibitor + DNA_methyltransferase_inhibitor + azole_antifungal; BCL2_inhibitor + antimetabolite; BCL2_inhibitor + antimetabolite + azole_antifungal	BGB-11417-103	A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies	Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplastic Syndromes; Acute Myeloid Leukemia	0620 - Auckland - North Shore Hospital; 2025 - Auckland - Middlemore Hospital; 2139 - Sydney - Concord Hospital; 2217 - Sydney - St. George Hospital; 2800 - Orange - Orange Health Service; 3004 - Melbourne - The Alfred Hospital; 3065 - Melbourne - St. Vincent's Hospital Melbourne; 3084 - Heidelberg - Austin Hospital; 3168 - Melbourne - Monash Health; 4215 - Gold Coast - Gold Coast University Hospital; 4217 - Benowa - Pindara Private Hospital; 4224 - Tugun - John Flynn Hospital; 6009 - Nedlands - One Clinical Research; 6009 - Perth - Linear Clinical Research; 6021 - Wellington - Wellington Regional Hospital; 6150 - Murdoch - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT04771130
NCT04784715	D967UC00001	Phase 3	Recruiting	QLD, NSW	5/03/2021	26/04/2021	Pertuzumab; Pertuzumab + Trastuzumab Deruxtecan; Placebo; Trastuzumab; Trastuzumab Deruxtecan	placebo; anti-ERBB2_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_monoclonal_antibody,dimerization_inhibitor; anti-ERBB2_antibody-drug_conjugate	Pertuzumab + Trastuzumab Deruxtecan	anti-ERBB2_antibody-drug_conjugate + anti-ERBB2_monoclonal_antibody,dimerization_inhibitor	D967UC00001	Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)	Breast Cancer; HER2-positive; Metastatic	2065 - St Leonards - Research Site - (Withdrawn); 2109 - Macquarie University - Research Site - (Withdrawn); 4066 - Auchenflower - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04784715
NCT04786847	ProstACTSelect	Phase 1	Not yet recruiting	WA	8/03/2021		177Lu-DOTA-rosopatamab	177Lu-PSMA-radioconjugate	177Lu-DOTA-rosopatamab	177Lu-PSMA-radioconjugate	177Lu-TLX591-001	A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591 With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer	Metastatic Prostate Cancer	6009 - Perth - Diagnostic Nuclear Imaging at Hollywood Private Hospital; 6150 - Perth - GenesisCare SJOg Medical Centre,Murdoch	https://clinicaltrials.gov/ct2/show/NCT04786847
NCT04789096	TUGETHER	Phase 2	Not yet recruiting	VIC	9/03/2021		Capecitabine; Pembrolizumab; Trastuzumab; Tucatinib	anti-ERBB2_monoclonal_antibody; antimetabolite; ERBB2_inhibitor,third_generation; anti-PD-1_monoclonal_antibody			BCT 2102	A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer	Breast Cancer; HER2-positive Breast Cancer	3002 - Parkville - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04789096
NCT04799054	transcendIT-101--TCTLR-101	Phase 1/Phase 2	Recruiting	NSW, VIC	16/03/2021	18/03/2021	Pembrolizumab; Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist	TLR7/8_agonist; anti-PD-1_monoclonal_antibody; TLR7/8_agonist + anti-PD-1_monoclonal_antibody	Pembrolizumab + TransCon TLR7/8 agonist; TransCon TLR7/8 agonist	TLR7/8_agonist; TLR7/8_agonist + anti-PD-1_monoclonal_antibody	transcendIT-101  TCTLR-101	Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Locally Advanced Solid Tumor; Advanced Solid Tumor; Metastatic Solid Tumor	2500 - Wollongong - Ascendis Pharma Investigational Site; 3199 - Frankston - Ascendis Pharma Investigational Site	https://clinicaltrials.gov/ct2/show/NCT04799054
NCT04799249	PRESERVE-2	Phase 3	Recruiting	NSW, VIC, QLD, NT	16/03/2021	15/04/2021	Carboplatin; Carboplatin + Gemcitabine + Trilaciclib; Gemcitabine; Placebo; Trilaciclib	CDK4/6_inhibitor; placebo; platinum-based_antineoplastic_agent; antimetabolite; CDK4/6_inhibitor + antimetabolite + platinum-based_antineoplastic_agent	Carboplatin + Gemcitabine + Trilaciclib	CDK4/6_inhibitor + antimetabolite + platinum-based_antineoplastic_agent	2020-004930-39  G1T28-208	A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)	TNBC - Triple-Negative Breast Cancer; Breast Cancer	08006 - East Melbourne - Peter MacCallum Cancer Centre - Oncology - (Not yet recruiting); 2050 - Camperdown - 119-143 Missenden Road; 3144 - Malvern - Cabrini Malvern , Hospital (site#3150); 4575 - Birtinya - Sunshine Coast University Hospital	https://clinicaltrials.gov/ct2/show/NCT04799249
NCT04801095	WMS1030-101	Phase 1	Recruiting	WA, VIC	16/03/2021	14/07/2021	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	WM-S1-030	mutant_receptor_tyrosine_kinase_inhibitor	WMS1030-101	A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors	Pancreatic Cancer; Lung Cancer; Metastatic Solid Tumor; Advanced Solid Tumor; Colorectal Cancer; Head and Neck Cancer; Cholangiocarcinoma	3168 - Clayton - Monash Medical Center; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04801095
NCT04801966	TAILOR	Not Applicable	Recruiting	VIC	17/03/2021		Abemaciclib; Alpelisib; Atezolizumab; Binimetinib; Cobimetinib; Dabrafenib; Encorafenib; Nivolumab; Olaparib; Palbociclib; Pembrolizumab; Ribociclib; Talazoparib; Trametinib; Vemurafenib	anti-PD-1_monoclonal_antibody; PI3K_alpha_inhibitor; PARP_inhibitor; CDK4/6_inhibitor; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; BRAF_V600_inhibitor			20/029	Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study	Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04801966
NCT04802759	2020-004889-19--CO42867	Phase 1/Phase 2	Recruiting	VIC, WA	17/03/2021	20/06/2021	Abemaciclib; Abemaciclib + Giredestrant; Everolimus; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib; Inavolisib; Ipatasertib; Palbociclib; Ribociclib	selective_estrogen_receptor_degrader; MTORC1_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor; CDK4/6_inhibitor; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; PI3K_inhibitor; PI3K_inhibitor + selective_estrogen_receptor_degrader; MTORC1_inhibitor	Abemaciclib + Giredestrant; Everolimus + Giredestrant; Giredestrant; Giredestrant + Inavolisib; Giredestrant + Ipatasertib; Giredestrant + Palbociclib; Giredestrant + Ribociclib	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; MTORC1_inhibitor + selective_estrogen_receptor_degrader; PI3K_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	2020-004889-19  CO42867	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)	Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	3000 - Melbourne - Peter Maccallum Cancer Centre; 3199 - Frankston - Peninsula Health-Frankston Hospital; 6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT04802759
NCT04807972	2020-005767-31--M20-732	Phase 2	Recruiting	VIC	19/03/2021	28/05/2021	ABBV-927; ABBV-927 + Budigalimab; Budigalimab	anti-PD-1_monoclonal_antibody; anti-CD40_agonist_antibody; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody	ABBV-927; ABBV-927 + Budigalimab; Budigalimab	anti-CD40_agonist_antibody; anti-CD40_agonist_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	2020-005767-31  M20-732	A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Subjects With Untreated Metastatic Pancreatic Adenocarcinoma	Pancreatic Cancer	3084 - Heidelberg - Austin Health /ID# 231378; 3168 - Clayton - Monash Medical Centre /ID# 231379	https://clinicaltrials.gov/ct2/show/NCT04807972
NCT04811027	TACTI-003	Phase 2	Recruiting	NSW	23/03/2021	27/08/2021	Eftilagimod Alpha; Pembrolizumab	T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody	Eftilagimod Alpha; Pembrolizumab	T-cell_immunostimulatory_factor; anti-PD-1_monoclonal_antibody	Keynote- PNC-34  TACTI-003	TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)	HNSCC	2109 - Macquarie Park - Macquarie University Hospital; 2640 - East Albury - Border Medical Oncology Research Unit	https://clinicaltrials.gov/ct2/show/NCT04811027
NCT04814108	ZN-c3-004	Phase 2	Recruiting	VIC, NSW	24/03/2021	1/06/2021	ZN-C3	WEE1_inhibitor	ZN-C3	WEE1_inhibitor	ZN-c3-004	A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma	Uterine Serous Carcinoma	2065 - St Leonards - Site 2703; 3000 - Melbourne - Site 2704; 3144 - Malvern - Site 2706	https://clinicaltrials.gov/ct2/show/NCT04814108
NCT04819100	LIBRETTO-432	Phase 3	Recruiting	VIC, QLD, NSW	26/03/2021	20/12/2021	Placebo; Selpercatinib	placebo; RET_inhibitor	Selpercatinib	RET_inhibitor	J2G-MC-JZJX  18126	LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC	Carcinoma, Non-Small-Cell Lung	2640 - Albury - Border Medical Oncology; 3280 - Warrambool - South West Healthcare; 3350 - Ballarat - Ballarat Health Services; 3550 - Bendigo - Bendigo Health; 3630 - Shepparton - Goulburn Valley Health; 4575 - Birtinya - Sunshine Coast University Hospital - (Not yet recruiting); 4700 - Rockhampton - Rockhampton Hospital - (Not yet recruiting); 4814 - Douglas - The Townsville Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04819100
NCT04821622	TALAPRO-3--C3441052	Phase 3	Recruiting	NSW, QLD, VIC, SA	29/03/2021	12/05/2021	Enzalutamide; Enzalutamide + Talazoparib; Placebo; Talazoparib	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation; placebo; PARP_inhibitor	Enzalutamide; Enzalutamide + Talazoparib	PARP_inhibitor + antiandrogen,nonsteroidal,second_generation; antiandrogen,nonsteroidal,second_generation	TALAPRO-3  C3441052	TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER	Prostate Cancer	2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 2500 - Wollongong - Southern Medical Day Care Centre; 3002 - East Melbourne - Epworth Freemasons-Epworth HealthCare; 3021 - St Albans - Western Health, Sunshine Hospital; 3144 - Malvern - Cabrini Hospital - (Not yet recruiting); 4120 - Brisbane - Gallipoli Medical Research Foundation, Greenslopes Private Hospital; 4215 - Southport - Gold Coast University Hospital - (Not yet recruiting); 5011 - Woodville South - The Queen Elizabeth Hospital	https://clinicaltrials.gov/ct2/show/NCT04821622
NCT04822298	NCT04822298	Phase 1	Recruiting	NSW	30/03/2021	31/08/2021	AMG 160	PSMA_bispecific_T-cell_engager			20180273	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer	NSCLC; Non-small Cell Lung Cancer	2050 - Camperdown - Chris OBrien Lifehouse	https://clinicaltrials.gov/ct2/show/NCT04822298
NCT04822961	IMP4297-202	Phase 2	Not yet recruiting	NSW, QLD, VIC	30/03/2021		Docetaxel; IMP4297; Placebo	PARP_inhibitor; placebo; taxane	IMP4297	PARP_inhibitor	IMP4297-202	A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment	mCRPC 0 0	Brisbane - Princess Alexandra Hospital; Melbourne - Cabrini Hospital; Sydney - Macquarie University Hospital; Tugun - John Flynn Hospital	https://clinicaltrials.gov/ct2/show/NCT04822961
NCT04829604	ACE-Breast03	Phase 2	Recruiting	QLD, VIC, WA	2/04/2021	5/04/2021	ARX788; ARX788 + Trastuzumab Emtansine + Tucatinib; Trastuzumab Emtansine; Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate; anti-ERBB2_antibody-drug_conjugate; ERBB2_inhibitor,third_generation	ARX788 + Trastuzumab Emtansine + Tucatinib	ERBB2_inhibitor,third_generation + anti-ERBB2_antibody-drug_conjugate	ACE-Breast-03	A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens	HER2 Positive Metastatic Breast Cancer	3168 - Clayton - Monash Medical Centre; 3199 - Frankston - PASO Medical; 4102 - Woolloongabba - Princess Alexandria Hospital; 6009 - Nedlands - Breast Cancer Research Centre - WA; Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04829604
NCT04834973	KN-B16--QB46C-H06	Phase 1/Phase 2	Recruiting	NSW	8/04/2021	7/05/2021	Pembrolizumab; Pembrolizumab + Tigilanol Tiglate; Tigilanol Tiglate	anti-PD-1_monoclonal_antibody + protein_kinase_C_regulator; anti-PD-1_monoclonal_antibody; protein_kinase_C_regulator	Pembrolizumab + Tigilanol Tiglate	anti-PD-1_monoclonal_antibody + protein_kinase_C_regulator	KN-B16  QB46C-H06	A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma	Melanoma	2065 - Wollstonecraft - Melanoma Institute Australia	https://clinicaltrials.gov/ct2/show/NCT04834973
NCT04835805	2020-003674-41--GO42273	Phase 1	Recruiting	WA, VIC, NSW	8/04/2021	13/05/2021	Atezolizumab; Atezolizumab + Belvarafenib + Cobimetinib; Belvarafenib; Belvarafenib + Cobimetinib; Cobimetinib	anti-PD-L1_monoclonal_antibody; MEK_inhibitor; RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor + anti-PD-L1_monoclonal_antibody; MEK_inhibitor + RAF_dimer_inhibitor	Atezolizumab + Belvarafenib + Cobimetinib; Belvarafenib; Belvarafenib + Cobimetinib	MEK_inhibitor + RAF_dimer_inhibitor; MEK_inhibitor + RAF_dimer_inhibitor + anti-PD-L1_monoclonal_antibody; RAF_dimer_inhibitor	2020-003674-41  GO42273	A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy	Melanoma	2298 - Waratah - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre-East Melbourne; 6009 - Nedlands - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT04835805
NCT04844073	CP-MVC-101-01	Phase 1/Phase 2	Recruiting	SA, VIC, NSW	14/04/2021	8/03/2021	MVC-101	bispecific_T_cell_engager_targeting_EGFR	MVC-101	bispecific_T_cell_engager_targeting_EGFR	CP-MVC-101-01	A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA™) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer	Squamous Cell Carcinoma of the Head and Neck; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms	2031 - Randwick - Scientia Clinical Research Limited, Corner High &amp; Avoca Street, 5th Floor, Bright Building; 3052 - Melbourne - Peter MacCallum Cancer Centre, Grattan Street, Parkville, Medical Oncology, Level 2 - (Not yet recruiting); 3084 - Heidelberg - Austin Hospital, 145 Studley Road, Intensive Care Unit - (Not yet recruiting); 3168 - Clayton - Monash Health, Monash Medical Center, 246 Clayton Road - (Not yet recruiting); 5042 - Bedford Park - Southern Oncology Clinical Research Unit, 1 Flinders Drive	https://clinicaltrials.gov/ct2/show/NCT04844073
NCT04849273	TPX-0131-01	Phase 1/Phase 2	Recruiting	WA, VIC, NSW	19/04/2021	2/08/2021	TPX-0131	ALK_inhibitor,fourth_generation	TPX-0131	ALK_inhibitor,fourth_generation	TPX-0131-01	A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC	Metastatic Solid Tumor; NSCLC; Non-Small Cell Lung Cancer; ALK Gene Mutation; Non Small Cell Lung Cancer; Advanced Solid Tumor	2148 - Blacktown - Blacktown Cancer and Hematology Centre; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3084 - Heidelberg - Austin Health; 6009 - Nedlands - Linear Clinical Research	https://clinicaltrials.gov/ct2/show/NCT04849273
NCT04851834	XNTR-20-02	Phase 1/Phase 2	Recruiting	NSW, SA	20/04/2021		Temozolomide	alkylating_agent	Temozolomide	alkylating_agent	XNTR-20-02	A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)	Platinum-Resistant Ovarian Cancer; Advanced Solid Tumor; Platinum-Resistant Urothelial Carcinoma; High-grade Glioma	2010 - Darlinghurst - St. Vincent's Hospital - The Kinghorn Cancer Center; 2217 - Kogarah - St. George Private Hospital; Bedford Park - Southern Oncology Clinical Research Unit	https://clinicaltrials.gov/ct2/show/NCT04851834
NCT04854499	2020-005708-20--GS-US-548-5916	Phase 2	Recruiting	QLD, NSW	22/04/2021	7/09/2021	Carboplatin; Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Cisplatin; Docetaxel; Docetaxel + Magrolimab; Fluorouracil; Fluorouracil + Magrolimab + Pembrolizumab; Magrolimab; Magrolimab + Pembrolizumab; Pembrolizumab	anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; anti-CD47_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody; platinum-based_antineoplastic_agent; antimetabolite; anti-PD-1_monoclonal_antibody; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; taxane; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Carboplatin + Cisplatin + Fluorouracil + Magrolimab + Pembrolizumab; Carboplatin + Cisplatin + Fluorouracil + Pembrolizumab; Docetaxel + Magrolimab; Fluorouracil + Magrolimab + Pembrolizumab; Magrolimab + Pembrolizumab	anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite; anti-CD47_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-CD47_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent	2020-005708-20  GS-US-548-5916	A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma	Head and Neck Squamous Cell Carcinoma	2010 - Darlinghurst - St. Vincent's Hospital Sydney - (Not yet recruiting); 2109 - Macquarie University - Macquarie University - (Not yet recruiting); 2145 - Westmead - Blacktown Hospital - (Not yet recruiting); 4870 - Cairns - Cairns Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04854499
NCT04857372	CIAG933A12101	Phase 1	Recruiting	VIC	23/04/2021	21/10/2021	IAG933	YAP-TEAD_inhibitor			CIAG933A12101	An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors	Mesothelioma	3000 - Melbourne - Novartis Investigative Site	https://clinicaltrials.gov/ct2/show/NCT04857372
NCT04861779	HSK29116-101	Phase 1	Not yet recruiting	NSW, WA	27/04/2021		HSK29116	PROTAC_antineoplastic_drug	HSK29116	PROTAC_antineoplastic_drug	HSK29116-101	A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy	Relapsed/Refractory B-Cell Malignancies	Perth - One Clinical Research; Phillip - Woden Dermatology	https://clinicaltrials.gov/ct2/show/NCT04861779
NCT04862663	CAPItello-292	Phase 3	Recruiting	NSW, WA	28/04/2021	10/05/2021	Capivasertib; Capivasertib + Fulvestrant + Palbociclib; Fulvestrant; Fulvestrant + Palbociclib; Palbociclib; Placebo	CDK4/6_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader; CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; pan-AKT_inhibitor; placebo; CDK4/6_inhibitor	Capivasertib + Fulvestrant + Palbociclib; Fulvestrant + Palbociclib	CDK4/6_inhibitor + pan-AKT_inhibitor + selective_estrogen_receptor_degrader; CDK4/6_inhibitor + selective_estrogen_receptor_degrader	D361DC00001	A Phase Ib/III Randomised Study of Capivasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer	Locally Advanced (Inoperable) or Metastatic Breast Cancer	2010 - Darlinghurst - Research Site; 2010 - Darlinghurst - Research Site - (Not yet recruiting); 2228 - Miranda - Research Site - (Not yet recruiting); 6009 - Nedlands - Research Site	https://clinicaltrials.gov/ct2/show/NCT04862663
NCT04865419	D8241C00001	Phase 1/Phase 2	Recruiting	VIC	29/04/2021	11/06/2021	AZD0466	dual_Bcl2/xL_inhibitor	AZD0466	dual_Bcl2/xL_inhibitor	D8241C00001	A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies	Haematological Malignancies	3004 - Melbourne - Research Site; 3050 - Parkville - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04865419
NCT04871282	RINGSIDE	Phase 2/Phase 3	Recruiting	QLD, VIC, SA	4/05/2021	30/03/2021	AL102; Placebo	placebo; gamma_secretase_inhibitor	AL102	gamma_secretase_inhibitor	AL-DES-01	RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors	Desmoid Tumor; Desmoid	3000 - Melbourne - Peter MacCallum Cancer Centre; 4102 - Woolloongabba - Princess Alexandra Hospital; 5037 - Kurralta Park - Adelaide Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04871282
NCT04876651	PROSTACT	Phase 3	Not yet recruiting	WA	6/05/2021		177Lu-DOTA-rosopatamab	177Lu-PSMA-radioconjugate			177Lu-TLX591-002	A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug	Metastatic Prostate Cancer	6009 - Perth - Diagnostic Nuclear Imaging at Hollywood Private Hospital; 6150 - Perth - GenesisCare SJOG Medical Centre, Murdoch WA	https://clinicaltrials.gov/ct2/show/NCT04876651
NCT04879368	INTEGRATEIIb	Phase 3	Recruiting	TAS, NZ, ACT, NT, WA, SA, QLD, VIC, NSW	10/05/2021	1/06/2021	Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Regorafenib	pan-FGFR_inhibitor; RET_inhibitor; taxane; topoisomerase_inhibitor; PDGFR_inhibitor; anti-PD-1_monoclonal_antibody; KIT_inhibitor,first_generation; VEGFR_inhibitor			2020-004617-12  AG0315OG/CTC0140	A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Gastro-Oesophageal Cancer	0810 - Tiwi - Royal Darwin Hospital; 1023 - Auckland - Auckland Hospital - (Not yet recruiting); 2010 - Darlinghurst - St Vincent's Public Hospital; 2031 - Randwick - Prince of Wales Hospital; 2035 - New Lambton Heights - Newcastle Private Hospital; 2065 - St Leonards - Royal North Shore Hospital; 2139 - Concord - Concord Repatriation General Hospital - (Not yet recruiting); 2145 - Westmead - Westmead Hospital; 2217 - Kogarah - St George Hospital; 2250 - Gosford - Gosford Hospital; 2444 - Port Macquarie - Port Macquarie Base Hospital; 2450 - Coffs Harbour - Coffs Harbour Health Campus; 2485 - Tweed Heads - The Tweed Hospital; 2640 - Albury - Border Cancer Hospital; 3084 - Heidelberg - Austin Hospital; 3084 - Heidelberg - Olivia Newton-John Cancer Wellness and Research Centre - (Not yet recruiting); 3168 - Clayton - Monash Health; 3168 - Clayton - Monash Medical Centre; 3355 - Wendouree - Ballarat Oncology and Haematology Services; 3931 - Mornington - Peninsula Health/Frankston Hospital - (Not yet recruiting); 4029 - Herston - Royal Brisbane Hospital - (Not yet recruiting); 4029 - Herston - Royal Brisbane and Women's Hospital - (Not yet recruiting); 4029 - Herston - Royal Brisbane and Womens Hospital; 4560 - Sunshine Coast - Sunshine Coast University Hospital; 4814 - Douglas - The Townsville Hospital; 5011 - Woodville South - The Queen Elizabeth Hospital; 5035 - Ashford - Ashford Cancer Centre Research - (Not yet recruiting); 5042 - Bedford Park - Flinders Medical Centre; 5042 - Bedford Park - Flinders Medical Centre - (Not yet recruiting); 6008 - Subiaco - St John of God Hospital Subiaco; 6009 - Nedlands - Sir Charles Gairdner Hospital; 700 - Hobart - Royal Hobart Hospital; Adelaide - Queen Elizabeth Hospital / Lyell McEwin Centre - (Not yet recruiting); Adelaide - Royal Adelaide Hospital - (Not yet recruiting); Ballarat - Ballarat Health Service - (Not yet recruiting); Box Hill - Eastern Health - (Not yet recruiting); Canberra - Canberra Hospital - (Not yet recruiting); Christchurch - Christchurch Hospital - (Not yet recruiting); Melbourne - Austin Health; Melbourne - Box Hill Hospital - (Not yet recruiting); Melbourne - Frankston Hospital - (Not yet recruiting); Melbourne - Peter MacCallum Cancer Institute - (Not yet recruiting); Newcastle - Calvary Mater Newcastle; Perth - Fremantle Hospital - (Not yet recruiting); Sydney - Campbelltown Hospital - (Not yet recruiting); Sydney - Liverpool Hospital - (Not yet recruiting); Sydney - Nepean Hospital - (Not yet recruiting); Sydney - North Shore Private Hospital - (Not yet recruiting); Tamworth - Tamworth Base Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04879368
NCT04880564	CN1-201	Phase 1/Phase 2	Recruiting	VIC	10/05/2021	28/07/2021	CN1	anti-OX40_agnostic_monoclonal_antibody	CN1	anti-OX40_agnostic_monoclonal_antibody	CN1-201	An Open-label, Multi-centre, Phase I/II Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies	Refractory Lymphoid Malignancies; Relapsed Lymphoid Malignancies	3168 - Bentleigh - Monash Health - Monash Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04880564
NCT04891718	PBI-MST-02	Phase 0	Not yet recruiting	SA, NSW	18/05/2021		MVC-101; MVC-101 + Nivolumab; Nivolumab	bispecific_T_cell_engager_targeting_EGFR; anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + bispecific_T_cell_engager_targeting_EGFR	MVC-101 + Nivolumab	anti-PD-1_monoclonal_antibody + bispecific_T_cell_engager_targeting_EGFR	PBI-MST-02	A Phase 0 Master Protocol Using the CIVO® Platform to Evaluate Intratumoural Microdoses of Anti-Cancer Therapies in Patients With Solid Tumours	Solid Tumour	2050 - Camperdown - Chris O'Brien Lifehouse; 2500 - Wollongong - Wollongong Hospital; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04891718
NCT04895358	2020-005407-38--3475-B49	Phase 3	Recruiting	WA, VIC, NSW	20/05/2021	18/06/2021	Capecitabine; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab; Dexamethasone; Nab-paclitaxel; Paclitaxel; Pegylated liposomal doxorubicin; Pembrolizumab; Placebo	anthracycline; anti-PD-1_monoclonal_antibody; taxane; anthracycline + antimetabolite + taxane; placebo; antimetabolite; anthracycline + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; glucocorticoid	Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin; Capecitabine + Nab-paclitaxel + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab	anthracycline + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; anthracycline + antimetabolite + taxane	2020-005407-38  3475-B49	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)	Breast Neoplasms	2109 - Macquarie Park - Macquarie University-MQ Health Clinical Trials Unit ( Site 2102); 2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 2101); 3199 - Frankston - Frankston Hospital-Oncology and Haematology ( Site 2103); 6009 - Nedlands - Breast Cancer Research Centre-WA ( Site 2104)	https://clinicaltrials.gov/ct2/show/NCT04895358
NCT04907851	RXC004-0003	Phase 2	Not yet recruiting	NSW	1/06/2021		Denosumab; RXC004	PORCN_inhibitor; anti-RANK_L_monoclonal_antibody	RXC004	PORCN_inhibitor	RXC004/0003	A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care	Advanced Solid Tumours	2500 - Wollongong - Wollongong Hospital	https://clinicaltrials.gov/ct2/show/NCT04907851
NCT04909125	SVIFT-Nodal-Trial	Not Applicable	Recruiting	NSW	1/06/2021	1/06/2021	Radiotherapy	radiotherapy			SVIFT Nodal Trial	Standard Versus Investigatioinal Fractionation Trial - Nodal Radiation	Post Mastectomy; Breast Cancer	2065 - St Leonards - Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT04909125
NCT04913220	U1111-1254-0189--ACT16845	Phase 1/Phase 2	Recruiting	VIC, NSW	4/06/2021	15/07/2021	Cemiplimab; THOR-707	anti-PD-1_monoclonal_antibody; IL-2_variant	Cemiplimab	anti-PD-1_monoclonal_antibody	U1111-1254-0189  ACT16845	A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers	Squamous Cell Carcinoma of Skin; Malignant Melanoma	2109 - Macquarie Park - Investigational Site Number :0360001; 3081 - Heidelberg West - Investigational Site Number :0360002	https://clinicaltrials.gov/ct2/show/NCT04913220
NCT04914117	RC118G001	Phase 1	Recruiting	NSW, VIC, SA	4/06/2021		RC118	antibody-Claudin_18.2_antibody-drug_conjutate	RC118	antibody-Claudin_18.2_antibody-drug_conjutate	RC118G001	Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours	Metastatic Solid Tumor; Unresectable Solid Tumor; Locally Advanced Solid Tumor	2109 - Macquarie Park - Remegen Site #12; 3144 - Malvern - Remegen Site #11; 3199 - Frankston - Remegen Site #13; 5042 - Bedford Park - Remegen Site #14 - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04914117
NCT04914897	U1111-1254-0107--ACT16849	Phase 2	Recruiting	VIC, NSW	7/06/2021	23/09/2021	Carboplatin; Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Cisplatin; Nab-paclitaxel; Nab-paclitaxel + Paclitaxel + Pembrolizumab; Paclitaxel; Pembrolizumab; Pemetrexed; THOR-707	antimetabolite; IL-2_variant; platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; taxane	Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed; Nab-paclitaxel + Paclitaxel + Pembrolizumab; Pembrolizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-1_monoclonal_antibody + taxane	U1111-1254-0107  ACT16849	A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma	Non-small Cell Lung Cancer; Pleural Mesothelioma	2109 - Macquarie Park - Investigational Site Number :0360001; 3121 - Richmond - Investigational Site Number :0360002	https://clinicaltrials.gov/ct2/show/NCT04914897
NCT04918810	GUIDE	Phase 2	Not yet recruiting	VIC, NSW	9/06/2021		Docetaxel	taxane	Docetaxel	taxane	ANZUP 1903	A Randomised Non-comparative Phase II Trial of Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC)	Castration Resistant Prostatic Cancer	2050 - Camperdown - Chris O'Brien Lifehouse; 2460 - Albury - Border Medical Oncology Research Unit / The Border Cancer Hospital; 2830 - Dubbo - Dubbo Base Hospital; 3630 - Shepparton - Goulburn Valley Health; Sydney - Concord Repatriation General Hospital	https://clinicaltrials.gov/ct2/show/NCT04918810
NCT04921358	BGB-A317-Sitravatinib-301	Phase 3	Recruiting	NSW, QLD, VIC, SA	10/06/2021	27/07/2021	Docetaxel; Sitravatinib; Sitravatinib + Tislelizumab; Tislelizumab	VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor; RET_inhibitor; KIT_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor; RET_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor; anti-PD-1_monoclonal_antibody; KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; taxane	Docetaxel; Sitravatinib + Tislelizumab	KIT/PDGFR/RET/VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; KIT_inhibitor + anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + anti-PD-1_monoclonal_antibody; RET_inhibitor + anti-PD-1_monoclonal_antibody; VEGFR_inhibitor + anti-PD-1_monoclonal_antibody; taxane	BGB-A317-Sitravatinib 301	A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody	Non-Small Cell Lung Cancer (NSCLC)	2148 - Blacktown - Blacktown Cancer and Haematology Centre; 2217 - Kogarah - St George Hospital - (Not yet recruiting); 2560 - Campbelltown - Campbelltown Hospital - (Not yet recruiting); 3002 - East Melbourne - St Vincent's Hospital Melbourne - (Not yet recruiting); 3021 - Saint Albans - Sunshine Hospital, Western Health - (Not yet recruiting); 3076 - Epping - Northern Hospital - (Not yet recruiting); 4120 - Greenslopes - Gallipoli Medical Research Foundation (Greenslopes Private Hospital) - (Not yet recruiting); 4556 - Sippy Downs - University of the Sunshine Coast - (Not yet recruiting); 5000 - Adelaide - Cancer Research South Australia - (Not yet recruiting); Clayton - Monash Health - (Not yet recruiting); Tweed Heads - The Tweed Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04921358
NCT04925648	PICASSO	Phase 2	Recruiting	NSW, VIC	14/06/2021	18/10/2021	Darolutamide; Dasatinib	SRC_inhibitor; KIT_inhibitor; YES1_inhibitor; antiandrogen,nonsteroidal,second_generation; BCR-ABL1_inhibitor,second_generation; PDGFRA_inhibitor	Dasatinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFRA_inhibitor; SRC_inhibitor; YES1_inhibitor	PICASSO	PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction	Metastatic Prostate Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital; 3000 - Melbourne - Peter MacCallum Cancer Centre - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04925648
NCT04931342	GOG-3051--WO42178	Phase 2	Recruiting	VIC	18/06/2021	7/10/2021	Atezolizumab; Atezolizumab + Bevacizumab; Bevacizumab; Cobimetinib; Ipatasertib; Ipatasertib + Paclitaxel; Paclitaxel; Trastuzumab Emtansine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; anti-ERBB2_antibody-drug_conjugate; taxane; pan-AKT_inhibitor + taxane; anti-PD-L1_monoclonal_antibody; MEK_inhibitor; pan-AKT_inhibitor; anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab; Cobimetinib; Ipatasertib + Paclitaxel; Trastuzumab Emtansine	MEK_inhibitor; anti-ERBB2_antibody-drug_conjugate; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody; pan-AKT_inhibitor + taxane	GOG-3051  WO42178	A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors	Ovarian Cancer	3144 - Malvern - Cabrini Hospital; Cabrini Foundation	https://clinicaltrials.gov/ct2/show/NCT04931342
NCT04935359	CNIS793B12301	Phase 3	Recruiting	WA	23/06/2021	30/09/2021	Gemcitabine; Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel; NIS793; Nab-paclitaxel; Placebo	anti-TGF-beta_monoclonal_antibody; taxane; antimetabolite; antimetabolite + taxane; anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; placebo	Gemcitabine + NIS793 + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel	anti-TGF-beta_monoclonal_antibody + antimetabolite + taxane; antimetabolite + taxane	CNIS793B12301	A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Metastatic Pancreatic Ductal Adenocarcinoma	- Perth	https://clinicaltrials.gov/ct2/show/NCT04935359
NCT04958785	2021-001074-27--GS-US-586-6144	Phase 2	Recruiting	QLD, VIC	12/07/2021		Magrolimab; Magrolimab + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Nab-paclitaxel + Paclitaxel; Paclitaxel	taxane; anti-CD47_monoclonal_antibody; anti-CD47_monoclonal_antibody + taxane	Magrolimab + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel + Paclitaxel	anti-CD47_monoclonal_antibody + taxane; taxane	2021-001074-27  GS-US-586-6144	A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer	Triple-Negative Breast Cancer	3128 - Box Hill - Box Hill Hospital; 4556 - Sippy Downs - University of the Sunshine Coast	https://clinicaltrials.gov/ct2/show/NCT04958785
NCT04964375	ABSK043-101	Phase 1	Not yet recruiting	QLD, VIC, NSW	16/07/2021		ABSK043	PD-L1_inhibitor,oral	ABSK043	PD-L1_inhibitor,oral	ABSK043-101	A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor	Neoplasms	4101 - Brisbane - Icon Cancer Centre South Brisbane; Frankston - Peninsula &amp; South Eastern Haematology and Oncology Group; Liverpool - Sydney South West Private Hospital	https://clinicaltrials.gov/ct2/show/NCT04964375
NCT04964934	SERENA-6	Phase 3	Recruiting	QLD, NSW, WA	16/07/2021	30/06/2021	Abemaciclib; Abemaciclib + Anastrozole + Letrozole + Palbociclib; Anastrozole; Letrozole; Palbociclib; Placebo	CDK4/6_inhibitor + aromatase_inhibitor; aromatase_inhibitor; placebo; CDK4/6_inhibitor	Abemaciclib + Anastrozole + Letrozole + Palbociclib	CDK4/6_inhibitor + aromatase_inhibitor	D8534C00001	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study	ER-Positive HER2-Negative Breast Cancer	2010 - Darlinghurst - Research Site; 4575 - Birtinya - Research Site; 6008 - Subiaco - Research Site - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04964934
NCT04969887	MOST-CIRCUIT	Phase 2	Recruiting	VIC, NSW	21/07/2021	3/08/2021	Ipilimumab; Ipilimumab + Nivolumab; Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Ipilimumab + Nivolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	CA209-6D6  ONJ2021-002	Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers	Neuroendocrine Tumors; Advanced Biliary Tract Cancer; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor	2145 - Sydney - Blacktown Hospital; 2640 - Albury - Border Medical Oncology Unit; 3084 - Heidelberg - Austin Health; Bendigo - Bendigo Health Services	https://clinicaltrials.gov/ct2/show/NCT04969887
NCT04975308	EMBER-3	Phase 3	Recruiting	SA, QLD, VIC, NSW	23/07/2021	4/10/2021	Exemestane; Exemestane + Fulvestrant; Fulvestrant; LY3484356	aromatase_inhibitor; aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	Exemestane + Fulvestrant; LY3484356	aromatase_inhibitor + selective_estrogen_receptor_degrader; selective_estrogen_receptor_degrader	J2J-OX-JZLC  18175	EMBER-3: A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy	Breast Neoplasms; Neoplasm Metastasis	2010 - Darlinghurst - St Vincent's Hospital; 3128 - Box Hill - Box Hill Hospital - (Not yet recruiting); 4102 - Woolloongabba - Princess Alexandra Hospital - (Not yet recruiting); 5000 - Adelaide - Cancer Research SA	https://clinicaltrials.gov/ct2/show/NCT04975308
NCT04985721	IMPARP-HRD	Phase 2	Not yet recruiting	VIC	2/08/2021		Pamiparib; Pamiparib + Tislelizumab; Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody; PARP_inhibitor; anti-PD-1_monoclonal_antibody	Pamiparib + Tislelizumab	PARP_inhibitor + anti-PD-1_monoclonal_antibody	20/044	An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects	Cancer	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT04985721
NCT04986865	PROBE	Phase 1	Not yet recruiting	NSW, VIC	3/08/2021		ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101	bispecific_PD-L1/4-1BB_antibody	ATG-101-001	A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas	Metastatic Solid Tumor; Advanced Solid Tumor; Mature B-cell Non-Hodgkin Lymphoma	2031 - Randwick - Scientia Clinical Research Ltd; 3004 - Melbourne - The Alfred Hospital; 3084 - Heidelberg - Austin Health - Olivia Newton-John Cancer Centre; 8006 - East Melbourne - Peter MacCallum Cancer Centre (PMCC) - Victorian Comprehensive Cancer Centre Location (Peter MacCallum Cancer Centre - East Melbourne)	https://clinicaltrials.gov/ct2/show/NCT04986865
NCT04995523	ARTEMIDE-01	Phase 1/Phase 2	Recruiting	VIC	9/08/2021	14/09/2021	AZD2936	bispecific_PD-1/TIGIT_antibody	AZD2936	bispecific_PD-1/TIGIT_antibody	2021-000857-23  D7020C00001	A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic Non-small Cell Lung Cancer	Non-Small-Cell Lung Carcinoma	3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT04995523
NCT05006716	BGB-16673-101	Phase 1	Recruiting	VIC, WA	16/08/2021		BGB-16673	BTK-PROTAC	BGB-16673	BTK-PROTAC	BGB-16673-101	A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies	Follicular Lymphoma; B-cell Malignancy; Waldenström Macroglobulinemia; Non-hodgkin Lymphoma; Marginal Zone Lymphoma	3000 - Melbourne - Peter MacCallum Cancer Institute; 6005 - West Perth - Perth Blood Institute	https://clinicaltrials.gov/ct2/show/NCT05006716
NCT05021120	AK127-101	Phase 0	Not yet recruiting	SA, VIC, NSW	25/08/2021		AK104; AK127	anti-TIGIT_monoclonal_antibody; bispecific_PD-1/CTLA-4_antibody			AK127-101	A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours	Advanced or Metastatic Solid Tumours	Adelaide - Ashford Cancer Care; Melbourne - Austin Health; Melbourne - Monash Health; Sydney - Southside Cancer Care Centre; Sydney - The Kinghorn Cancer Centre, St Vincents Hospital Sydney	https://clinicaltrials.gov/ct2/show/NCT05021120
NCT05040932	YH004002	Phase 1	Recruiting	VIC, NSW	10/09/2021	7/12/2021	Toripalimab; YH004	anti-PD-1_monoclonal_antibody; 4-1BB_agonist_antibody	YH004	4-1BB_agonist_antibody	YH004002	A First-In-Human, Multicenter, Open-Label, Phase I Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of YH004 As A Single Agent And Combination With Toripalimab In Subjects With Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma	Cancer	2145 - Sydney - Westmead Hospital - (Not yet recruiting); 2217 - Wollongong - Southside Cancer Care Centre, School of Medicine, University of Wollongong - (Not yet recruiting); 3144 - Malvern East - Cabrini Health Limited	https://clinicaltrials.gov/ct2/show/NCT05040932
NCT05042128	ASCEND	Phase 2	Not yet recruiting	SA, WA	13/09/2021		CEND-1; CEND-1 + Gemcitabine + Nab-paclitaxel; Gemcitabine; Gemcitabine + Nab-paclitaxel; Nab-paclitaxel; Paclitaxel; Placebo	antimetabolite + taxane; tumor-homing_peptide_iRGD; antimetabolite; placebo; taxane; antimetabolite + taxane + tumor-homing_peptide_iRGD	CEND-1 + Gemcitabine + Nab-paclitaxel; Gemcitabine + Nab-paclitaxel	antimetabolite + taxane; antimetabolite + taxane + tumor-homing_peptide_iRGD	CTC0304	A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma	Metastatic Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma	5011 - Woodville South - Queen Elizabeth Hospital; 6008 - Subiaco - St John of God	https://clinicaltrials.gov/ct2/show/NCT05042128
NCT05043090	SAMETA	Phase 3	Recruiting	NSW, VIC	13/09/2021	28/10/2021	Durvalumab; Durvalumab + Savolitinib; Savolitinib; Sunitinib	anti-PD-L1_monoclonal_antibody; MET_inhibitor,type_1; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; KIT_inhibitor,first_generation; VEGFR_inhibitor	Durvalumab; Durvalumab + Savolitinib; Sunitinib	KIT_inhibitor,first_generation; MET_inhibitor,type_1 + anti-PD-L1_monoclonal_antibody; PDGFR_inhibitor; VEGFR_inhibitor; anti-PD-L1_monoclonal_antibody	2021-000336-55  D5086C00001	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)	Papillary Renal Cell Carcinoma	2065 - St Leonards - Research Site - (Not yet recruiting); 2145 - Westmead - Research Site; 3128 - Box Hill - Research Site; 3128 - Box Hill - Research Site - (Not yet recruiting); 3144 - Malvern - Research Site - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05043090
NCT05053854	PARLuNET	Phase 1	Recruiting	VIC	23/09/2021		Octreotate; Octreotate + Talazoparib; Talazoparib	PARP_inhibitor; peptide_receptor_radionuclide_therapy; PARP_inhibitor + peptide_receptor_radionuclide_therapy	Octreotate + Talazoparib	PARP_inhibitor + peptide_receptor_radionuclide_therapy	PMC67199	Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor	Neuroendocrine Tumors	3000 - Melbourne - Peter MacCallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05053854
NCT05059262	MOTION	Phase 3	Recruiting	VIC	28/09/2021	14/10/2021	Placebo; Vimseltinib	CSF1R_inhibitor; placebo	Vimseltinib	CSF1R_inhibitor	DCC-3014-03-001	A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)	Tenosynovial Giant Cell Tumor, Diffuse; Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath; Tenosynovial Giant Cell Tumor, Localized	Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05059262
NCT05061134	MONETTE	Phase 2	Not yet recruiting	VIC	29/09/2021		Ceralasertib; Ceralasertib + Durvalumab; Durvalumab	anti-PD-L1_monoclonal_antibody; ATR_inhibitor + anti-PD-L1_monoclonal_antibody; ATR_inhibitor	Ceralasertib; Ceralasertib + Durvalumab	ATR_inhibitor; ATR_inhibitor + anti-PD-L1_monoclonal_antibody	D533AC00001	A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition	Melanoma	3002 - East Melbourne - Research Site; 4029 - Herston - Research Site	https://clinicaltrials.gov/ct2/show/NCT05061134
NCT05064059	2021-001309-60--4280A-007	Phase 3	Recruiting	SA, VIC, QLD, NSW, WA	1/10/2021	10/11/2021	MK-4280; Pembrolizumab; Regorafenib; Regorafenib + Trifluridine/Tipiracil; Trifluridine/Tipiracil	RET_inhibitor + Trifluridine; KIT_inhibitor,first_generation; Tipiracil Hydrochloride; pan-FGFR_inhibitor + thymidine_phosphorylase_inhibitor; PDGFR_inhibitor + thymidine_phosphorylase_inhibitor; VEGFR_inhibitor; KIT_inhibitor,first_generation + antimetabolite; KIT_inhibitor,first_generation + thymidine_phosphorylase_inhibitor; antimetabolite + pan-FGFR_inhibitor; anti-PD-1_monoclonal_antibody; PDGFR_inhibitor + antimetabolite; PDGFR_inhibitor; KIT_inhibitor,first_generation + Trifluridine; anti-LAG3_monoclonal_antibody; VEGFR_inhibitor + antimetabolite; PDGFR_inhibitor + Tipiracil Hydrochloride; PDGFR_inhibitor + Trifluridine; RET_inhibitor + Tipiracil Hydrochloride; Tipiracil Hydrochloride + VEGFR_inhibitor; antimetabolite; Trifluridine; VEGFR_inhibitor + thymidine_phosphorylase_inhibitor; KIT_inhibitor,first_generation + Tipiracil Hydrochloride; Trifluridine + pan-FGFR_inhibitor; Tipiracil Hydrochloride + pan-FGFR_inhibitor; Trifluridine + VEGFR_inhibitor; thymidine_phosphorylase_inhibitor; RET_inhibitor + thymidine_phosphorylase_inhibitor; pan-FGFR_inhibitor; RET_inhibitor + antimetabolite; RET_inhibitor	Pembrolizumab; Regorafenib + Trifluridine/Tipiracil	KIT_inhibitor,first_generation + Tipiracil Hydrochloride; KIT_inhibitor,first_generation + Trifluridine; KIT_inhibitor,first_generation + antimetabolite; KIT_inhibitor,first_generation + thymidine_phosphorylase_inhibitor; PDGFR_inhibitor + Tipiracil Hydrochloride; PDGFR_inhibitor + Trifluridine; PDGFR_inhibitor + antimetabolite; PDGFR_inhibitor + thymidine_phosphorylase_inhibitor; RET_inhibitor + Tipiracil Hydrochloride; RET_inhibitor + Trifluridine; RET_inhibitor + antimetabolite; RET_inhibitor + thymidine_phosphorylase_inhibitor; Tipiracil Hydrochloride + VEGFR_inhibitor; Tipiracil Hydrochloride + pan-FGFR_inhibitor; Trifluridine + VEGFR_inhibitor; Trifluridine + pan-FGFR_inhibitor; VEGFR_inhibitor + antimetabolite; VEGFR_inhibitor + thymidine_phosphorylase_inhibitor; anti-PD-1_monoclonal_antibody; antimetabolite + pan-FGFR_inhibitor; pan-FGFR_inhibitor + thymidine_phosphorylase_inhibitor	2021-001309-60  4280A-007	A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer	Colorectal Cancer	2145 - Westmead - Westmead Hospital ( Site 0057); 3021 - St Albans - Western Health-Sunshine &amp; Footscray Hospitals ( Site 0052); 3199 - Frankston - Frankston Hospital ( Site 0056); 4029 - Herston - Royal Brisbane and Women s Hospital ( Site 0058); 5011 - Woodville South - Queen Elizabeth Hospital ( Site 0050); 6008 - Perth - St John of God Subiaco Hospital ( Site 0051)	https://clinicaltrials.gov/ct2/show/NCT05064059
NCT05073484	BAT-6021-002-CR	Phase 1	Recruiting	NSW	11/10/2021	29/10/2021	BAT6021	anti-TIGIT_monoclonal_antibody	BAT6021	anti-TIGIT_monoclonal_antibody	BAT-6021-002-CR	A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With BAT1308 in Patients With Advanced Solid Tumors	Advanced Solid Tumor	2170 - Liverpool - Medical Oncologist at cancer Therapy, Liverpool Hospital	https://clinicaltrials.gov/ct2/show/NCT05073484
NCT05082545	SHR-2002-I-102--SHR-2002-102	Phase 1	Recruiting	NSW, QLD, WA	19/10/2021	23/11/2021	SHR-1316	anti-PD-L1_monoclonal_antibody	SHR-1316	anti-PD-L1_monoclonal_antibody	SHR-2002-I-102  SHR-2002-102	A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection in Combination With SHR-1316 in Patients With Advanced Malignant Tumors	Advanced Malignant Tumors	2031 - Sydney - Scientia Clinical research; 2170 - Sydney - Sydney South West Private Hospital (SSWP) - (Not yet recruiting); 4101 - Brisbane - Icon Cancer Centre; 6009 - Perth - Linear clinical research	https://clinicaltrials.gov/ct2/show/NCT05082545
NCT05086692	MDNA11-01	Phase 1/Phase 2	Recruiting	VIC, QLD, NSW	21/10/2021	27/08/2021	MDNA11	IL-2_superkine	MDNA11	IL-2_superkine	MDNA11-01	A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors	Squamous Cell Carcinoma of Head and Neck; Sarcoma; Basal Cell Carcinoma; Cervical Cancer; Renal Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Uterine Cancer; Non-Small Cell Lung Cancer Squamous; Merkel Cell Carcinoma; Gallbladder Cancer; Advanced Solid Tumor; Cutaneous Squamous Cell Carcinoma; Gastric Cancer; Non-Small Cell Lung Cancer Non-squamous; Ovarian Cancer; Unresectable Solid Tumor; Melanoma; Colorectal Cancer; Bladder Cancer; Cholangiocarcinoma; Biliary Tract Cancer; Triple Negative Breast Cancer	2031 - Randwick - Scientia Clinical Research; 2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 3144 - Malvern - Cabrini Research; 4101 - South Brisbane - ICON Cancer Center; 4120 - Greenslopes - Gallipoli Medical Research Foundation	https://clinicaltrials.gov/ct2/show/NCT05086692
NCT05116202	BO43328	Phase 1/Phase 2	Recruiting	NSW, WA	10/11/2021		Atezolizumab; Atezolizumab + Tiragolumab; Ipilimumab; Ipilimumab + Nivolumab; Nivolumab; Tiragolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody	Atezolizumab + Tiragolumab; Ipilimumab + Nivolumab; Tiragolumab	anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; anti-TIGIT_monoclonal_antibody	BO43328	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)	Melanoma	6009 - Nedlands - Linear Clinical Research Limited	https://clinicaltrials.gov/ct2/show/NCT05116202
NCT05123482	D6900C00001	Phase 1/Phase 2	Recruiting	VIC	17/11/2021	18/10/2021	AZD8205	unknown_antibody-drug_conjugate	AZD8205	unknown_antibody-drug_conjugate	D6900C00001	A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies	Breast Cancer; Cholangiocarcinoma; Ovarian Cancer; Endometrial Cancer	VIC 3000 - Melbourne - Research Site	https://clinicaltrials.gov/ct2/show/NCT05123482
NCT05150236	EVOLUTION	Phase 2	Not yet recruiting	SA, VIC, QLD, NSW, WA	9/12/2021		Ipilimumab; Ipilimumab + Lutetium-177-PSMA-617 + Nivolumab; Lutetium-177-PSMA-617; Nivolumab	anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody; 177Lu-PSMA-radioconjugate + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; 177Lu-PSMA-radioconjugate	Ipilimumab + Lutetium-177-PSMA-617 + Nivolumab; Lutetium-177-PSMA-617	177Lu-PSMA-radioconjugate; 177Lu-PSMA-radioconjugate + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	ANZUP 2001	Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)	Genital Neoplasms, Male; Prostatic Neoplasms; Neoplasms by Site; Prostate Cancer; Prostatic Disease; Neoplasms; Urogenital Neoplasms	2010 - Darlinghurst - St Vincents Hospital; 2076 - Wahroonga - Sydney Adventist Hospital; 2298 - Newcastle - Calvary Mater Newcastle; 3000 - Melbourne - Peter MacCallum Cancer Centre; 3004 - Melbourne - Alfred Hospital; 3084 - Heidelberg - Austin Health; 4029 - Herston - Royal Brisbane and Womens hospital; 5000 - Adelaide - Royal Adelaide Hospital; 6009 - Nedlands - Sir Charles Gairdner; 6150 - Perth - Fiona Stanley Hospital	https://clinicaltrials.gov/ct2/show/NCT05150236
NCT05150457	BNA035-101	Phase 1	Not yet recruiting	NSW	9/12/2021						BNA035-101	A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Refractory Solid Tumors	2217 - Kogarah - St George Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05150457
NCT05156892	TICTOC	Phase 1	Not yet recruiting	NSW	14/12/2021		Itraconazole Dispersion In Polymer Matrix; Itraconazole Dispersion In Polymer Matrix + Tamoxifen; Tamoxifen	azole_antifungal; azole_antifungal + selective_estrogen_receptor_modulator; selective_estrogen_receptor_modulator	Itraconazole Dispersion In Polymer Matrix + Tamoxifen	azole_antifungal + selective_estrogen_receptor_modulator	TICTOC	A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer	Ovarian Cancer	2010 - Sydney - Kinghorn Cancer Centre, St. Vincent's Hospital	https://clinicaltrials.gov/ct2/show/NCT05156892
NCT05166577	VT3996-301	Phase 1/Phase 2	Recruiting	NSW	22/12/2021	7/10/2021	Nanatinostat; Nanatinostat + Pembrolizumab; Pembrolizumab	HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody; HDAC_inhibitor,class_1_selective	Nanatinostat; Nanatinostat + Pembrolizumab	HDAC_inhibitor,class_1_selective; HDAC_inhibitor,class_1_selective + anti-PD-1_monoclonal_antibody	VT3996-301	An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma	EBV-Related Sarcoma; EBV Related Carcinoma; EBV-Related Gastric Carcinoma; EBV-Related Leiomyosarcoma; Nasopharyngeal Carcinoma	2148 - Blacktown - Blacktown Hospital	https://clinicaltrials.gov/ct2/show/NCT05166577
NCT02296580	NCT02296580	N/A	Unknown status	VIC	19/11/2014		Ifosfamide	alkylating_agent				A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)	Glioblastoma Multiforme	Melbourne - St Vincent's Hospital Melbourne	https://clinicaltrials.gov/ct2/show/NCT02296580
NCT02426281	NCT02426281	Phase 2	Unknown status		21/04/2015		Gemcitabine; Gemcitabine + Nab-paclitaxel + Paclitaxel; Nab-paclitaxel; Paclitaxel	antimetabolite; antimetabolite + taxane; taxane	Gemcitabine + Nab-paclitaxel + Paclitaxel	antimetabolite + taxane		A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma	Pancreatic Ductal Adenocarcinoma		https://clinicaltrials.gov/ct2/show/NCT02426281
NCT02513849	NCT02513849	Phase 1	Unknown status		30/07/2015	01/12/2015	Tamoxifen	selective_estrogen_receptor_modulator	Tamoxifen	selective_estrogen_receptor_modulator	163909	A Pilot Study of Tamoxifen in Oesophageal Cancer	Cancer; Gastrointestinal Neoplasms		https://clinicaltrials.gov/ct2/show/NCT02513849
NCT03386526	NCT03386526	Phase 1	Recruiting		21/12/2017		APG-1387	SMAC_mimetic; IAP_inhibitor	APG-1387	IAP_inhibitor; SMAC_mimetic		A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as a Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies	Advanced Solid Tumors or Hematologic Malignancies		https://clinicaltrials.gov/ct2/show/NCT03386526
NCT03595059	NCT03595059	Phase 1	Recruiting	NSW, VIC	12/07/2018		Docetaxel; Docetaxel + Paclitaxel; Paclitaxel	taxane	Docetaxel + Paclitaxel; Paclitaxel	taxane		A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors	Advanced Solid Tumors	3000 - Melbourne - Peter MacCallum Cancer Center /ID# 241676 - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT03595059
NCT03806764	CReSCT	N/A	Enrolling by invitation	VIC	15/01/2019							Assessing the Impact and Complications of Cytomegalovirus (CMV) Reactivation in a Multi-site Study of Allogeneic Haematopoietic Stem Cell Transplant Recipient	Cytomegalovirus Infections; Haematological Malignancy; Organ or Tissue Transplant; Complications; Immune Suppression	3050 - Parkville - Royal Melbourne Hospital	https://clinicaltrials.gov/ct2/show/NCT03806764
NCT04093362	FOENIX-CCA3	Phase 3	Recruiting	NSW, VIC, SA	16/09/2019		Cisplatin; Cisplatin + Gemcitabine; Futibatinib; Gemcitabine	antimetabolite; platinum-based_antineoplastic_agent; pan-FGFR_inhibitor,irreversible; antimetabolite + platinum-based_antineoplastic_agent	Cisplatin + Gemcitabine; Futibatinib	antimetabolite + platinum-based_antineoplastic_agent; pan-FGFR_inhibitor,irreversible	2019-004630-42	A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3	Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements	2305 - Newcastle - Newcastle Private Hospital; 3002 - Melbourne - Peter MacCallum Cancer Centre; 5042 - Bedford Park - Flinders Medical Centre	https://clinicaltrials.gov/ct2/show/NCT04093362
NCT04471844	EF-32	N/A	Recruiting	QLD, SA, NSW	13/07/2020		Radiotherapy; Temozolomide	alkylating_agent; radiotherapy	Temozolomide	alkylating_agent		EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma	Glioblastoma Multiforme	2010 - Darlinghurst - GenesisCare St Vincent's Hospital - (Withdrawn); 2220 - Hurstville - GenesisCare Hurstville - Centre for radiation oncology Waratah Private Hospital - (Withdrawn); 2290 - Gateshead - GenesisCare Newcastle - (Withdrawn); 4066 - Brisbane - GenesisCare Wesley - Wesley Medical Centre - (Withdrawn); 5037 - Kurralta Park - GenesisCare Kurralta Park - (Withdrawn)	https://clinicaltrials.gov/ct2/show/NCT04471844
NCT04631731	ICEMELT	Phase 1/Phase 2	Recruiting	NSW	10/11/2020							Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity	Lung Cancer, Nonsmall Cell; Renal Cell Carcinoma; Melanoma; Gastric Cancer; Hepatocellular Carcinoma; Endometrial Cancer; Mesothelioma	2145 - Sydney - Westmead Hospital; 2148 - Sydney - Blacktown Mt Druitt Hospital	https://clinicaltrials.gov/ct2/show/NCT04631731
NCT04676828	ASPECT	N/A	Recruiting	NSW	15/12/2020		Radiotherapy	radiotherapy	Radiotherapy	radiotherapy		Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial	Lung Cancer; Radiation-Induced Disorder; Radiation Pneumonitis; Pulmonary Disease; Lung Function Decreased	2145 - Sydney - Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04676828
NCT04685135	KRYSTAL-12	Phase 3	Recruiting	QLD, SA	23/12/2020		Adagrasib; Docetaxel	taxane; KRAS_G12C_inhibitor	Adagrasib; Docetaxel	KRAS_G12C_inhibitor; taxane		A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation	Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer	Bedford Park - Research Site; Saint Leonards - Research Site; Woolloongabba - Research Site	https://clinicaltrials.gov/ct2/show/NCT04685135
NCT04691804	NCT04691804	Phase 3	Recruiting	VIC, SA, NSW	30/12/2020		Abiraterone; Placebo; Prednisone	glucocorticoid; placebo; CYP17A1_inhibitor				A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Bendigo - Bendigo Health - (Not yet recruiting); Concord - Concord Repatriation General Hospital - (Not yet recruiting); Fitzroy - St Vincents Hospital Melbourne - (Not yet recruiting); Gosford - Gosford Hospital - (Not yet recruiting); Kurralta Park - Ashford Cancer Centre Research; Melbourne - The Alfred Hospital - (Not yet recruiting); St Albans - Western Health - (Not yet recruiting); Sydney - Macquarie University; Wagga Wagga - Riverina Cancer Care Centre; Wahroonga - Sydney Adventist Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT04691804
NCT04739670	BELLA	Phase 2	Not yet recruiting		01/02/2021		Atezolizumab; Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine; Bevacizumab; Carboplatin; Gemcitabine	platinum-based_antineoplastic_agent; antimetabolite; anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent; anti-PD-L1_monoclonal_antibody; anti-VEGF_monoclonal_antibody	Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine	anti-PD-L1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + antimetabolite + platinum-based_antineoplastic_agent		A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer	Metastatic Triple Negative Breast Cancer		https://clinicaltrials.gov/ct2/show/NCT04739670
NCT04814875	NCT04814875	Phase 1/Phase 2	Not yet recruiting		23/03/2021		ATX-101; ATX-101 + Carboplatin + Pegylated liposomal doxorubicin; Carboplatin; Pegylated liposomal doxorubicin	cell_penetrating_peptide; platinum-based_antineoplastic_agent; anthracycline + cell_penetrating_peptide + platinum-based_antineoplastic_agent; anthracycline	ATX-101 + Carboplatin + Pegylated liposomal doxorubicin	anthracycline + cell_penetrating_peptide + platinum-based_antineoplastic_agent		Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer		https://clinicaltrials.gov/ct2/show/NCT04814875
NCT04914286	NCT04914286	Phase 1/Phase 2	Recruiting	WA	31/05/2021		Toripalimab	anti-PD-1_monoclonal_antibody	Toripalimab	anti-PD-1_monoclonal_antibody		A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid Tumors	Advanced Solid Tumor	Perth - Linear Clinical Research Ltd	https://clinicaltrials.gov/ct2/show/NCT04914286
NCT04938817	MK-3475-B98	Phase 1/Phase 2	Recruiting	NSW, QLD	21/06/2021		Lenvatinib; Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab; Quavonlimab	anti-PD-1_monoclonal_antibody; VEGF_inhibitor; anti-CTLA-4_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Lenvatinib + Pembrolizumab + Quavonlimab; Pembrolizumab; Pembrolizumab + Quavonlimab	VEGF_inhibitor + anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-CTLA-4_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody	MK-3475-B98; KEYNOTE-B98	A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)	Small Cell Lung Carcinoma	2145 - Westmead - Westmead Hospital-Department of Medical Oncology ( Site 4004); 4032 - Brisbane - The Prince Charles Hospital-Oncology Clinical Trials ( Site 4003)	https://clinicaltrials.gov/ct2/show/NCT04938817
NCT05005273	U1111-1263-4850	Phase 2	Not yet recruiting	QLD, VIC, NSW	09/08/2021		BMS-986207; Ipilimumab; Nivolumab; Placebo	anti-TIGIT_monoclonal_antibody; placebo; anti-CTLA-4_monoclonal_antibody; anti-PD-1_monoclonal_antibody			2021-000039-29; U1111-1263-4850	A Phase 2 Randomized Double-blind Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	2076 - Wahroonga - Local Institution; 2800 - Orange - Local Institution; 3280 - Warrnambool - Local Institution; 4814 - Douglas - Local Institution	https://clinicaltrials.gov/ct2/show/NCT05005273
NCT05014815	2021-001075-17	Phase 2	Recruiting	QLD, VIC, TAS	16/08/2021		Ociperlimab; Ociperlimab + Tislelizumab; Placebo; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-TIGIT_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody; placebo	Ociperlimab + Tislelizumab; Tislelizumab	anti-PD-1_monoclonal_antibody; anti-PD-1_monoclonal_antibody + anti-TIGIT_monoclonal_antibody	2021-001075-17	A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing EGFR or ALK Mutations Who Have Received No Previous Treatment for Metastatic Disease	Non Small Cell Lung Cancer	3199 - Frankston - Peninsula &amp; South Eastern Hematology and Oncology Group; 4814 - Douglas - Townsville University Hospital - (Not yet recruiting); 7250 - Launceston - Launceston general hospital; Wodonga - Border Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT05014815
NCT05028478	NCT05028478	Phase 1/Phase 2	Not yet recruiting		25/08/2021							An Open-Label, Multi-center, Phase I/II Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies	Locally Advanced Solid Tumor; Metastatic Solid Tumor; Hematologic Malignancies		https://clinicaltrials.gov/ct2/show/NCT05028478
NCT05031494	NCT05031494	Phase 2	Recruiting	VIC	26/08/2021		Gemcitabine; Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Nab-paclitaxel; Toripalimab; Toripalimab + YH003; YH003	anti-OX40_agnostic_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane; antimetabolite; anti-OX40_agnostic_monoclonal_antibody; taxane; anti-PD-1_monoclonal_antibody; anti-OX40_agnostic_monoclonal_antibody + anti-PD-1_monoclonal_antibody	Gemcitabine + Nab-paclitaxel + Toripalimab + YH003; Toripalimab + YH003	anti-OX40_agnostic_monoclonal_antibody + anti-PD-1_monoclonal_antibody; anti-OX40_agnostic_monoclonal_antibody + anti-PD-1_monoclonal_antibody + antimetabolite + taxane		A Multi-center, Open-label Phase II Study to Evaluate the Safety and Efficacy of YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Patients With Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)	Melanoma; Pancreatic Ductal Adenocarcinoma	3121 - Richmond - Epworth Medical Centre	https://clinicaltrials.gov/ct2/show/NCT05031494
NCT05052801	FORTITUDE-101	Phase 3	Not yet recruiting	WA	13/09/2021		Bemarituzumab; Placebo	anti-FGFR2_monoclonal_antibody; placebo	Bemarituzumab	anti-FGFR2_monoclonal_antibody		A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression	Gastric Cancer; Gastroesophageal Junction Adenocarcinoma	6150 - Murdoch - St John of God Murdoch Hospital	https://clinicaltrials.gov/ct2/show/NCT05052801
NCT05059522	2021-002457-29	Phase 3	Recruiting	QLD	17/09/2021		Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib; Axitinib; PF-04518600; Pemetrexed; Talazoparib; Utomilumab	PARP_inhibitor + anti-PD-L1_monoclonal_antibody; PARP_inhibitor; anti-PD-L1_monoclonal_antibody; KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; anti-4-1BB_monoclonal_antibody; KIT_inhibitor,ATP-competitive; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; antimetabolite; anti-PD-L1_monoclonal_antibody + antimetabolite; VEGFR/PDGFR_inhibitor; anti-OX40_agnostic_monoclonal_antibody; anti-4-1BB_monoclonal_antibody + anti-OX40_agnostic_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Avelumab; Avelumab + Axitinib; Avelumab + PF-04518600 + Utomilumab; Avelumab + Pemetrexed; Avelumab + Talazoparib	KIT_inhibitor,ATP-competitive + anti-PD-L1_monoclonal_antibody; PARP_inhibitor + anti-PD-L1_monoclonal_antibody; VEGFR/PDGFR_inhibitor + anti-PD-L1_monoclonal_antibody; anti-4-1BB_monoclonal_antibody + anti-OX40_agnostic_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody + antimetabolite	2021-002457-29	Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.	Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors	4032 - Chermside - The Prince Charles Hospital - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05059522
NCT05084859	NCT05084859	Phase 1	Recruiting	NSW, QLD, SA	06/10/2021		Abiraterone; Abiraterone + Prednisone; Docetaxel; Panitumumab; Prednisone	anti-EGFR_monoclonal_antibody; taxane; CYP17A1_inhibitor; glucocorticoid; CYP17A1_inhibitor + glucocorticoid	Abiraterone + Prednisone; Docetaxel; Panitumumab	CYP17A1_inhibitor + glucocorticoid; anti-EGFR_monoclonal_antibody; taxane		A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors	Castration-resistant Prostate Cancer; Non-small Cell Lung Cancer; Colorectal Cancer	2010 - Darlinghurst - Saint Vincent's Hospital - (Not yet recruiting); 2050 - Camperdown - Chris O'Brien Lifehouse - (Not yet recruiting); 4215 - South Brisbane - Icon Cancer Care-South Brisbane - (Not yet recruiting); 5011 - Woodville South - The Queen Elizabeth Hospital (TQEH) - (Not yet recruiting)	https://clinicaltrials.gov/ct2/show/NCT05084859
NCT05102214	NCT05102214	Phase 1/Phase 2	Recruiting	QLD	20/10/2021		HLX301	bispecific-PD-L1/TIGIT_antibody	HLX301	bispecific-PD-L1/TIGIT_antibody		A Phase 1/2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients With Locally Advanced or Metastatic Solid Tumors	Locally Advanced or Metastatic Solid Tumors; Non-small Cell Lung Cancer	4575 - Birtinya - Sunshine Coast University Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05102214
NCT05116189	ENGOT-ov65	Phase 3	Recruiting	VIC	28/10/2021		Bevacizumab; Bevacizumab + Docetaxel + Paclitaxel; Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab; Docetaxel; Paclitaxel; Pembrolizumab; Placebo	anti-VEGF_monoclonal_antibody; placebo; anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + taxane; anti-PD-1_monoclonal_antibody; anti-VEGF_monoclonal_antibody + taxane; taxane	Bevacizumab + Docetaxel + Paclitaxel; Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab	anti-PD-1_monoclonal_antibody + anti-VEGF_monoclonal_antibody + taxane; anti-VEGF_monoclonal_antibody + taxane	MK-3475-B96; KEYNOTE-B96; ENGOT-ov65; 2020-005027-37	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)	Ovarian Cancer; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms	3002 - Melbourne - Epworth Freemasons ( Site 0204)	https://clinicaltrials.gov/ct2/show/NCT05116189
NCT05129280	2021-000624-35	Phase 1	Recruiting	VIC	19/11/2021		Tocilizumab	anti-IL-6_monoclonal_antibody			2021-000624-35	An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors	Solid Tumors	3000 - Melbourne - Peter Maccallum Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05129280
NCT05182931	I-FIRST	Phase 2	Not yet recruiting	WA, NSW, VIC, QLD	20/12/2021		Dabrafenib; Trametinib	MEK_inhibitor; BRAF_V600_inhibitor				A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)	Thyroid Cancer	3084 - Heidelberg - Austin Health; 3128 - Box Hill - Eastern Health; 3168 - Clayton - Monash Health; 4029 - Brisbane - Royal Brisbane and Women's Hospital; Melbourne - Peter MacCallum Cancer Centre; Perth - Sir Charles Gairdner Hospital; Prahran - Alfred Hospital; Sydney - Royal North Shore Hospital	https://clinicaltrials.gov/ct2/show/NCT05182931
NCT05187624	2021-001197-37	Phase 1	Recruiting	VIC	07/01/2022		RO7428731	anti-EGFRvIII_monoclonal_antibody	RO7428731	anti-EGFRvIII_monoclonal_antibody	2021-001197-37	An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III	Glioblastoma	3000 - Melbourne - Peter MacCallum Cancer Centre; Medical Oncology	https://clinicaltrials.gov/ct2/show/NCT05187624
NCT05188664	NCT05188664	Phase 1/Phase 2	Not yet recruiting		27/12/2021		Toripalimab	anti-PD-1_monoclonal_antibody	Toripalimab	anti-PD-1_monoclonal_antibody		A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Advanced Solid Tumor		https://clinicaltrials.gov/ct2/show/NCT05188664
NCT05199753	NCT05199753	Phase 1/Phase 2	Not yet recruiting	WA, SA, VIC, QLD, NSW	06/01/2022		LM-108	anti-CCR8_monoclonal_antibody	LM-108	anti-CCR8_monoclonal_antibody		A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours	Advanced Solid Tumor	NSW 2148 - Sydney - Blacktown Hospital; QLD 4101 - South Brisbane - ICON Cancer Centre; SA 5042 - Bedford Park - Southern Oncology Clinical Research Unit; VIC 3004 - Melbourne - Alfred Hospital; VIC 3144 - Malvern - Cabrini Health Limited; WA 6009 - Nedlands - One Clinical Research Pty Ltd.; WA 6009 - Nedlands - Ramsay Health Care Pty Ltd trading as Hollywood Private Hospital	https://clinicaltrials.gov/ct2/show/NCT05199753
NCT05200013	NCT05200013	Phase 1	Not yet recruiting	NSW	06/01/2022		BAT7104	bispecific_PD-L1/CD47_antibody				A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients With Advanced Solid Tumours	Patients With Advanced Solid Tumors	2109 - Sydney - Macquarie University	https://clinicaltrials.gov/ct2/show/NCT05200013
NCT05200273	NCT05200273	Phase 1	Not yet recruiting	SA	07/01/2022		AK114	anti-IL-1beta_monoclonal_antibody				A Phase 1a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 in Subjects With Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors; Malignancy; Metastasis	Kurralta Park - Ashford Cancer Centre	https://clinicaltrials.gov/ct2/show/NCT05200273
NCT05221840	PACIFIC-9	Phase 3	Not yet recruiting	SA	02/02/2022		Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab; Monalizumab; Oleclumab; Placebo; Radiotherapy	anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; radiotherapy; placebo; anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody; anti-CD73_monoclonal_antibody; anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody	Durvalumab; Durvalumab + Monalizumab; Durvalumab + Oleclumab	anti-CD73_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-NKG2A_monoclonal_antibody + anti-PD-L1_monoclonal_antibody; anti-PD-L1_monoclonal_antibody	2021-004346-37	A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy	Non-Small Cell Lung Cancer	5112 - Elizabeth Vale - Research Site	https://clinicaltrials.gov/ct2/show/NCT05221840
